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Bronchiectasis is a chronic inflammatory lung disease associated with failure of the 
normal mucociliary escalator, chronic bacterial colonisation of the airways, 
neutrophil mediated inflammation and a resulting clinical syndrome of respiratory 
infections, lung damage and symptoms such as cough, sputum production and 
shortness of breath. These are few effective treatments and the cause of 
bronchiectasis is unknown in the majority of patients. It is hypothesised that 
unrecognised immune defects may predispose to bronchiectasis or affect the severity 
of lung disease. 
Ficolin-2 is a circulating innate immune protein able to activate the lectin pathway of 
complement through interaction with mannose binding lectin associated serine 
protease-2. Through its structural and functional similarity to complement 
component C1q and mannose binding lectin, it is hypothesised that ficolin-2 may be 
involved in opsonophagocytosis of pathogens. A number of single nucleotide 
polymorphisms in the ficolin-2 gene have been described causing considerable 
variation in human ficolin-2 serum concentrations in healthy individuals.  
In this thesis, the role of the key lectin pathway components ficolin-2 and mannose 
binding lectin, are investigated in patients with bronchiectasis. 
We demonstrate a significant association between single nucleotide polymorphisms 
in the FCN2 gene and disease severity in bronchiectasis. Specifically, patients with 
low expressing FCN2 haplotypes have a higher frequency of chronic colonisation, 
colonisation with P. aeruginosa, more frequent exacerbations and worse health 
related quality of life. An association between MBL deficient genotypes and disease 
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severity is also demonstrated suggesting an important role for the lectin pathway of 
complement in modifying disease severity in bronchiectasis.  
In-vitro studies identify that ficolin-2 is the major lectin pathway component 
responsible for complement activation on P. aeruginosa and that ficolin-2 binds to a 
wide range of clinically relevant pathogens.  
Neutrophils isolated from the sputum of patients with bronchiectasis showed 
significant alterations in surface receptor expression and function compared to 
peripheral blood neutrophils, with a novel effect of neutrophil elastase cleavage of 
CD88 contributing to reduced phagocytosis by airway neutrophils. Despite loss of 
phagocytic receptors from sputum neutrophils, opsonisation by ficolin-2/MASP-2 
complexes still enhanced phagocytosis of P. aeruginosa by sputum neutrophils, 
suggesting that ficolin-2 may be relevant in the clearance of P. aeruginosa in the 
airway. 
In summary, ficolin-2 was found to be an important modifier of disease severity in 
bronchiectasis. 
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Bronchiectasis is a chronic lung disorder characterised by recurrent cough, sputum 
production and recurrent respiratory infections (Murray, 2009). Pathologically, there 
is permanent dilatation of one or more bronchi with failure of the normal mucociliary 
escalator, leading to chronic airway inflammation and, in turn, chronic bacterial 
colonisation (Laennec, 1834). 
Estimates of the prevalence of bronchiectasis vary, data from the United States 
reported a frequency of 52/100,000, from which it has been estimated there are a 
minimum of 30,000 patients with the disease in the UK (Weycker et al, 2005, 
DeSoyza et al, 2012). The prevalence increases with age (Weycker et al, 2005) and 
this is likely to be a significant underestimate of the true burden of the disease. For 
example 170 patients are followed up in secondary care for bronchiectasis at 
Ninewells Hospital, Dundee, which has a catchment population of 149,000 (General 
Register Office, Scotland) and approximately 800 patients are followed up in 
secondary care at the Royal Infirmary of Edinburgh with the population of NHS 
Lothian being 826,231 (General Register Office, Scotland). Given that only the most 
severe patients with bronchiectasis are typically followed-up in secondary care 
(Pasteur 2010) this gives an estimated prevalence of  97-114/100,000 for significant 
bronchiectasis followed up in secondary care, with the prevalence of less severe 
bronchiectasis likely to be much higher. Bronchiectasis may be underrecognised and 
underdiagnosed. O’Brien et al studied a cohort of 110 patients with a primary care 
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diagnosis of chronic obstructive pulmonary disease, performing high resolution 
computed tomography scanning and lung function testing. They identified 
bronchiectasis in 29% of patients, suggesting a high prevalence of bronchiectasis 
among COPD patients but also suggesting a degree of misdiagnosis as 19% of 
patients in this study had never smoked (O’Brien et al, 2000). Increasing awareness 
of the disease and improved diagnosis due to advances in computed tomography 
technology are likely to increase the reported prevalence. Recent data from the 
United States Medicare database found an annual increase in claims for 
bronchiectasis of 8.7% between 2000 and 2007 (Seitz et al, 2012). The rate of 
hospitalisations for bronchiectasis also increased significantly between 1993 and 
2006, emphasising the growing recognition of this disease (Sietz et al, 2010).  
 
Although in severe cases the appearances may be detected by chest x-ray (figure 1.1) 
radiologically, bronchiectasis is now defined by a characteristic appearance of 
bronchial dilatation on high-resolution chest computed tomography. In health, the 
overall diameter of a bronchus is approximately equal at any given level to its 
adjacent pulmonary artery, and a ratio of bronchus diameter : vascular diameter > 1 
denotes abnormal dilatation. Cylindrical/tubular bronchiectasis is the most common 
subtype, but varicose and cystic bronchiectasis are also seen. Examples of 





Figure 1.1 Chest radiograph from a 70 year old gentleman with severe 
bronchiectasis. The chest x-ray shows multiple thin walled cysts in the right upper 
lobe some of which contain fluid. There is peribronchial thickening in the right and 
left lower lobes. Incidentally there is slight cardiomegaly and old left sided rib 







Figure 1.2. Chest Computed Tomography (CT) scan showing mild tubular 
bronchiectasis in both lower lobes (arrows show two examples where the diameter of 





Figure 1.3. Chest CT scan showing varicose bronchiectasis in the right upper lobe- 






Figure 1.4. Chest CT scan showing severe cystic bronchiectasis in the right lower 
lobe. The arrow highlights one of the cysts.   
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Other radiological features associated with bronchiectasis include bronchial wall 
thickening, mucous plugging, mosaic attenuation , atelectasis, subsegmental, 
segmental or lobar collapse and emphysema (Kang et al 1995, Reiff et al 1995, 
McGuiness et al 2002). There is a relationship between the severity of bronchiectasis 
on CT scanning and the severity of clinical disease, although analysis of this is 
limited due to different scanning techniques and scoring systems (Lynch et al, 1999). 
There is no established scoring system for use in bronchiectasis and most studies 
have used scores validated in cystic fibrosis (Bhalla et al, 1991).  
 
1.1.2 The clinical syndrome of bronchiectasis 
The characteristic symptoms of bronchiectasis are cough and sputum production 
(Nicotra, 1995). Sputum may be mucoid, mucopurulent or purulent and the degree of 
purulence correlates with clinical markers of disease severity such as lung function, 
HRCT scanning and quality of life (Murray et al, 2009). Patients may also report 
dyspnoea (Smith et al, 1996), haemoptysis (Nicotra et al, 1995), chest pain (Munro et 
al, 1989, King et al 2012), fever, fatigue (Hester et al, 2012) and malaise. Patients 
may suffer recurrent respiratory tract infections, and this is a common reason for 
referral to secondary care. Bronchiectasis has a significant effect on health related 
quality of life, with mean total scores for the St.Georges Respiratory Questionnaire 
ranging from 36 (Chan et al, 2002), 41.1 (Murray et al, 2009), 44.4 (Wilson et al, 
1997) to 45.5 (Martinez-Garcia et al, 2005) in clinically stable patients. These values 
are similar to those observed in other serious respiratory diseases such as moderate to 
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severe COPD (Tashkin et al, 2008) or idiopathic pulmonary fibrosis (Raghu et al, 
2010).     
Lung function impairment is variable in adults with bronchiectasis. Patients may 
have airflow obstruction, restriction or may have normal spirometry values. (Bahous 
et al,1984). Airflow obstruction is the most common pattern and is associated with 
more severe disease (Pande et al 1971, Bahous et al 1984, Roberts et al 2000). A 
lower forced expiratory volume in one second is associated with the severity of 
breathlessness measured by the Medical Research Council dyspnoea scale and is also 
associated with extent of disease on HRCT (Roberts et al, 2000). Forced vital 
capacity may be normal or reduced. Forced expiratory flow25-75 (FEF25-75)  may be 
reduced and the RV/TLC ratio maybe increased suggestive of small airways disease 
and air trapping (Bahous et al 1984, Stockley et al 1984,Koulouris et al 2003). The 
response to bronchodilators is variable (Hill and Stockley 1986, Hassan et al 1999) 
between 1/3 and ¾ of patients with bronchiectasis may have a response to bronchial 
challenge testing with methacholine or histamine. (Bahous et al 1984, Pang et al 
1989)   
An exacerbation of bronchiectasis is defined as deterioration in a patient with known 
bronchiectasis from their stable condition, associated with increased cough, sputum 
production, increased sputum purulence or dyspnoea/wheeze (Pasteur et al, 2010). In 
addition to these subjective symptoms, patients may have objective evidence of 
reduction in forced expired volume in 1 second (FEV1) or a reduction in exercise 
capacity. The frequency of exacerbation varies substantially in the literature 
depending on the severity of the cohort studied, from a mean of 2 to 5 exacerbations 
per year (Tsang et al 1999, Wilson et al 1998). Severe exacerbations may require 
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hospital admission and the British Thoracic Society have proposed guidelines 
recommending inpatient management of exacerbations for patients with cyanosis or 
confusion, breathlessness with respiratory rate > 25/min, circulatory failure, 
respiratory failure, temperature > 38
O
C, inability to take oral therapy, inability to 
cope at home and failure of oral antibiotic therapy (Pasteur et al, 2010). 
 
   
1.1.3 The vicious cycle hypothesis 
Originally proposed by Cole, the vicious cycle hypothesis is central to our current 
understanding of bronchiectasis (Cole, 1986). Airway structural damage, regardless 
of the initial insult or immunodeficiency that causes it, permits increasing bacterial 
colonisation of the lower airway (Chmiel et al, 2003, Charlston et al, 2011). A 
dysregulated immune response then occurs that fails to clear the initial infection but 
causes further airway structural damage through multiple mechanisms (Smith, 2011). 
This cycle repeats itself leading to disease progression. The concept is summarised in 












Figure 1.5. The vicious cycle hypothesis of bronchiectasis. Abbreviations IL-
8=interleukin-8, LTB4= leukotriene B4, TNF-α= tumour necrosis factor α, IL-1β= 






Although a large body of data supports the vicious cycle hypothesis, there remain 
areas that are poorly understood. It appears that significant inflammation and disease 
progression may occur in some patients in the absence of bacterial infection (Angrill 
et al, 2001). In addition, implicit in the vicious cycle hypothesis is the idea that 
clearance of bacterial infection or an anti-inflammatory strategy will be effective by 
‘breaking the cycle’. The relatively disappointing results to date with anti-
inflammatory agents such as inhaled corticosteroids (Kapur et al, 2009) and with 
long term antibiotics (Evans et al, 2007, Tsang et al, 1999), leave this final question 
unresolved.  
If incorrect, the vicious cycle hypothesis may hamper our understanding of 
bronchiectasis by trapping researchers in the idea that neutrophilic inflammation is 
intrinsically harmful and that suppression of inflammatory responses is the primary 
goal of therapy. Neither of these statements has been convincingly proven and indeed 
there is some data to suggest they may be incorrect. For example in cystic fibrosis, if 
the vicious cycle hypothesis were true, a 24 week placebo controlled phase II trial of 
a Leukotriene B4 receptor antagonist (BIIL284) would have been expected to 
produce benefit by reducing neutrophil recruitment. In reality, the trial resulted in 
increase exacerbations and hospital admissions in cytic fibrosis  (Konstan et al, 
2005), an effective that subsequent mechanistic work demonstrated may be due to a 
critical role of neutrophils in preventing bacterial proliferation and bacteraemia 
(Doring et al 2013). Therefore “breaking the cycle” is not inherently beneficial and 
indeed there is even evidence that future treatment of chronic lung disease may 
involve augmenting neutrophil responses. In a recent study, CFTR null and wild-type 
mice were chronically infected with multi-drug resistant Pseudomonas aeruginosa 
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and subsequently treated with recombinant pentraxin-3 (PTX3), a molecule that 
promotes neutrophil inflammation and phagocytosis. After treatment with PTX3, a 
significant reduction in colony forming units was seen to a level even below that of 
the normal mice. Furthermore, in whole blood assay, preopsonisation of P. 
aeruginosa with recombinant PTX3 significantly increased internalization by CF 
neutrophils and decreased the number of surviving bacteria inside the neutrophils 
(Paroni et al 2013).    
 
1.1.4 Disorders associated with bronchiectasis 
The most frequent disorders associated with bronchiectasis identified by studies in 
specialist centres are shown in Table 1.1. In a significant proportion of cases in 
adults, a single underlying cause cannot be identified. The disease is said to be post-
infective where the patient gives a history of a previous severe infection such as 
pneumonia or pertussis in childhood (Nicotra et al, 1995, Pasteur et al, 2000, Kelly et 
al, 2003). Viral infections such as adenoviral pneumonia (Wynn-Williams 1953, 
Lanning et al 1980), measles (Kaschula, 1983), influenza (Laraya Cuasay et al, 1977) 
and respiratory syncytial virus (Massie and Armstrong, 1999) have also been 
associated with the development of bronchiectasis, often many years after the initial 
insult (Lanning et al, 1980). Determining whether a previous infection is directly 
related to the diagnosis of bronchiectasis is challenging, particularly when there is a 
long time interval between the infection and the onset of symptoms. Mycobacterial 
disease is an important infectious cause of bronchiectasis. Pulmonary 
Mycobacterium tuberculosis infection is implicated in around 15% of cases in 
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secondary care in the UK (Kelly, 2003) with the frequency likely to be much higher 
in areas where M. tuberculosis is endemic. Atypical Mycobacteria are also associated 
with bronchiectasis. Like all chronic lung diseases, bronchiectasis may be 
complicated by atypical mycobacterial infection. This has not been reported 
frequently in the UK, but appears to be very common in the United States, with rates 
of 23% isolated in sputum in one study (Nicotra et al, 1995) and a reported 
prevalence of 35% in the multicentre bronchiectasis research register in the United 
States (O’Connell et al, 2010).  Why a small proportion of patients developing 
bacteria or viral infections develop bronchiectasis as a complication is unclear.   
 
Bronchiectasis is associated with a number of inherited, acquired, infectious, allergic 
and autoimmune disorders (Table 1.1) (Nicotra et al, 1995, Pasteur et al, 2000, Kelly 












Table 1.1 Underlying causes of bronchiectasis in adult cohorts (Nicotra et al 1995, 
Pasteur et al, 2000, Kelly et al, 2003, Pasteur et al, 2010). 
 
 
Almost all immunological deficiencies can be associated with bronchiectasis but 
common variable immunodeficiency, X-linked agammaglobulinaemia and IgA 
deficiency are the most frequently recognised of these disorders (Notarangelo et al, 
2007). Although immunological defects may be diagnosed in childhood, they are 
increasingly recognised in adult patients with bronchiectasis (Pasteur et al, 2010). 
Such defects are reported to account for only 1-8% of cases of adult bronchiectasis, 
but even in specialist units, investigations are often limited to serum 
Underlying disorder Frequency Associations and clinical features 
Idiopathic 30-53%  










Allergic bronchopulmonary aspergillosis 1-7% Associated with asthma 
Immunodeficiency 1-8% Common variable immunodeficiency 
X-linked agammaglobulinaemia 
IgA deficiency 
Specific antibody deficiencies 
Cystic fibrosis 2-4% Atypical cases may be diagnosed in 
adulthood.  
Recurrent aspiration or inhaled foreign body 2-4% A history of this may be absent 
Primary ciliary dyskinesia 1-2% Often associated with upper 
respiratory tract symptoms 
Inflammatory bowel disease 1-2% Ulcerative colitis 
Crohn’s disease 
Congenital airway structural abnormality <1% e.g Mounier-Kuhn syndrome 
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immunoglobulins, protein electrophoresis and IgG subclass measurements (Pasteur et 
al, 2010, Pasteur et al, 2012). Although most research has focussed on primary 
immunodeficiencies, it is well recognised that bronchiectasis can complicate 
secondary immunodeficiency such as in leukaemia, lymphomas and human 
immunodeficiency virus infection (Kearney et al 1977, Knowles et al 1980, 
McGuinness et al 1993). It is presumed that a proportion of patients with 
“idiopathic” bronchiectasis have unrecognised immunodeficiency. 
Specific treatments are recommended for patients with certain underlying disorders 
such as antibody deficiencies (immunoglobulin replacement) and allergic 
bronchopulmonary aspergillosis (corticosteroids and anti-fungals). Although not 
listed currently as a recognised underlying cause (Pasteur, 2010), bronchiectasis 
appears to be very common in chronic obstructive pulmonary disease. Martinez-
Garcia et al studied 92 consecutive patients with moderate to severe COPD with 
HRCT scans and found a prevalence of bronchiectasis of 57.6%. Bronchiectasis in 
COPD was associated with more severe airflow obstruction, more positive sputum 
bacteriology and more frequent exacerbations (Martinez-Garcia et al, 2011). In the 
London COPD cohort, a study of 54 patients found a prevalence of bronchiectasis of 
50%, with bronchiectasis associated with bacterial colonisation and airway 
inflammation. There was an associated with exacerbation severity but not 
exacerbation frequency (Patel et al, 2004). Not all studies have found such a high 
prevalence however, in the multinational Evaluation of COPD Longitudinally to 
Identify Predictive Surrogate Endpoints (ECLIPSE) cohort, including 2,164 subjects, 
the prevalence of bronchiectasis was only 4% (Agusti et al, 2010). It seems likely 
that bronchiectasis associated with COPD will be recognised as a distinct subgroup. 
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Chronic asthma may also be a cause of bronchiectasis, although no studies have 
comprehensive excluded other possible causes in these patients (Paganin et al, 1996). 
The British Thoracic Society recommend that asthma should be considered as an 
underlying cause where no other cause can be found (Pasteur et al, 2010).  
The vicious cycle concept can be adapted to illustrate the possible underlying causes 
in terms of their likely pathophysiology, figure 1.6. This is likely to be a gross over-














Figure 1.6. Underlying causes of bronchiectasis illustrated in terms of the “vicious 








1.1.5 Bacteria as drivers of airway inflammation and remodelling 
Bacterial infection drives the vicious cycle of bronchiectasis. The most frequently 
isolated organisms in patients with non-CF bronchiectasis are Haemophilus 
influenzae, P. aeruginosa, Moraxella catarrhalis, Streptococcus pneumoniae and S. 
aureus (Pasteur 2010, Angrill, 2001, Angrill, 2002). Less frequently isolated 
pathogens include Aspergillus species, enteric gram negative organsisms, methicillin 
resistant S. aureus and atypical mycobacteria as has been discussed previously. The 
frequency of pathogens isolated in selected studies of adults with bronchiectasis 















Table 1.2. The frequency of bacterial isolates in adult patients with non-CF 
bronchiectasis. Adapated from Pasteur 2010. ND= not done. Dashes indicate data not 
reported. Some percentages may add up to more than 100% due to patients culturing 
more than one organism. 
Author Year Country N Age Method Hi PA Sa Sp Mc Asp Myco NP 
Nicotra 1995 USA 123 57 Sputum 30 31 7 11 2 5 23 23 
Evans 1996 UK 135 - Sputum ND 12 ND ND ND ND ND ND 
Cabello 1997 Spain 17 57 BAL 35 5 - - - - ND 60 
Wilson 1997 UK 87 54 Sputum 20 25 - - - - - 38 
Pasteur 2000 UK 150 53 Sputum 35 31 14 13 20 2 ND 5 
Angrill 2001 Spain 49 57 BAL 26 20 - 2 - - ND 28 
Palwatwichai 2002 Thailand 50 58 Sputum 14 20 - 6 4 - 6 36 
Angrill 2002 Spain 42 58 Sputum 26 9 - 14 5 2 0 60 
Angrill 2002 Spain 59 58 BAL 32 10 3 7 - - 0 32 
Kelly 2003 UK 100 57 Sputum 54 21 8 16 20 ND ND - 
Tsang  2005 Hong 
Kong 
86 58 Sputum 11 27 - - - - - 60 
King  2007 Australia 89 57 Sputum 47 12 4 7 8 2 2 21 
Garcia 2007 Spain 76 70 Sputum 18 20 - - - - - - 
O’Connell 2010 USA 230 - Sputum - 31 9 - - - 35 87 
Wong 2012 N.Zealand 141 60 Sputum 28 12 3 3 4 - - - 
Goeminne 2012 Belgium 479 67 Sputum 31 30 23 20 15 20 - - 
King 2012 Australia 178 58 Sputum 35 23 - - - - - 28 




1.1.6 Haemophilus influenzae 
H.influenzae is a Gram-negative rod shaped bacterium typically found as a 
commensal of the upper respiratory tract. H. influenzae is the most frequent pathogen 
causing chronic infection in non-CF bronchiectasis and chronic obstructive 
pulmonary disease. In cohorts of bronchiectasis patients, up to 50% will grow H. 
influenzae while clinically stable (Kelly et al, 2003), although the average across 
these studies is closer to 35% (Table 1.2). In contrast to Pseudomonas aeruginosa, 
there is little data about the impact of H. influenzae colonisation on clinical outcomes 
in bronchiectasis.   
The mechanisms of chronic infection by H. influenzae are also less well studied than 
for other organism, but H.influenzae can survive intracellularly within macrophages 
and invade bronchial epithelial cells (Forsgren et al, 1994). H.influenzae therefore 
has both an intracellular and extracellular niche within the respiratory tract. King et 
al found evidence of an abnormal Th2 cytokine response to H.influenzae infection 
with reduce expression of CD40 ligand in bronchiectasis (King, 2003). The 
mechanism of this abnormal cytokine response has not been established. 
H.influenzae are also able to form biofilms to evade host immune responses. 
 
1.1.7 Pseudomonas aeruginosa 
P.  aeruginosa is a ubiquitous Gram-negative, aerobic coccobacillus found in soil, 
water, skin flora and many man made surfaces. P. aeruginosa is an opportunistic 
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human pathogen able to undergo diverse adapatations to permit chronic infection of 
the lower respiratory tract (Davies et al, 2009).  
The phenotypic changes from acute to chronic P.aeruginosa infections have been 
extensively reviewed and include a reduction in invasive virulence factor expression 
such as flagellae, pili and toxins (Klausen et al, 2003). P. aeruginosa persistence is 
associated with transformation to a mucoid phenotype. Following a challenge, such 
as hypoxia, Pseudomonas strains expressing mucoid exopolysaccharide (alginate) are 
selected for and establish themselves within a protective environment (Li et al, 
2005). The ability to form biofilms is central to survival of these organisms within 
the lung. Biofilms protect bacteria against clearance by the host immune system and 
also increase resistance to antibiotics (Bragonzi et al, 2009). Neutrophils have been 
shown to promote biofilm formation and once established within biofilms 
Pseudomonas becomes highly resistant to neutrophil phagocytosis (Parks et al, 
2009). Pseudomonas within biofilms becomes non-motile, further protecting them 
from phagocytosis (Singh et al, 2000). Initiation of biofilm formation is dependent 
on the process of quorum sensing. As the number of bacteria within the lung 
increase, the concentrations of signalling molecules such as homoserine lactones 
increase. These diffuse freely into bacterial communities allowing organisms to sense 
the local population density. Once a critical mass of organisms is reached, quorum-
sensing molecules induce gene expression that promotes biofilm formation (Amiel et 
al, 2010). The ability of Pseudomonas to adapt so rapidly and extensively to the lung 
is due to the hypermutable nature of these organisms. Pseudomonas can quickly 
express or inactivate genes, but also increases the frequency of mutation events 
within its genome to ensure survival in the face of multiple environmental (hypoxia, 
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ionic strength), immunological (neutrophils, complement), and antimicrobial 
challenges (Oliver et al, 2000).
 
In cystic fibrosis bronchiectasis, it is well established that P.aeruginosa colonisation 
leads to a more rapid deterioration in lung function and earlier mortality (Li et al, 
2005). Consequently, eradication of P. aeruginosa is standard care in European 
Cystic fibrosis centres (Doring et al 2000, Ratjen et al 2010).
 
In non-cystic fibrosis bronchiectasis, the role of P.aeruginosa is less clearly 
established, with studies to date including relatively few patients. A recent study of 
91 patients with 27 deaths suggested that patients culturing P.aeruginosa (n=20) 
were at an increased risk of long term mortality.(Loebinger et al, 2009) The same 
researchers previously reported in a cohort of 22 patients with P.aeruginosa 
colonisation that colonisation was associated with worse lung function, greater 
severity of lung disease and poorer quality of life (Davies et al, 2006). In this cohort, 
an association between P.aeruginosa colonisation and decline in FEV1 and FVC over 
time was not found in contrast to the findings of Evans et al, who showed in 14 
P.aeruginosa colonised patients that lung function deteriorated more rapidly (Evans 
et al, 1996). There are no controlled trials of P. aeruginosa eradication in non-CF 
bronchiectasis. The authors of each of these reports conclude that it is difficult to 
know if P.aeruginosa colonisation simply reflects a more severe disease, or whether 






1.1.8 Staphylococcus aureus 
S.aureus is a major clinical problem in cystic fibrosis, particularly in children, and is 
also associated with ABPA or atypical CF in adults with bronchiectasis (Starner et al, 
2006). Similar to Pseudomonas, S.aureus downregulates virulence factors during 
conversion to chronic infection and can form biofilms (Shah et al, 1999). The ability 
to form small colony variants (SCV’s) is an important feature of S.aureus virulence. 
These variants are able to invade and persist within epithelial cells and are 
remarkably resistance to antibiotics (Shah et al, 1999, Kahl et al, 1998, Sandowska et 
al, 2002). Cystic fibrosis cells are more susceptible to invasion by SCVs and these 
variants are frequently isolated in CF (Mitchell et al, 2011). Their role in non-CF 
bronchiectasis is not known. Under anaerobic conditions, which can occur in poorly 
ventilated areas of the lung, S.aureus forms a polysaccharide intercellular adhesion 
that protects cells from neutrophil phagocytosis (Cramton et al, 2001). S. aureus is 
able to readily acquire resistance to antibiotics and the isolation of methicillin 
resistant S. aureus, while not common in non-CF bronchiectasis, is regarded as an 
indication for secondary care follow-up by the British Thoracic Society guidelines as 
it is difficult to treat and may be associated with a worse prognosis (Pasteur et al, 
2010).  
 
1.1.9. The relationship between bacterial infection and airway inflammation 
In a study of patients with COPD, α-1-antitrypsin and bronchiectasis, Hill et al 
demonstrated a direct relationship between spontaneous sputum airway bacterial load 
and multiple markers of airway inflammation including myeloperoxidase, neutrophil 
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elastase, interleukin-8 and an inverse relationship with secretory leukocyte peptidase 
inhibitor (Hill et al, 2000). Similar results were shown by Angrill in a bronchoscopic 
study showing a direct relationship between bronchial colonisation, neutrophil count 
and airway inflammation (Angrill et al, 2001, Angrill et al, 2002). After initially 
disappointing data for long-term antibiotic therapies in bronchiectasis (Tsang et al, 
2000), recent data with nebulised gentamicin among others suggests that bacterial 
clearance can reduce markers of inflammation and improve clinical outcome 
(Murray et al, 2010). This study randomised 27 patients to 12 months of nebulised 
gentamicin and 30 patients to nebulised 0.9% saline. 30.8% of patients infected with 
P.  aeruginosa achieved eradication with gentamicin (3.7% with 0.9% nebulised 
saline). In patients that did not achieve eradication the study demonstrated a 
reduction in sputum bacterial load in the gentamicin group from 8.06 log10 cfu/ml at 
baseline to 6.17 log10 cfu/ml at the end of treatment in the gentamicin group. These 
changes in bacterial infection were associated with a significant reduction in sputum 
myeloperoxidase and neutrophil elastase activity (Murray et al, 2010). Improvements 
in clinical outcomes including the St.Georges respiratory questionnaire and Leicester 
cough questionnaire scores and a significant reduction in the frequency of 
exacerbations were also observed.    
 
1.1.10 Other organisms 
The frequencies of S. pneumoniae, M. catarrhalis and enteric Gram-negative 
organisms are variable but generally they account for a small minority of isolates 
(table 1.2). Bacterial persistence in bronchiectasis is the result of multiple inherited 
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and acquired immunological defects along with bacterial adaptations to promote 
chronic infection. Much of our understanding of the pathophysiology bronchiectasis 
is incomplete or is extrapolated from cystic fibrosis. A greater understanding of the 
mechanisms of immunological dysfunction and bacterial colonisation in 
bronchiectasis is essential for the development of new therapies. 
 
1.1.11 Studies of immune function in bronchiectasis 
1.1.12 The role of neutrophils 
Bronchiectasis is believed to be primarily a neutrophil-driven disorder. Consistently 
neutrophils are found to be the most abundant cell type in bronchiectasis airway 
fluids (sputum and bronchoalveolar lavage) (Eller et al, 1994, Angrill et al, 2002). 
The number of neutrophils migrating to the airway is increased in stable patients and 
the numbers increase further with bacterial infection and exacerbation (Watt et al, 
2004). This recruitment to the airway requires a number of co-ordinated processes 
that are highly active in patients with bronchiectasis.  
 
1.1.13 Neutrophil recruitment and migration in bronchiectasis 
Recruitment is driven by chemoattractants, with interleukin-8 (CXCL-8), 
Leukotriene B4, Interleukin-1 beta and tumour necrosis factor alpha believed to be of 
major importance (Mikami et al, 1998, Schleimer et al, 1991). Elevated levels of 
these pro-inflammatory cytokines have all been demonstrated in bronchiectasis 
airway secretions (Tsang et al, 1998, Stockley et al, 2000). Complement component 
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C5a is also a potent neutrophil chemoattractant but there is limited data to support a 
role for C5a in non-CF bronchiectasis (Fick et al, 1986).  
Neutrophil detection of chemotactic stimuli leads to a co-ordinated process of cell 
signalling, cytoskeletal rearrangement and changes in surface receptor expression to 
facilitate migration. 
Key to this process of transendothelial migration are the expression of the integrins 
CD11/CD18 on neutrophils and the expression of adhesion molecules on endothelial 
cells, principally intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion 
molecule-1 (VCAM-1) and the selectins (Downey et al, 2009, Cowburn et al, 2008). 
During the first stage of recruitment, rolling adhesion, upregulation of E-selectin and 
P-selectin on endothelial cells and an increase in the binding capacity of the 
leukocyte receptor L-selectin allow the neutrophil to adhere to and roll along the 
endothelial surface. During the second stage of this process, strong adhesion to the 
endothelial cell is achieved through binding of CD11/CD18 integrins present on the 
neutrophil to ICAM-1 and ICAM-2 (Bevilacqua et al, 1993). ICAM-2 is 
constitutively expressed on endothelial cells, but ICAM-1 expression is rapidly 
increased at sites of inflammation by the action of pro-inflammatory cytokines, 
principally tumour necrosis factor alpha but also Interleukin-1 beta (Yang et al, 
2005). TNF-alpha and IL-1β are both elevated in the airway in patients with 
bronchiectasis (Fushillo rt al, 2008). Increased peripheral blood concentrations of 
ICAM-1, along with E-selectin and VCAM-1, have also been demonstrated in 
bronchiectasis patients (Zheng et al, 2000). During the process of neutrophil 
activation there is shedding of L-selectin and upregulation of CD11. Lower levels of 
CD11 have been shown on neutrophils from patients with cystic fibrosis during 
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exacerbations (Downey et al, 2007), but Pasteur et al found no abnormal values of 
CD11b in stable patients with bronchiectasis (Pasteur et al, 2000). Following strong 
adhesion, neutrophils migrate through the endothelial barrier, through the interstitium 
and finally through gaps between type I and type II pneumocytes to enter the alveolar 
lumen.  
Up to 70% of transmigrating neutrophils cross the endothelial barrier by active 
engulfment by endothelial cells in a process that is dependent on the small GTPase 
RhoG (van Buul et al, 2007). Neutrophils are then able to migrate through the 
pericyte sheath and basement membrane using areas of low basement membrane 
density that appear to provide low resistance “tracks” for leukocyte recruitment 
(Wang et al, 2006).
 
Once neutrophils have migrated to the site of inflammation, they move towards a 
chemotactic stimulus along a concentration gradient until the rising concentration of 
chemoattractant serves to inhibit neutrophil migration and instead triggers its 
bacteriocidal functions (phagocytosis and degranulation). The chemotactic responses 
of bronchiectasis neutrophils appear to be intrinsically normal but the high levels of 
neutrophil chemoattractants in bronchiectasis sputum serve to enhance this process 
(Stockley et al, 1988).
 
The process of neutrophil adhesion and migration to the lung 








Figure 1.7. Neutrophil migration. The process begins with expression of E/P selectin 
on the surface of endothelial cells, followed by neutrophil activation with shedding 
of L-selectin and upregulation of CD11/CD18. CD11/CD18 binds to ICAM-1 
leading to strong adhesion between neutrophils and endothelial cells. Neutrophils 
then migrate either by active engulfment by endothelial cells or at endothelial cell 







Increasing knowledge of the mechanisms of neutrophil migration may lead to 
targeted therapies in bronchiectasis. A phase II study of an anti-Interleukin-8 
monoclonal antibody in COPD has been shown to be safe and was associated with 
symptomatic improvement (Mahler et al, 2004). Although monoclonal antibodies 
such as this are promising new treatments, anti-TNF-α therapy was not found to be 
effective in COPD (Rennard et al, 2007) or asthma (Wenzel et al, 2009), and was 
associated with a trend towards increased malignancy and pneumonia in the COPD 
trial. Similarly, as previously mentioned ,although LTB4 is thought to be important in 
neutrophil recruitment in many chronic lung disorders, an LTB4 receptor antagonist 
(BIIL284) result paradoxically increased respiratory exacerbations in phase II trial in 
cystic fibrosis (Konstan et al, 2005). 
 
1.1.14 Neutrophil phagocytosis and killing 
Phagocytosis is dependent on FcY and complement receptors, specifically FcγRIIIB 
(CD16), FcγRIIA (CD32), complement receptor 1 (CD35). and complement receptor 
3 (CD11b/CD18). Fcγ receptors recognise phagocytic targets opsonised with IgG, 
while complement receptor 1 recognises the complement components C3b/C4b 
deposited on microorganisms and complement receptor 3 recognises complement 
component iC3b.  
Ligation of phagocytic receptors initiates the process by which bacteria are engulfed 
by the neutrophil phagosome. Neutrophil granules then fuse with the phagosome 
releasing their toxic contents, resulting in bacterial killing. 
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Degranulating neutrophils release a range of mediators that have important effects in 
bronchiectasis. Neutrophil elastase is the most extensively studied, but cathepsin G, 
proteinase-3 and the matrix metalloproteinases are also increased in the airways of 
patients with bronchiectasis and have important effects (Tsang et al, 2000)
 
It is clear that neutrophils present in the bronchiectasis lung fail to effectively 
phagocytose and kill microorganisms, but the mechanism for this is complex and 
poorly understood. The mechanisms that bacteria use to evade neutrophil killing will 
be discussed in subsequent sections. King et al found no evidence of reduced 
phagocytosis by peripheral blood neutrophils in patients with bronchiectasis, 
suggesting that neutrophils from bronchiectasis may be relatively normal before they 
enter the inflamed airway (King et al, 2006). The inflammatory milieu in the airway 
is therefore strongly implicated in phagocytic dysfunction. 
Large concentrations of neutrophil elastase are released into the bronchiectasis 
airway which overwhelm natural antiprotease defences such as α-1-antitrypsin and 
secretory leukocyte peptidase inhibitor. Elastase has multiple damaging effects in-
vitro include directly damaging epithelial cells, slowing ciliary beat frequency and 
promoting mucous hypersecretion through effects on goblet cells (Voynow et al, 
1999, Amitani et al, 1991). Elastase is directly pro-inflammatory. In clinical studies, 
elastase correlates with markers of disease severity such as lung function, 
radiological severity and 24-hour sputum volume (Tsang et al, 2000, Lloberes et al, 
1992). Destruction of elastin, basement membrane collagen and proteoglycans by 
neutrophil proteases may contribute directly to progression of the disease (Shun et al, 




Importantly, however, there is strong evidence that elastase also impairs neutrophil 
phagocytosis by multiple mechanisms. Elastase cleaves FcγRIIIb, and has also been 
shown to cleave complement receptor 1 in patients with cystic fibrosis (Voglis et al, 
2009, Berger et al, 1989). Elastase also cleaves iC3b from the surface of pathogens, 
leading to an important opsonin/receptor mismatch (Tosi et al, 1990). This evidence 
makes elastase a leading candidate for therapeutic manipulation in bronchiectasis and 
a number of pharmaceutical companies are developing oral elastase inhibitors for use 
in bronchiectasis and other chronic respiratory disorders (Stevens et al, 2011). Short 
and long term antibiotic therapy is also effective in suppressing levels of sputum 
neutrophil elastase activity (Chalmers et al, 2012).  
Human neutrophil peptides (HNPs) – also known as α defensins – are the most 
abundant proteins stored in azurophilic granules by neutrophils. These peptides are 
found in high concentrations in the lungs of bronchiectasis patients and are essential 
for neutrophil killing of micro-organisms. Voglis et al, however, demonstrated that 
high concentrations of HNPs inhibit neutrophil function via a negative feedback loop 
resulting in reduced phagocytosis (Vogilis et al, 2009).  Voglis et al also 
demonstrated reduced expression of Fcγ receptors and complement receptor 1 in the 
airway neutrophils of patients with bronchiectasis (Voglis et al, 2009).
 
Some of the mechanisms of neutrophil phagocytic dysfunction in bronchiectasis are 





Figure 1.8. Neutrophil phagocytic impairment in bronchiectasis. Neutrophil elastase 
and neutrophil peptides released by activated neutrophils impair neutrophil functions 
through cleavage or downregulation of Fcϒ receptors and complement receptor 1. 
Opsonisation of bacteria occurs through activation of complement via the classical or 
mannose binding lectin pathways. Elastase is also involved in the fragmentation of 
immunoglobulin which impairs the classical complement pathway, and in cleaving 
iC3b from bacterial surfaces thereby further reducing opsonic phagocytosis. 







Less is known about the role of macrophages in bronchiectasis, although along with 
other inflammatory cells increased numbers of macrophages are demonstrable in 
endobronchial biopsies from patients with bronchiectasis (Zheng et al, 2001). 
Macrophages co-ordinate inflammatory responses by secreting inflammatory 
mediators including those mentioned previously (tumour necrosis factor alpha, 
interleukin-8 and leukotriene B4).  
A crucial role of macrophages is the process of efferocytosis (Walker et al, 2005). 
The clearance of apoptotic cells by macrophages is a critical mechanism for the 
resolution of inflammation (Walker et al, 2005). Failure to clear apoptotic 
neutrophils from the airway is associated with increased inflammation and airway 
damage through secondary necrosis and unregulated release of granule products 
(Haslett et al, 1999). Large numbers of apoptotic and secondary necrosis neutrophils 
have been demonstrated in the airway of patients with bronchiectasis (Watt et al, 
2004).  Vandivier demonstrated that neutrophil elastase cleavage of 
phosphatidylserine on the surface of apoptotic cells prevents macrophage 
phagocytosis in patients with bronchiectasis (Vandivier et al, 2002). Vitamin D 
binding protein (VDBP) also appears to play a role in efferocytosis by activating 
alveolar macrophages, and Wood et al found an association between the GC2 variant 
of the VDBP gene and bronchiectasis in patients with α-1-antitrypsin deficiency 
(Wood et al, 2011). Macrophage clearance of apoptotic cells is a target for future 
therapeutic manipulation. The macrolide azithromycin, which has recently been 
shown to reduce exacerbations of bronchiectasis in a placebo controlled randomised 
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trial (Wong et al, 2012), has been shown to enhance phagocytosis of apoptotic cells 
by increasing expression of mannose receptor (Hodge et al, 2008).      
 
 
1.1.16 T cells 
T cell infiltration has been demonstrated in multiple studies of bronchiectasis patients 
(Silva et al, 1989, Sepper et al, 1995). The proportions of CD4+ and CD8+ cells are 
variable in biopsy studies and no consistent pattern of infiltration has been 
demonstrated. Th17 cells are controlled by the transcription factor RORγt and secrete 
interleukin-17, a potent pro-inflammatory cytokine and neutrophil chemoattractant 
(Dublin et al, 2008). They have an important role in the clearance of extracellular 
bacteria and fungi but may also be deleterious by exacerbating neutrophilic airway 
inflammation. A study of endobronchial biopsies from 17 patients with non-CF 
bronchiectasis found increased Th17 cells compared to healthy controls, with 
equivalent numbers of Th17 cells in non-CF bronchiectasis compared to CF patients. 
Similarly, increased levels of IL-17 were identified in bronchoalveolar lavage in non-
CF bronchiectasis compared to controls (Tan et al, 2011). A crucial role for CD8+ T 
cells is demonstrated in patients with Transporter antigen peptide (TAP) deficiency. 
These patients are unable to make CD8+ T lymphocytes and suffer from severe 
recurrent infections often leading to bronchiectasis (Zimmer et al, 2005). Human 
immunodeficiency syndrome (HIV) patients also suffer recurrent infections and may 
develop bronchiectasis (Bard et al, 1998). A key role for CD4+ T cells was suggested 
by a study by Boyton et al who demonstrated an increased prevalence of the HLA-
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DR1,DQ5 haplotype in bronchiectasis patients compared to control subjects (Boyton 
et al, 2006). The same group also identified a role for natural killer cells in 
susceptibility to bronchiectasis (Boyton et al, 2008). 
 
1.1.17 Eosinophils 
Little is known about the role of eosinophils in bronchiectasis, although some 
patients have been found to have high levels of eosinophils in sputum (Ip et al, 
2003). Ip et al found high levels of sputum eosinophils to be associated with a lower 
FEV1 (Ip et al, 1993). There is an apparent association between asthma and 
bronchiectasis that requires further study (Takemura et al, 2004). Increased serum 
levels of eosinophil cationic protein have been demonstrated in the serum of patients 
with bronchiectasis, although the clinical significance of this is unclear (Kroegel et 
al, 1998). 
 
1.1.18 Epithelial cells 
Bronchial epithelial cells serve multiple functions in innate immunity, providing a 
physical barrier to invasion, clearing micro-organisms and particulates through 
mucociliary function and participating in neutrophil recruitment through secretion of 
pro-inflammatory cytokines and adhesion of leukocytes (Devalia et al, 1993). The 
critical importance of the mucociliary escalator in airway defence is demonstrated in 
ciliary disorders such as primary ciliary dyskinesia which are associated with the 
early development of bronchiectasis (Noone et al, 2004). Nuclear medicine studies 
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have shown markedly delayed and disordered clearance of a radioactive aerosol in 
bronchiectatic regions of lung with normal clearance from the contralateral healthy 
regions of lung even in patients with bronchiectasis that is not due to a primary 
ciliary disorder (Isawa et al, 1990). Airway epithelium is covered by a thin film of 
liquid referred to as the airway surface liquid (ASL) (Matsui et al, 1998). This is 
separated into two compartments, the mucous layer and the periciliary layer. The 
periciliary layer is designed to facilitate ciliary function while the mucous layer traps 
particulates and microorganisms for clearance. Chloride and Sodium ion transport is 
tightly regulated to maintain ASL hydration and efficient mucociliary clearance 
(Sermet-Gaudelus et al, 2011). ASL homeostasis is maintained through the action of 
the amiloride-sensitive epithelial sodium channel (ENaC) and the cystic fibrosis 
transmembrane conductance regulator (CFTR) (Stutts, 1995). Dysfunction of the 
CFTR due to autosomal recessive mutations in the CFTR gene cause the clinical 
disorder of cystic fibrosis (Riordan et al, 1989). The mechanism by which CFTR 
dysfunction disrupts ASL homeostasis has been the subject of intense debate but is 
thought to be the result of ASL dehydration (Matsui et al, 1998). Active apical 
sodium reabsorption through ENaC occurs excessively due to a failure of tonic 
inhibition by CFTR (Knowles et al, 2002). This causes ASL dehydration which 
would normal be corrected by a switch from net NaCl absorption to secretion by 
chloride secretion through apical chloride channels (Mall et al, 2010). CF airway 
epithelia are unable to enhance chloride transport and therefore are unable to 
rehydrate depleted ASL (Caldwell et al, 2002). Loss of ASL effects both the 
periciliary layer and mucus layer leading to both ciliary dysfunction and vicious 
mucus plugs which are difficult to clear. This impairment of mucociliary clearance 
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leading to the clinical syndrome of CF. The detailed mechanisms of this process 
relevant to CF have been previously reviewed (Boucher et al, 2007). 
Although the above focusses on cystic fibrosis, where the majority of this research 
has taken place, this is of great relevance to non-CF bronchiectasis. It has been 
shown that 30-50% of patients with bronchiectasis are heterozygous for mutations in 
the CFTR gene (Dumur et al, 1990, Bienvenu et al 2010), much more frequent than 
would be expected in the general population. The presence of CFTR mutations was 
associated with an increased frequency of P.  aeruginosa colonisation in one study, 
as was evidence of epithelial dysfunction measured by nasal potential difference 
(Bienvenu et al, 2010). In addition, channelopathies such as variants in ENaC alone 
or in combination with CFTR mutations have been reported to be associated with 
diffuse bronchiectasis (Sermet-Gaudelus et al, 2011). 
As mentioned above, epithelial cells play an important role in the recruitment of 
neutrophils to sites of inflammation. Airway epithelium expresses ICAM-1 in 
response to bacterial challenge, leading to increased adherence of leukocytes. This 
enhances phagocytic functions and promotes increased inflammation (Humlicek et 
al, 2004). Airway secretions in bronchiectasis enhance the expression of ICAM-1 by 
bronchial epithelial cells, an effect that will promote neutrophil recruitment (Chan et 
al, 2008). ICAM-1 is also the receptor for cellular entry of rhinovirus infections in 
humans (Staunton et al, 1989). It has been hypothesised that upregulation of 
epithelial ICAM-1 in chronic lung diseases will increase susceptibility to viral 
exacerbations. Rhinovirus is an important cause of COPD exacerbations (Malia et al, 
2011). The role of viruses in bronchiectasis exacerbations has not been established. 
Evidence suggests that pro-inflammatory responses are excessive in airway epithelial 
58 
 
cells from patients with bronchiectasis when exposed to a bacterial trigger (Hill et al, 
1998). Bronchial epithelial cells produce endothelin-1 which has been shown to 
promote neutrophil adhesion to endothelial cells, neutrophil recruitment to the airway 
and release of elatase (Zheng et al, 2000).  There is limited additional clinical data 
regarding the role of epithelial cells in bronchiectasis and further studies are needed. 
HMG co-A reductase inhibitors (statins) have multiple pleiotropic properties beyond 
their cholesterol lowering effects (Chalmers et al, 2010), and two randomised 
controlled trials of statins in bronchiectasis are currently recruiting. Among their 
potential effects, statins inhibit release from bronchial epithelial cells of IL-8, IL-6, 
granulocyte colony stimulating factor (GM-CSF) and VEGF in response to IL-17, 
and suppress matrix metalloproteinase, IL-6 and GM-CSF release in response to 
TGF-beta (Murphy et al, 2008). 
 
1.1.19 Anti-inflammatory mechanisms in the airways 
While much of the above has focussed on the pro-inflammatory responses of 
inflammatory cells and epithelial cells in the bronchiectasis airway, there is also a 
simultaneous couter-regulatory anti-inflammatory response which limits 
inflammation induced damage and attempts to restore homeostasis. The active 
process of resolving inflammation is termed catabasis and is driven by the action of 
anti-inflammatory cytokines, pro-resolution lipid mediators and by apoptosis and 
clearance of inflammatory cells. 
There has been a great deal of attention around the role of the pro-resolution lipid 
mediators resolvins, protectins and lipoxins all of which have been shown to have 
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pro-resolution effects in models of acute lung inflammation. Among the specialised 
pro-resolution effects of these mediators they can promote cessation of neutrophil 
infiltration, reduced chemokine and cytokine production and stimulation of 
efferocytosis and clearance of bacteria (Serhan and Chiang 2013).   
Macrophages are critical to the suppression of lung inflammation and are the main 
orchestrators of this response. Interleukin-10 and TGF-β represent anti-inflammatory 
cytokines that can suppress the production of pro-inflammatory mediators 
(Raychaudhuri et al. 2000, Pittet et al 2001). Release of IL-1 receptor antagonist by 
macrophages prevents the pro-inflammatory effects of IL-1β and also downregulates 
neutrophil chemoattractants and the epithelial adhesion molecular ICAM-1 (Herold 
et al 2011). Macrophage derived matrix metalloproteinase 12 cleaves CXC 
chemokines impairing their function and reducing neutrophil recruitment 
(McQuibban et al 2002). Macrophages produce a range of mediators that promote 
neutrophil apoptosis including TNF-related apoptosis inducing ligand (TRAIL) 
(Herold et al 2008). Phagocytosis of apoptotic cells by macrophages induces an anti-
inflammatory phenotype in macrophages in contrast to phagocytosis of necrotic cells 
which provokes pro-inflammatory cytokine release (Voll et al 1997).  
Therefore the resolution of established inflammation is an active process co-
ordinated by macrophages and a range of mediators. Unfortunately, there is an 






1.1.20 Immunoglobulin, complement and antimicrobial peptides 
All primary antibody deficiency syndromes have been associated with 
bronchiectasis, due to reduced or absent levels of one of more immunoglobulin class 
or subset. Most of these disorders, such as common variable immunodeficiency 
(CVID) and X-linked agammaglobulinaemia, are diagnosed in childhood but rare 
cases are identified in adulthood (Pasteur et al, 2010). Acquired immunoglobulin 
deficiencies associated with haematological malignancy can cause bronchiectasis. 
Cohort studies have found a limited role of IgG subclass deficiencies or antibody 
deficiencies in general among unselected adult cohorts with bronchiectasis (Hill et al, 
1998). Failure to produce specific antibody responses to organisms such as 
H.influenzae and S.pneumoniae can be demonstrated after vaccination and may occur 
in patients with normal total IgG levels (Stead et al, 2002).  
An unresolved paradox in cystic fibrosis and bronchiectasis is the failure to 
effectively clear bacteria such as P.aeruginosa from the airway despite high levels of 
detectable antibodies against these pathogens. This occurs in part due to the ability of 
organisms to resist antibody binding and subsequent complement activation through 
biofilm formation and virulence factors. Immunoglobulin is also directly fragmented 
in the airway by neutrophil proteases leading failed opsonisation (Fick et al, 1984).
 
Additional innate defence mechanisms in the lung include lactoferrin, lysozyme, 
defensins, complement components, cathelicidins, surfactant proteins and other 
collectins. It has been suggested that abnormal salt concentrations in the airway of 
patients with cystic fibrosis impair the function of defensins, cathelicidin and others 
(Goldman et al, 1997, Smith et al, 1996), although this hypothesis is controversial 
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and the ionic conditions in the non-CF bronchiectasis have not been described. 
Mannose binding lectin deficiency has been described as a predisposing factor for 
bronchiectasis in patients with CVID (Gregersen et al, 2010, Fevang et al, 2005), and 
predispose to earlier infection with Pseudomonas aeruginosa, worse lung function 
and earlier death in adults with cystic fibrosis (Garred et al 1999, Chalmers et al, 
2011). A small study of a related molecule, L-ficolin (ficolin-2), found a higher 
incidence of relative L-ficolin deficiency in bronchiectasis patients compared to 
controls (Kilpatrick et al, 2009). These pattern recognition molecules of the lectin 
pathway of complement are the major focus of this thesis and are described in detail 




1.2 The lectin pathway of complement and mannose binding lectin 
Mannose binding lectin (also called mannan binding lectin, MBL) is a serum protein 
produced by the liver and encoded by the MBL2 gene on chromosome 10 (Kilpatrick, 
2003). It was the first molecule described as being able to activate the lectin pathway 
of complement and is also the most extensively studied. This section of the 
introduction therefore focusses on mannose binding lectin and specifically its 
relationship to cystic fibrosis.  
 
1.2.1 Mannose binding lectin 
Disease association studies (Kilpatrick, 2002) and experimental work in murine 
models (Shi et al, 2004; Molle-Kristensen et al, 2006) in vivo suggest a crucial role 
for MBL in innate immune responses to micro-organisms (Neth et al, 2000; Molle-
Kristensen et al, 2006). MBL is a pattern recognition receptor that distinguishes self 
from non-self by binding glycoconjugates containing mannose, fucose or N-
acetylglucosamine that are present on a wide variety of bacteria, viruses and fungi 
(Molle-Kristensen et al, 2006). Upon binding, MBL may activate the lectin pathway 
of complement (figure 1.9) via MBL associated serine protease 2 (MASP-2) leading 
to complement activation, with subsequent opsonisation or direct lysis of the target 
(Wallis et al, 2010). MBL also interacts independently of MASPs with receptors on 
phagocytes, and stimulates phagocytosis by “bridging” between phagocytes and 








Figure 1.9 Complement activation pathways. The classical, lectin and alternative 
pathways are shown. The classical pathway is triggered by activation of the C1-
complex on binding to immunoglobulin/antigen complexes. The lectin pathway is 
antibody independent and is triggered by binding of mannose binding lectin (MBL) 
or the ficolins to carbohydrates on the surface of microorganisms. The alternative 
pathway is triggered by spontaneous C3 hydrolysis independent of pathogen binding. 
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C3 is subsequently bound to complement factor B (B) in the presence of complement 
factor D (D) to form the alternative pathway C3 convertase. Each pathway 
progresses through the same route from this point to the formation of the membrane 
attack complex. 
The concentration and activity of serum MBL is genetically determined to a major 
extent. Three single nucleotide polymorphisms in exon 1 of the MBL2 structural gene 
(at codons 52, 54 and 57, referred to as the D, B and C alleles, and collectively 
designated “O”) have an additive effect on serum MBL levels. The normal or wild 
type codons at those loci are termed “A”. In addition, three variants in the promoter 
region of MBL2 can influence serum levels, with the X/Y dimorphism (low and high 
respectively) having a marked effect. The X polymorphism at position -221 has a 
dominant negative effect on serum MBL concentrations, leading to reduced levels 
similar to the structural polymorphisms. As a consequence an individual carrying the 
X promoter polymorphism and the wild type structural allele has similar MBL serum 
levels to individuals carrying the structural variant alleles.  
 There is strong linkage disequilibrium between the promoter and structural gene 
variants. Consequently, only seven haplotypes (out of a possible 64) are commonly 
found combining to form twenty-eight genotypes (Garred et al, 2009). In disease 
association studies, these genotypes are usually grouped into assumed low (YO/YO 
and YO/XA), medium (YA/YO and XA/XA) and high (YA/YA and YA/XA) 
conferring categories (Wallis and Lynch, 2007). Most, but not all, individuals with 
A/A genotypes have serum MBL > 600 ng/ml and those with O/O genotypes 
generally have serum MBL < 200 ng/ml (Swierzko et al, 2009). The A/O groups, 
however, are highly heterogeneous with respect to serum MBL values, despite 
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average values being reported at approximately 400 ng/ml and perhaps a majority 
having concentrations < 600 ng/ml.  
MBL deficiency or insufficiency is an imprecise concept with cut-off values used in 
the literature ranging from <100 to <1000 ng/ml serum MBL. Similarly, the A/A 
genotypes are sometimes compared with O/O or (O/O + O/XA), but at times both the 
homozygous and heterozygous (O/O + A/O) genotypes are regarded as insufficient. 
Some studies use both genotype grouping and serum MBL values to compare 
patients with healthy controls, but usually either one or the other is analysed on its 
own.   
The MBL2 gene products form a basic subunit consisting of a collagen-like triple 
helix with 3 globular heads. The basic subunit is capable of multimer formation up to 
hexamers. Only the higher multimers (trimers and above) bind to glycoconjugates 




Figure 1.10. Structure of MBL. A representation of the single gene product, triplet 
subunit and MBL multimer is shown. Only the higher multimers are able to bind to 
glycoconjugates and activate the lectin pathway of complement. The variant alleles 
(B, C and D) result in fewer high order multimers and therefore functional MBL 







The gravimetric values used for serum MBL are based on the multimeric protein 
from A/A homozygotes; the effect of variant alleles of the MBL2 gene is to impair 
multimer formation from the basic subunits. The exon 1 variants B and C lead to 
disruption of the Gly-X-Y repeats, in turn leading to altered interchain disulfide 
bonding in the N-terminal cross-linking region. The D variant leads to aberrant 
disulphide bond formation resulting from a substitution of a cysteine for an arginine 
(Wallis and Cheng, 1999).  
 
1.2.2 Cystic fibrosis and MBL 
Cystic fibrosis (CF) is a chronic, multisystem disease arising from mutations in the 
gene encoding the cystic fibrosis transmembrane regulator (CFTR). Over 1000 
mutations in the CFTR gene are recognised but the ∂F508 mutation accounts for 
approximately 70% of cases in Caucasian populations (Andersen et al, 1938; Riordan 
et al, 1989).
 
The phenotypic defect in CF is in epithelial chloride transport and is responsible for 
abnormally thick mucus production manifesting itself as pancreatic and pulmonary 
insufficiency. Progressive lung disease is the major cause of morbidity and mortality. 
Airway damage leads to severe bronchiectasis (permanent dilation of the airways 
leading to fluid filled “cysts”) and chronic colonisation of the airway with bacteria. 
Colonisation with Pseudomonas aeruginosa, S. aureus, Burkholderia cepecia 
complex and other opportunistic pathogens leads to recurrent pulmonary 
exacerbations, airway inflammation and progressive loss of lung function (Zemanick 




There are, however, large variations in the progression of pulmonary disease in CF 
that are not accounted for by CFTR genotype. Consequently, it has been postulated 
that other “modifier genes” may account for the variable phenotype observed in CF 
(Collaco and Cutting, 2008).
 
A potential role for MBL as a modifier of severity in cystic fibrosis is suggested by 
the finding that MBL binds P. aeruginosa, S. aureus and Burkholderia cepecia 
complex along with other clinically relevant bacteria (Neth et al, 2000; Molle-
Kristensen et al, 2006). MBL deficient mice are susceptible to more severe infections 
with P. aeruginosa (Molle-Kristensen et al, 2006) and S. aureus (Shi et al, 2004) 
than wild-type animals. Furthermore, although MBL is a serum protein, it 
accumulates in the lung during acute inflammation in cystic fibrosis in quantities 
sufficient to promote phagocytosis and cause complement activation (Fidler et al, 
2009; Reading et al, 1997). MBL replacement therapy has been developed and has 
been suggested as a new therapeutic avenue for a disease with few effective 
treatments (Garred et al, 2002).
 
Studies of MBL as a disease modifier in cystic fibrosis have given inconsistent 
results. The first two studies to examine this topic (Garred et al, 1999; Gabolde et al, 
1999) were in agreement that impaired lung function was associated with 
homozygosity for variant alleles (O/O). Further, Garred et al (1999) found a 
relationship between MBL insufficient alleles and earlier age of acquisition of P. 
aeruginosa, more frequent colonisation with B. cepacia and earlier age at death or 
lung transplantation. Although the relationship with reduced lung function was 
confirmed and extended to A/O heterozygotes in some studies (Yarden et al, 2004; 
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Trevisiol et al, 2005), it was not confirmed in others (Carlsson et al, 2005; Drumm et 
al, 2005).  
Davies et al (2004) investigated age non-overlapping adult and paediatric groups and 
found that adults homozygous for variant alleles had worse lung function than 
patients with wild-type alleles. This relationship was not evident in adult 
heterozygotes or in children. This apparent relationship with age was given some 
support from Muhlebach et al (2006) who found that low (<200 ng/ml) serum MBL 
was linked to better lung function in patients under 15 years of age but poorer lung 
function in adult patients. Muhlebach et al suggested that low circulating MBL 
concentrations accelerate the age-related decline in lung function and that future 
studies should address that aspect carefully. This was convincingly done by 
Dorfmann et al (2008) in a large series, showing that MBL insufficiency (YO/YO 
and YO/XA genotypes) was associated with a more rapid decline in pulmonary 
function, especially in patients who also had high-producing genotypes of 
transforming growth factor β1.   
Several other recent MBL genotyping studies are consistent with some aspects of 
previous studies. In agreement with Muhlebach et al (2006) and Davies et al (2004), 
Olesen et al (2006) found that lung function was actually better in patients (mostly 
children) with insufficient MBL2 genotypes. Choi et al (2006) reported that variant 
alleles were associated with poor lung function in adult patients.  
Although lung function impairment is the outcome most frequently studied with 
regard to MBL and disease severity, microbiology outcomes have also been 
extensively studied. Following the study by Garred et al (1999), the relationship with 
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earlier acquisition of P.  aeruginosa was confirmed by Trevisiol et al (2005). 
Subsequently a number of studies examined the frequency of colonisation with 
P.aeruginosa in MBL insufficient vs MBL sufficient groups- the majority of these 
studies found no association with MBL insufficiency (including Buanawuti et al, 
(2007), Davies et al, (2004), Olesen et al (2006) and Trevisiol et al (2005)). Carlsson 
et al (2005) even found that P.aeruginosa was significantly less frequent in MBL 
insufficient individuals. P.aeruginosa colonisation is highly age dependent and the 
majority of cystic fibrosis patients become colonised over time. Age at acquisition is 
a potentially more useful outcome as earlier age at acquisition correlates with poor 
outcome. This was subsequently investigated in two large series by Dorfman et al 
(2008) and McDougal et al (2010), both of which confirmed the previous observation 
of earlier acquisition of P.aeruginosa in MBL, insufficient individuals. 
Colonisation with B. cepacia complex also correlates with poor outcome in CF, but 
is less frequent. Following the study by Garred et al (2009), five other studies 
reported the frequency of B.cepacia colonisation (Davies et al (2004), Olesen et al 
(2006), McDougal et al (2010), Buranawuti et al (2007) and Carlsson et al (2005)) 
but none found a statistically significant association.  
Studies of survival have also given conflicting results. In support of the observation 
by Garred et al (2009), Buranawuti et al (2007) found O/O genotypes (compared 
with A/A or A/O) to be associated with non-survival in adults. However, Carlsson et 
al (2005), Drumm et al (2005) and, most recently, McDougal et al (2010) found no 
significant association with survival or lung transplantation.   
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The discussion above focuses entirely on the pulmonary manifestations of cystic 
fibrosis. Three studies have also investigated the role of MBL in CF liver disease. 
The study by Gabolde et al (2001) found a strong association between MBL 
insufficient genotypes and liver disease, but this was not confirmed by subsequent 
studies by Tomaiuolo et al (2009) and Bartlett et al (2009). 
Therefore, the literature on MBL as a disease modifier in cystic fibrosis has given 
conflicting results.  
Consequently, we investigated the role of MBL insufficiency on several clinically 
important markers of disease severity by performing a systematic review and meta-
analysis of the gene association studies. 
The methodology of this systematic review has been described in the associated 
publication (Chalmers et al, 2011). The systematic review yielded 42 titles from 
which 19 were immediately excluded as irrelevant following title and abstract 
review. There were a further 7 exclusions from the 23 studies examined in depth. 
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Table 1.3 Studies of Mannose binding lectin in cystic fibrosis. Abbreviations: 
MBL=mannose binding lectin, SD=standard devation, SE= standard error, 
IV=intravenous
, 
FEV1= forced expiratory volume in 1 second. DLCO=Diffusing 
capacity of carbon monoxide.  
 
1.2.3 Mannose binding lectin and bacterial colonisation in cystic fibrosis 
P. aeruginosa and B. cepacia are opportunistic pathogens. The presence of these 
organisms in the sputum of patients with cystic fibrosis is associated with poor 
outcome and deterioration in lung function (Ledson et al, 2002).  
 
Pseudomonas aeruginosa 
Seven studies reported the frequency of P. aeruginosa between MBL insufficient and 
sufficient groups. Reporting of data was inconsistent, with 2 studies combining the 
A/O and O/O groups into a single cohort and one study combining the A/A and A/O 
groups into a single cohort. This limited our ability to perform a pooled analysis. The 
acquisition of P.  aeruginosa is age dependent and insufficient data was available to 
account for this in the analysis. The limited analysis did not suggest that the O/O 
genotype was associated with P. aeruginosa colonisation (OR 1.42; 95% CI 0.43 to 




Age at first acquisition of pseudomonas aeruginosa 
Age of first acquisition is potentially a more useful outcome since earlier acquisition 
of P. aeruginosa is associated with poor outcome (Emerson et al, 2002). Data 
reporting for this outcome was inconsistent. Garred et al (1999) and Trevisiol et al 
(2005) combined the O/O and A/O groups into a single cohort while Dorfman et al 
(2008) and McDougal et al (2010) considered the O/O or XA/O group separately. 
Defining MBL insufficiency as reported in the papers (O/O or A/O for Garred et al 
(1999) and Trevisiol et al (2005), O/O or XA/O for Dorfman et al (2008) and 
McDougal et al (2010)) showed that all 4 studies indicated that MBL insufficiency 
was associated with earlier acquisition of P. aeruginosa: mean difference, 2.83 years; 
95% CI 1.63 to 4.03 years, p<0.0001 (figure 1.6). However the results show 
significant heterogeneity (I
2
=73%) that may be due to the different definitions of 
insufficiency used in each study. 
 
Chronic colonisation with Burkholderia cepacia 
Seven studies reported the frequency of colonisation with B. cepacia complex. The 
analysis includes six separate cohorts as Davies et al (2004) reported paediatric and 
adult cohorts separately. Only one individual study found a statistically significant 
association with B.cepacea colonisation and MBL insufficiency (Garred et al, 1999). 
When comparing MBL insufficient (O/O) patients with MBL sufficient patients, 
there was a significant association with B.cepacia colonisation: OR 3.46; 95% CI, 
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1.14-10.52,p=0.03 (Figure 1.11). There were, however, only nine patients with 
B.cepacea colonisation across the seven studies in the O/O group. Combining the 
O/O and A/O group into a single cohort, we found no significant association between 
variant MBL alleles and B.cepacea colonisation (OR 1.26 95% CI 0.79 to 
2.01,p=0.3).  
Figure 1.11. Age at acquisition of Pseudomonas aeruginosa and chronic 
colonisation with Burkholderia cepacia. Abbreviations, IV= inverse variance, M-





1.2.4 MBL insufficiency and lung function in cystic fibrosis 
Forced Expiratory Volume in 1 second 
FEV1 is an important marker of disease severity in cystic fibrosis. In total, nine 
studies contained valid data for FEV1 as an outcome. Seven studies presented data 
for the exon 1 mutations (A/O) while one study presented a combination of exon 1 
and the promoter -221 X/Y polymorphisms. One study used serum levels <200 
ng/ml. In two studies, the adult and paediatric cohorts were presented separately.  
The initial pooled analysis (figure 4A) suggested no significant effect of MBL 
insufficiency (defined as O/O or XA/O or a serum level <200 ng/ml) on reduced 
FEV1 % predicted (mean difference -7.10% 95% CI -15.59 to 1.38, p=0.1). There 
was significant heterogeneity in the analysis, however. Visual inspection of the forest 
plots revealed the majority of the heterogeneity was due to three studies of 
exclusively paediatric cohorts (Dorfman et al (2008), Davies et al (2004) and 
Muhlebach et al (2006)) and the study by Olesen et al (2006), in which the median 
age was 14 years. The MBL insufficient group in the study by McDougal et al (2010) 
was significantly younger than the control group and hence was excluded.  
 
FEV1:  subanalyses in predominantly adult cohorts 
Excluding the above studies left six cohorts containing a majority of adult patients.  
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This sub-analysis revealed a correlation between MBL insufficiency and reduced 
FEV1 % predicted: mean difference, -19.65; 95% CI -10.83 to -28.48, p<0.0001, 
with non-significant heterogeneity (p=0.10) (figure 1.7).  
The intermediate expressing MBL genotypes (A/O or XA/XA) were next compared 
to the wild-type or “high” expressing MBL genotypes. Seven studies contained 
sufficient data for this analysis. In the pooled analysis there was no statistically 
significant relationship between intermediate expressing genotypes and FEV1: mean 
difference, -4.31; -9.25 to +0.64, p=0.09, with no significant heterogeneity (p=0.5). 
Only three “adult” studies contained sufficient data to make a meaningful 
comparison between the O/O group and the intermediate expressing A/O group. 
These 3 studies, however, suggested a significantly lower FEV1 % predicted in O/O 





FEV1 subanalysis in predominantly paediatric cohorts 
The five predominantly paediatric cohorts pooled together showed no significant 





Forced vital capacity 
Four studies contained satisfactory data for analysis of forced vital capacity. As 
before, there was a marked difference between the predominantly paediatric and the 
predominantly adult cohorts (figure 1.12). With the paediatric cohorts excluded, 
there was a significant association between MBL insufficiency (as defined above) 






Figure 1.12. MBL insufficiency and lung function in cystic fibrosis.  The top graph 
shows the effect of MBL deficiency on lung function across all studies that reported 
FEV1 data. The bottom panel shows the sub-analysis in adult cohorts. Abbreviations 







Considering the impact of age on lung function, it is known that lung function 
declines with time in both children and adults with cystic fibrosis. This is potentially 
a major confounder if there are significant differences in age between MBL 
sufficient and insufficient groups. The studies included in this analysis variously 
attempted to adjust for the effects of age. Muhlebach et al (2006) and Davies et al 
(2004) divided their studies into adult and paediatric cohorts and there were no 
significant differences in age between the insufficient and sufficient adult cohorts. 
Garred et al (1999) similarly showed no significant differences in age between 
groups. The patients in the study by Gabolde et al (1999) were age matched. We 
excluded data from the study by McDougal et al (2010) as the MBL insufficient 
group was significantly younger than the control group, and therefore would be 
expected to have better lung function. It therefore seems unlikely that the differences 
observed in this analysis are due to imbalances in age between the insufficient and 
sufficient cohorts. 
 
1.2.5 Death or end stage lung disease requiring transplantation 
In cystic fibrosis studies, the end-point of death or transplantation is frequently 
combined as “end-stage cystic fibrosis”. Seven studies reported data for these end-
points. The methodology for assessing survival/end stage lung disease varied in each 
study. Garred et al (1999) followed their cohort for 10 years from 1989 to 1999. 
Similarly the study by McDougal et al (2010) was derived from the US cystic 
fibrosis twin and sibling study and provided follow-up data over several years. 
Buranawuti et al (2007) selected 38 samples from non-surviving adults patients for 
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analysis. Carlson et al (2005) and Muhlebach et al (2006) included patients attending 
a CF clinic who had undergone lung transplantation. Olesen et al (2006) followed up 
patients for 2-3 years following CF genotyping and recorded death or requirement 
for lung transplantation. Follow-up periods were unclear in the other studies.  
In the analysis, the low expressing MBL group (O/O or XA/O) was compared to the 
wild type (A/A or high expressing groups). This analysis consisted of four studies 
and just failed to reach statistical significance (OR 3.96; 95% CI, 0.97-16.24, 
p=0.06). Combining the intermediate and high expressing MBL genotypes into a 
single group, as was done in seven studies, revealed a significant association of low 
expressing MBL genotypes with mortality or lung transplantation: OR 2.36 (1.06-
5.22, p=0.03) without significant heterogeneity (p=0.14) (figure 1.13). This 
conclusion is, however, based on only 22 events in the MBL insufficient group 
across seven studies.  
 
 




1.2.6 MBL insufficient genotypes and chronic liver disease 
Data were available from four studies. Only two studies considered the X/Y 
promoter polymorphisms.  In the pooled analysis, O/O was not associated with 
presence of liver disease when compared to all other alleles (OR 2.65; 95% CI, 0.60 
to 11.78, p=0.2), or to the A/A genotype only (OR 2.29; 95% CI, 0.62 to 8.44, 
p=0.21) but these three studies included only 51 patients with the O/O genotype. 
Similarly, the XA/O or O/O genotypes combined did not increase the risk of liver 
disease (OR 1.20; 95% CI, 0.73 to 1.97, p=0.5). There was no significant 
heterogeneity in this analysis. 
Similarly, in the pooled analysis, intermediate expressing MBL genotypes were not 
associated with liver disease compared to wild-type: OR 0.95 (0.68 to 1.35), p=0.8, 
with no significant heterogeneity (I
2
=0%). Pooling the intermediate and low 
expressing MBL genotypes also produced no significant effect: OR 1.00 (0.72 to 




There were insufficient data regarding other outcomes identified in the cystic fibrosis 
literature, including decline in FEV1 over time; pulmonary exacerbation rates; health 
related quality of life; measures of airway inflammation; radiographic severity by 
high resolution computed tomography; or growth during childhood. Investigators 
may wish to consider these in future studies. 
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1.2.7 Limitations of the analysis 
Meta-analyses are entirely dependent on the quality of the source studies.  Although 
we contacted each author to request additional (including unpublished) data, and 
assessed statistically for publication bias, it is possible, particularly in the smaller 
studies, that authors selectively report positive findings and do not report negative 
associations. We encountered heterogeneity in the alleles genotyped, as some studies 
only examined the exon 1 mutations while others also studied the promoter variants. 
We encountered heterogeneity in methodology, such as the duration of follow-up for 
survival studies that significantly limit these analyses. In some cases, lung function 
data were not fully reported and had to be obtained from authors or converted to 
allow meta-analysis. This introduces a degree of error and bias into the assessment of 
lung function. Some studies were not limited to patients with the ∂F508 mutation. 
Other gene modifiers appear to influence the CF phenotype. Along with the CFTR 
genotype, TGFβ and MASP2 have been identified as severity modifiers and appear to 
interact with MBL2 in CF patients. This cannot be adjusted for in this analysis and 
requires further study.  
 
1.2.8 MBL replacement therapy 
If mannose binding lectin insufficiency is associated with a poorer prognosis in 
patients with cystic fibrosis, can replacement of mannose binding lectin by 
intravenous infusion be used to improve outcomes in these patients? 
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The safety and tolerability of intravenous MBL therapy has been assessed by 
Valdimarsson et al (2004) and Petersen et al (2006), using plasma-derived and 
recombinant MBL respectively. Both studies showed that administration of MBL 
could restore the ability to activate the lectin pathway of complement, and was well 
tolerated by patients. Frakking et al (2009) and Brouwer et al (2009) extended these 
observations to children with chemotherapy-induced neutropenia, a group of patients 
at higher risk of opportunistic infections. Twice weekly infusions of MBL in this 
patient group effectively restored the activity of the lectin pathway of complement. 
In addition, MBL replacement increased neutrophil phagocytosis of zymosan ex vivo. 
High doses of MBL were required to restore MBL pathway activity to normal levels 
in this patient cohort, but the treatments were well tolerated with no evidence of 
systemic complement activation. 
Although MBL replacement appears to be effective in restoring the MBL pathway in 
adults and children with MBL insufficiency, there is as yet no evidence from 
randomised clinical trials to show a beneficial effect in treatment or prevention of 
infectious disease. The only clinical evidence in support of mannose binding lectin 
replacement in cystic fibrosis comes from a case report (Garred et al, 2002). In this 
case, the authors administered purified mannose binding lectin to a patient with 
severe cystic fibrosis and P. aeruginosa infection. The infusions were well tolerated. 
Assessing the influence of MBL is impossible in an uncontrolled study but the 
authors report that the patient’s condition stabilised during treatment. On the basis of 
the available studies a controlled trial of MBL replacement therapy is cystic fibrosis 
may be justified.  
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Several factors limit enthusiasm for the potential of MBL replacement therapy in CF. 
First, the results of the present analysis suggest any benefit may be limited to the 
small proportion (approximately 10-15%) of patients with most severe (O/O, XA/O) 
insufficiency. Second, all studies so far have used intravenous infusions of MBL. In 
the Garred report, the patient received twice weekly infusions. Given that MBL 
replacement may be required long term, there are practical and economic 
considerations to treating patients indefinitely with intravenous infusions. The 
potential cost of MBL replacement therapy would require careful consideration 
relative to the potential benefits.  
On the other hand, a few patients seem to experience long-term benefits from short 
courses of MBL therapy (Valdimarsson, 2003).  
 
1.2.9 Conclusions 
The available evidence suggests that the MBL2 gene is a major modifier of lung 
disease in cystic fibrosis. MBL deficiency is associated with reduced lung function, 
earlier infection with P. aeruginosa, colonisation with B. cepacia and a higher rate of 
end-stage CF. This justifies an in-depth study of the lectin pathway of complement in 
non-CF bronchiectasis to determine if MBL or other lectin pathway components are 




1.3 Ficolins and Ficolin-2 
1.3.1 Discovery of ficolins 
Ficolins were initially described as transforming growth factor β-binding proteins 
present in porcine uterus, characterised by the possession of both fibrinogen-related 
and collagen-like domains (Ichijo et al, 1991).  Subsequently, a molecule designated 
P35 was described capable of binding to N-acetylglucosamine and function as an 
opsonin for phagocytosis of Salmonella by neutrophils (Matsushita et al 1996). This 
initial study was the first indication that ficolins may function as part of the innate 
immune response to pathogens. A very similar molecule named L (for liver)-ficolin 
was independently purified from human plasma on GlcNAc-Sepharose (Le et al, 
1997). Both resembled two other previously discovered plasma proteins: EBP-37, 
which bound elastin (Harumiya et al, 1995), and hucolin, which bound a 
corticosteroid derivative (Edgar, 1996).   
It soon became clear that authors were identifying the same molecule, a 35kDa 
innate immune protein composed of a fibrinogen-like domain combined with a 
collagen-like domain that is now designated ficolin-2 (or L-ficolin). Ficolin-2 is 
structurally and functionally related to mannose binding lectin and complement 
component C1q, but the presence of the fibrinogen-like domain distinguishes ficolins 
from the collectins, which by definition are composed of a collagen-like domain with 
a C-type lectin domain.  
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1.3.2 Human ficolins 
Three human ficolins have been identified, all of which circulate in serum: Ficolin-1 
(Monocyte ficolin or M-ficolin); Ficolin-2 (Liver ficolin or L-ficolin) and Ficolin-3 
(Hakata antigen or H-ficolin). Ficolins 1 and 2 have 80% homology at amino-acid 
level while ficolin-3 has only approximately 50% homology with the other ficolins 
(Matsushita, 2012). Ficolin-1 is predominantly found in monocytes and granulocytes, 
while ficolin-2 is only expressed in the liver and circulates in serum (Honore et al, 
2008). Ficolin-3 was originally identified and defined by autoantibodies present in a 
small group of patients with systemic lupus erythematosus (Sugimoto et al, 1998). 
Like ficolin-2, ficolin-3 is synthesised in the liver (secreted into bile as well as blood) 
but it is also synthesised in the lung where it is secreted into the alveolus and bronchi 
(Akaiwa et al, 1999). Ficolin-3 is present at the highest concentration of all of the 
lectin pathway components in serum and is also reported to be the most potent at 
activating complement (Hummelshoj et al, 2008). 
A comparison of the properties of the ficolins is summarised in Table 1. All three 
have the ability to activate the lectin pathway of complement, an activity known to be 
shared with just two collectins, mannan-binding lectin (MBL) and CL-L1 (Keshi et 
al, 2006, Hansen et al, 2010, Ma et al, 2004).  
All three ficolins share the ability to bind acetylated sugars like GlcNAc. Ficolin-2 
(like MBL) appears to be a major pattern recognition molecule in human plasma (Ma, 
2004). It has a uniquely complex set of binding sites, potentially conferring the ability 




 Ficolin-1 Ficolin-2 Ficolin-3 
Molecular size (subunit) 35K 35K 34K 
Molecular size (native) 900K 420K 610K 
Location Monocytes; lung; 
spleen 
liver; serum liver; bile; lung; serum 












LPS from Hafnia alvei 
Microbial specificity E. coli; S. aureus; S. 
agalactiae  
S. aureus; S. 
pneumoniae;  
S .typhimurium;  
E. coli;  
P. aeruginosa;  
M. bovis; G. lamblia; 





Complement activation Yes Yes Yes 
Opsonic activity Presumed Yes ? 
Collagenase sensitivity Yes Yes No 
 





1.3.3 Ficolins in other species. 
Mice possess two ficolins. Ficolin A is present in liver and serum and is said to be 
analogous to ficolin-2 in humans, while ficolin B is expressed in bone marrow and 
spleen and is associated with macrophages similar to human ficolin-1 (Fujimori et al, 
1998, Ohashi and Erickson, 1998). The two murine ficolins have approximately 60% 
homology at amino-acid level. There is no homologue of ficolin-3 in mice and FCN3 
exists as a pseudogene containing several stop codons. (Endo, 2004) 
In pigs, ficolins also consist of two homologous molecules, designated ficolin-α and 
ficolin-β. Although first discovered in uterine tissue, porcine ficolin-α is more 
abundant in liver and blood where two isoforms, “little ficolin” (Mr~400 000) and 
“big ficolin” (Mr~800 000) were described (Ohashi and Erickson, 1997). Ficolin-β, 
with around 80% identity to ficolin-α, was found to be expressed mainly in 
neutrophils (Ohashi and Erickson, 1998, Fujimori et al, 1998). 
These findings have prompted the generalisation that ficolins can be classified into 
soluble serum ficolins and cell-bound ficolins whatever the species. This view is 
supported by a similar dichotomy in the toad, Xenopus laevis (Kakinuma et al, 2003).  
 
1.3.4. Structure of ficolins 
The primary structure of ficolin-2 is composed of 288 amino acids forming a gene 
product of apparent Mr 35 000 after glycosylation (Matsushita, 1996). A short N-
terminal region implicated in multimer formation is followed by a series of 19 (Gly-
X-Y) repeats forming the collagen-like region or domain. This is attached via a short 
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linking sequence to a large globular domain with a distinctive fold, homologous to 
the C-terminal domains found in fibrinogen chains. This fibrinogen-like domain 
occurs in several apparently unrelated proteins, including tenascins, the acetylated 
sugar-binding tachylectins from a horseshoe crab (Tachypleus tridentatus), and the 
sialic acid-binding lectin from the slug, Limax flavus (MacDonald and Kilpatrick, 
2007). 
The combination of fibrinogen-like domain and collagen-like region in ficolin-2 (and 
other ficolins) permits the gene product to form a basic subunit consisting of a triple 
helical tail and a trio of globular heads. This 3-dimensional structure is often likened 
to a bowl of tulips and resembles the shape of the complement component C1q and 
the collectin family, despite those other molecules not having primary sequence 
homology with ficolins or with each other. The triplet subunits can then associate to 
form higher multimers. The major form in plasma is believed to be a tetramer of 
subunits (12-mer) with an apparent Mr of approximately 400 000 (Ohashi and 
Erickson, 1998, MacDonald and Kilpatrick, 2007). 
Ficolin-2 uniquely possesses a complex set of binding sites constituting a recognition 
surface that can detect various acetylated structures and neutral sugars in the context 
of extended polysaccharides. This conclusion is based on studies of its trimeric 
recombinant recognition domains solved by X-ray crystallography (Garlatti et al, 
2007, Garlatti et al, 2010). There is an outer binding site (S1) close to the only 
calcium binding site. This could be considered the ancestral binding site, as it is 
homologous to that of the horseshoe crab tachylectin 5A as well as that found in 
human ficolin-1 and ficolin-3. Surprisingly, S1 is not responsible for recognition of 
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acetylated sugars, unlike its counterpart in tachylectin 5A. Instead, ficolin-2 
possesses three inner binding sites (S2, S3, S4) that are located on both sides of a 
cleft between the upper parts of the protomers. It is S3 that is mainly responsible for 
binding acetylated structures. It also binds 1,3-β-glucans with assistance from the 
minor site, S4. The innermost S2 has affinity for galactose. The ficolin-2 recognition 
groove with its contiguous subsites (S2-S4) is reminiscent of the peptidoglycan 
binding proteins of invertebrates (Garlatti, 2007). 
The ficolins, collectins and complement component C1q, all have a similar 3-
dimensional shape suited to function as multivalent recognition molecules with 
increased affinity for ligands achieved by multiple protein–oligosaccharide 
interactions. It is noteworthy that ficolin-2 possesses a semi-open structure 
intermediate between the compact assembly of C1q and the wide open arrangement 
of MBL, the latter of which has little interaction between the lectin domains and a 
buried surface 8% the size of that of C1q (Garlatti, 2007).  
The collagen-like region is responsible for the formation of the helical tails of the 
molecule and also for functional signalling. In particular, the lysine-57 residue is a 
key component of the binding site for MBL-associated serine proteases and also for 
calreticulin, a putative complement/collectin/ficolin receptor on phagocytes (Lacriox 






1.3.5 Biochemical specificity 
The complex arrangement of binding sites described allows ficolin-2 to bind a wide 
range of ligands. Ficolin-2 binds acetylated sugars and also to non-saccharide 
acetylated compounds (Krarup et al, 2004). Nevertheless, glycan array studies have 
established that ficolin-2 does not bind to most acetylated oligosaccharides found on 
mammalian glyco-conjugates (Krarup et al, 2008). Rather, ficolin-2 has complex 
recognition requirements, and binding probably requires the presence of two or more 
acetylated sugar groups presented in an appropriate conformation. In another glycan 
array study, ficolin-2 preferentially recognised disulphated N-acetyllactosamine and 
tri- and tetrasaccharides containing terminal galactose or N-acetylglucosamine, and 
binding was sensitive to the orientation of the bond between N-acetyllactosamine and 
the adjacent saccharide (Gout et al, 2010). 
Ficolin-2 is the major 1,3-β-glucan binding protein in human plasma (Ma et al, 2004) 
and can bind to lipoteichoic acid a major component of the Gram-positive bacterial 
cell wall (Lynch et al, 2004). Potentially, therefore, ficolin-2 could bind to a wide 
variety of fungi and Gram-positive bacteria. Ficolin-2 recognises and binds to the 
viral envelope glycoproteins (E1 and E2) of the hepatitis C virus and triggers the 
lectin pathway of complement by binding to a virally-infected human hepatoma cell 
line (Lui et al, 2009). 
Ficolin-2 also appears to bind human DNA, suggesting a mechanism for attaching to 
apoptotic or necrotic autologous cells. Clearance of apoptotic cells is a critical 
mechanism for the resolution of inflammation. Two reports support the view that 
ficolin-2 can opsonise autologous dead or dying cells and cellular debris (Jensen et 
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al, 2007, Kuraya et al, 2005) . Kuraya et al concluded that ficolin-2 binds to 
apoptotic cells and activates complement via the lectin pathway. Jensen et al, 
however, observed binding to necrotic but not apoptotic cells, and only at supra-
physiological concentrations of ≥20 μg/ml. High concentrations of ficolin-2 also 
promoted the uptake of necrotic Jurkat cells by monocyte-derived macrophages in a 
phagocytosis assay (Jensen et al, 2007) The importance of ficolin-2 to this clearance 
of apoptotic cells has not been established. It has already been mentioned that 
ficolin-2 can bind to a protein, elastin (Hariymiya, 1995) and a lipid (Edgar, 1996). 
Significantly, it can bind to the pentraxins, C-reactive protein (Zhang et al, 2009) and 
pentraxin 3 (PTX3) (Ma et al, 2009). Under inflammatory conditions, pentraxins 
appear to enhance complement activation via ficolin-2.  
 
1.3.6 Binding to micro-organisms  
Ficolin-2 has been found to bind to the Gram-negative bacteria, Salmonella 
typhimurium (Ra strain) (Matsushita, 1995), Escherichia coli and Gram-positive 
capsuled bacteria such as S. aureus and S. pneumoniae (Krarup et al, 2004, Krarup et 
al, 2005, Aoyagi et al, 2008). All interactions were partially sensitive to GlcNAc. 
Ficolin-2 binding to the intracellular bacterium Mycobacterium bovis has also been 
reported (Carroll, 2009). It also binds the opportunistic fungal pathogen, Aspergillus 
fumigatus (Ma et al, 2009). This last interaction can be partially inhibited by GlcNAc 
or Curdlan (a β-1,3-glucose polymer). The interaction with Aspergillus fumigatus is 
enhanced in the presence of pentraxin-3. Similar synergy was observed between 
ficolin-2 and C-reactive protein in response to P. aeruginosa (Zhang et al, 2009).  
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Binding of ficolin-2 to the protozoan causing Chagas’ disease, Trypanosoma cruzi, 
(Cestari et al, 2009), as well as to the intestinal protozoan, Giardia lamblia (Evans-
Osses et al, 2010), has been demonstrated. 
 
1.3.7 Complement activation 
As previously mentioned, ficolin-2 is one of the few molecules known to activate the 
lectin pathway of complement, along with mannose binding lectin, ficolin-1, ficolin-
3 and the collectin CL-11/CL-K1. (Matsushita et al, 2000) This arises after forming a 
complex with MBL-associated serine proteases (MASP)-1, -2 and -3, of which 
MASP-2 is crucial for complement activation. MASP-2 binding takes place at a site 
on the collagen-like region (Lacroix, 2009). Ficolin-2-MASP-2 interaction leads to 
activation of the latter, enabling it to cleave complement components C2 and C4 in a 
manner similar to the C1q,r,s complex of the classical pathway initiated by antigen-
antibody formation. The roles of MASP-1 and its alternatively spliced gene product 
MASP-3 are less clear, but evidence is accumulating that MASP-1 may link 
complement to the coagulation system (Presanis et al, 2004, Krarup et al, 2007, 
Krarup et al, 2008, Gulla et al, 2009) as well as collaborating with MASP-2 in the 
generation of the C3 convertase (Kocsis, 2010). MASP-3 is primarily found 
complexed to ficolin-3 and appears to regulate ficolin-3 mediated complement 
activation (Skjoedt et al, 2010). 
Unsurprisingly, ficolin-2 has been shown to possess opsonic activity by enhancing 
phagocytosis of Salmonella by human neutrophils (Matsushita, 1995). Although such 
opsonisation may be mediated by complement activation, it has also been suggested 
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that ficolin-2 can opsonise bacteria by binding calreticulin on phagocytes via its 
collagen-like domain (Lacroix, 2009). Ficolin-2 can co-operate with pentraxins to 
opsonise bacteria and initiate the lectin pathway, as mentioned earlier. 
 
1.3.8. Genetics 
The human ficolin-2 gene (FCN2) has been localised to chromosome 9 (9q34) 
(Endo, 1996). The ficolin-1 gene (FCN1) is similarly located on chromosome 9, 
while FCN3 is found on chromosome 1.  The ficolin-2 gene has eight exons (Figure 
1.9). The first exon encodes a signal sequence and the first nine N-terminal residues. 
Exons 2 and 3 encode a collagen-like region similar to that found in collectins. The 
fourth exon encodes a link or connecting region. Exons five to eight encode a domain 
similar in structure to that of the C-terminal portion of the human fibrinogen β and γ 
chains that is characterized by the conservation of 24 mainly hydrophobic amino acid 
residues. 
A large number of functionally important single nucleotide polymorphisms in the 
FCN2 gene have been described (Hummelshoj et al, 2005). Hummmelelshoj et al 
first described five polymorphisms in the promoter region and nine in the structural 
gene from a Danish population. Compatible results were reported by Herpers et al 
(Herpers et al, 2006), describing ten single nucleotide polymorphisms in 1888 Dutch 
blood donors. A later study compared five different ethnic groups; some ethnic-
specific polymorphisms were noted, but most were found in all populations 
(Hummelshoj, 2008).  
97 
 
The most intensively studied single nucleotide polymorphisms are the promoter 
polymorphisms rs3124952 (-986 G>A), rs3124953 (-602G>A), rs28969369 (-
64A>C) rs17514136 (-4A>G), and the exon 8 polymorphisms rs7851696 
(Ala258Ser) and rs17549193 (Thr236Met). A frame shift mutation at position +6442 
in exon 8 is theoretically capable of causing complete ficolin-2 deficiency, but 
homozygosity for this mutation has not been described. Indeed no example of 
complete ficolin-2 deficiency has yet been described. The single nucleotide 
polymorphisms implicated in influencing protein concentration in one or more 
studies are listed in Table 2. Although individual SNPs have a statistically significant 
impact on ficolin-2 serum levels at population level, they are not particularly useful 
for predicting individual ficolin-2 serum levels (Munthe-Fog et al, 2007). As yet, 
little data exists on whether non-genetic factors such as acute-phase responses 
influence circulating ficolin-2 levels.  It has also been reported that the two common 
SNPs in exon 8 cause changes in the fibrinogen binding domain, leading to altered 
binding to GlcNAc. The T236M SNP is associated with significantly reduce GlcNAc 




Fig.1.14. The human FCN2 gene. The position of the major single nucleotide 













rs3124952 promoter –986 A>G - 
rs3124953 promoter –602 G>A - 
rs3811140 promoter –557 A>G - 
rs28969369 promoter –64 A>C - 
rs17514136 promoter –4 A>G - 
rs17549193 exon 8  +6359 C>T Thr236Met 
rs7851696 exon 8  +6424 G>T Ala258Ser 
 





Considerable linkage disequilibrium exists between pairs of promoter and structural 
gene dimorphisms, complicating the investigation of the relationship between allele 
expression and protein concentration. The majority of SNP’s can be classified into 6 
functional haplotypes which strongly influence serum levels. Authors (Munthe-Fog, 
2007) have stratified serum ficolin-2 concentration according to those haplotypes as 









1.4 Ficolin-2 in health and disease 
1.4.1 Ficolin-2 in healthy subjects 
In healthy adult individuals, the distribution of serum ficolin-2 is Gaussian, so the 
mean and median are exactly the same. That value has generally been reported to be 
between 3 and 4 μg/ml (Kilpatrick, 2007) although more recently it has been 
determined at 5.4μg/ml (Munthe-Fog, 2007). Most normal values fall within the 
range 1000 to 6000 ng/ml, although occasionally much higher values are detected.  
One study has investigated serum ficolin-2 throughout life (Sallenbach, 2011). The 
highest values were found between 1 and 4 years of life (median 11300 ng/ml), then 
dropped during later childhood (4-16 years, median 8660 ng/ml) before reaching a 
stable adult level (median 3370) after 16 years of age.  
Although no absolute deficiency of ficolin-2 has yet been discovered, it seems 
possible that relative deficiency (“insufficiency”) defined by low serum ficolin-2 ± 
immunogenetics could contribute to disease susceptibility.  
 
1.4.2 Ficolin-2 in neonatal and perinatal infections 
Ficolin-2 insufficiency was associated with perinatal infections in preterm Polish 
babies (St Swierzko et al, 2009). In a cohort of over 1800 consecutive deliveries, the 
rate of perinatal infections in babies with cord blood ficolin-2 < 1000 ng/ml (the 
lowest 9%) was twice that of babies with higher concentrations (13.7% v. 7.7%; 
p<0.01). This relationship was not independent of gestational age and birthweight, 
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but suggests that ficolin-2 insufficiency could be one of several factors that 
contribute to the adverse consequences of prematurity and low birthweight. 
A further study, however, found no significant relationship between low cord blood 
ficolin-2 and sepsis in 47 premature infants (Schlapback et al, 2010). This was 
despite finding significant relationships between low ficolin-3 and Gram-positive 
sepsis and between low MBL and Gram-negative sepsis.  
 
1.4.3 Infections in adults 
Uraemic patients have an increased susceptibility to infection, and peritonitis is a 
common complication in patients on continuous ambulatory peritoneal dialysis 
(CAPD). The +6359 C>T variant in the FCN2 gene, causing a Thr ►Met alteration 
and a concomitant decrease in lectin activity, was found to be more frequent in 
CAPD patients with a history of staphylococcal peritonitis, compared with CAPD 
patients without such a history (Meijvis et al, 2011). In the former, exit site S. aureus 
was also more prevalent (Meijvis et al, 2011).    
A study of patients with neutropenic sepsis following haematological malignancy 
found no evidence of an effect from ficolin-2 (Kilpatrick et al, 2003).  
However, the situation appears to be very different in the context of liver 
transplantation, where the recipient assumes the phenotype of the donor. The variant 
FCN2 +6359 allele was associated with a doubling of the bacterial infection risk 
within the first year post-transplant and the risk was enhanced by co-inheritance of 
MBL2 variant alleles (de Rooij et al, 2010). Patients with one or more lectin pathway 
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genetic variants and infection had an increased mortality rate which was statistically 
significant. As well as those bacterial infections causing sepsis and pneumonia, the 
normal (high lectin activity) FCN2 +6359 was associated with protection from 
cytomegalovirus after liver transplantation (de Rooij, 2011). Again, the combination 
of FCN2 and MBL2 risk alleles conferred a particularly high degree of susceptibility 
(De Rooij et al, 2011). 
 
1.4.4 Respiratory infections 
There is a strong theoretical basis to believe ficolin-2 may be important in respiratory 
infections. As discussed previously, ficolin-2 binds to and opsonises a wide variety 
of important respiratory pathogens (including capsulated S.pneumoniae and 
S.aureus).  
In perhaps the first disease association study involving ficolin-2, an association 
between ficolin-2 insufficiency and recurrent respiratory infections in children was 
reported. This relationship was particularly marked for patients with co-existing 
allergic disorders (mostly rhinitis and/or asthma with high IgE) (Atkinson et al, 
2004). This preliminary observation prompted a fresh, prospective study on children 
aged 1 to 16 years (mean 8.9) to confirm or refute the previous retrospective 
findings, and to distinguish between infection and allergy (Cedzynski et al, 2009). 
Ficolin-2 insufficiency was indeed significantly associated with asthma and/or 
allergic rhinitis in the context of recurrent respiratory infections, but not with those 
allergic disorders in the absence of infection or with recurrent respiratory infections 
in the absence of allergy (Cedzynski, 2009). The reason for this relationship is not 
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clear, but it is possible that ficolin-2 confers some protection from microorganisms 
that exacerbate allergic inflammation in the lung. 
Studies of ficolin-2 genetics in respiratory infections are in their infancy but a study 
of FCN2 genotypes and invasive pneumococcal disease found no significant 
association (Chapman et al, 2007).  
Our pilot study demonstrated a clear association between low serum ficolin-2 and 
idiopathic bronchiectasis (Kilpatrick et al, 2009). Children with cystic fibrosis 
develop bronchiectasis and chronic bacterial colonisation, particularly with the 
opportunistic pathogen P. aeruginosa. A study of 96 children with cystic fibrosis 
followed up longitudinally found a significant relationship between polymorphism in 
the FCN1 (rs2989727 and rs1071583) and FCN2 genes (rs7865453 and rs7851696), 
and earlier age of onset of P.aeruginosa colonisation (Haerynck et al, 2012). 
Rs7865453 is particularly interesting as this is the Ala258Ser mutation in exon 8 that 
is most strongly associated with low serum ficolin-2 levels (Haerynck et al, 2012)  
 
1.4.5 Other infectious diseases and disorders 
The distribution of FCN2 haplotypes in leprosy patients differed significantly from 
healthy controls (de Messias-Reason, 2009). The authors interpreted their findings as 
an indication that normal (relatively high) ficolin-2 concentrations protect against M. 
leprae infections, but serum ficolin-2 was not actually measured. 
A comparison of mild and severe Plasmodium falciparum malaria revealed that 
serum ficolin-2 concentration is highest during acute severe disease, but this 
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difference was not reflected in the distribution of the FCN2 haplotypes (Faik et al, 
2011).  
The distribution of FCN2 variants was found to be altered in post-streptococcal 
disease (Messias-Reason, 2009). A haplotype associated with low levels of ficolin-2 
was slightly but significantly more frequent in patients with chronic rheumatic heart 
disease (CRHD) compared with healthy controls. Conversely, another haplotype was 
more common in controls than in either CRHD or rheumatic fever patients. Since 
ficolin-2 can readily bind to Streptococcus pyogenes and thereby activate 
complement (Aoyagi, 2008), it is conceivable that these immunogenetic differences 
are related to an altered innate response. 
A similar FCN2 investigation in Behcet’s disease was essentially negative (Chen et 
al, 2006) as was the outcome of serum ficolin-2 measurements in sarcoidosis 
(Svenden et al, 2008). Nevertheless there was a trend towards lower circulating 
ficolin-2 in sarcoid patients, in contrast to an increase noted for MBL. 
 
1.4.6. Animal studies 
The differences between human and animal ficolins have previously been discussed. 
It is difficult to extrapolate the results of animal studies directly from mice to humans 
because of these differences. In addition to the absence of ficolin-3 in mice, although 
ficolin-A in mice is analogous to ficolin-2 in humans, there are significant 
differences in binding specificity (Hummelshoj et al, 2012). Mannose binding lectin 
is represented by two proteins (MBL-A and MBL-C) in mice compared to a single 
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molecule in humans (Liu et al, 2001) In addition, given the emerging evidence of a 
role for pentraxins in amplifying the lectin pathway, it is important to note essential 
differences between human and mice pentraxins. In humans, C-reactive protein is the 
major acute phase reactant in human plasma, in contrast to mice where serum 
amyloid P is the major acute phase reactant and CRP is virtually absent (Yuste et al, 
2007).  
Having noted these differences, studies of animal ficolins are informative. Porcine 
ficolin-α was found to neutralise porcine reproductive and respiratory virus (a major 
pathogen of swine) in-vitro in a GlcNAc-dependent manner (Keirstead et al, 2011). 
However, variant alleles of ficolin-α were not associated with common infectious 
diseases (pneumonia, enteritis, serositis, septicemia) at necropsy, despite significant 
associations with MBL-A, MBL-C and surfactant protein A (Keirstead et al, 2011).  
The lectin pathway of complement has been described as important in mice for host 
defence against S. pneumoniae pneumonia (Ali et al, 2012). MASP-2 knockout mice, 
with no functioning lectin pathway activity, had an increased severity of infection in 
a model of S. pneumoniae pneumonia. In this study, ficolin-A was the major lectin 
pathway component opsonising S. pneumoniae, and ficolin A null mice also had 
increased susceptibility to infection. Using MASP-2 knockout mice, it has also been 
reported that the lectin pathway of complement is not critical to defence against P. 
aeruginosa pneumonia (Kenawy et al, 2012) but is a major contributor to ischaemia 
reperfusion injury (Schwaeble et al, 2011). The role of ficolins in these particular 
contexts has not been fully explored. Ficolin-A knockout mice were found to be 
more susceptible to influenza A infection (Pan et al, 2012). The authors found that 
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human ficolin-2 could bind to influenza A virus and activate the lectin pathway of 
complement, preventing viral entry into cells.  
Human ficolin-2 cDNA has been cloned into an expression plasmid and used in a 
murine model of Salmonella typhimurium infection (Ma et al, 2011). Administration 
of ficolin-2 in that form protected mice from a potentially lethal challenge with 
Salmonella, with bacterial counts dramatically reduced a week after infection, 
compared with empty vector-treated controls. The recombinant ficolin-2 enhanced 
monocyte phagocytosis of Salmonella in a dose-dependent manner (Ma et al, 2011).  
 
1.4.8 Conclusions 
Ficolin-2 is a major pattern recognition molecule in human serum, capable of binding 
to a wide range of micro-organisms and activating the lectin pathway of complement.  
Emerging data links ficolin-2 to defence against several important human pathogens, 
as well as diverse processes including apoptotic cell clearance. There are large 
variations in ficolin-2 serum levels due to genetic polymorphisms in humans. 
Disease association studies have thus far been limited. Studies in humans and 






1.5   Aims and hypothesis 
The lectin pathway of complement is involved in pattern recognition against a range 
of micro-organisms that are relevant to human respiratory infections. Work in 
humans and animals suggest that ficolin-2 and related molecules modify immune 
responses relevant to non-CF bronchiectasis, including apoptotic cell clearance, 
collaboration with the pentraxins and opsonophagocytosis. 
Our review of data from studies of mannose binding lectin and cystic fibrosis, 
support the hypothesis that MBL is a modifier of disease severity. 
We hypothesised that single nucleotide polymorphisms in the ficolin-2 and MBL 
genes would be important disease modifiers in bronchiectasis. Further we 
hypothesise that ficolin-2 would be important for opsonophagocytosis of 
Pseudomonas aeruginosa and other important bacteria. 
Based on previous data, primarily from cystic fibrosis, we hypothesised that 
bronchiectasis would be associated with impaired neutrophil phagocytosis. We 
hypothesised that in-vitro this inflammation and neutrophil dysfunction could be 








The aims of this thesis are therefore: 
1) To define disease severity in non-CF bronchiectasis by investigating the 
association between airway bacterial load, airway inflammation and clinical 
markers such as exacerbations, health related quality of life and lung 
function. These investigations will be used to inform the studies of genetic 
modifiers of disease severity reported in subsequent chapters. 
2)  To determine if single nucleotide polymorphisms in the ficolin-2 and 
mannose binding lectin genes or serum levels of these proteins are associated 
with disease severity and chronic colonisation in bronchiectasis. 
3) To investigate the role of ficolin-2 and MBL in opsonophagocytosis of 
Pseudomonas aeruginosa. 
4) To investigate the mechanisms of inflammation and neutrophil dysfunction in 





Materials and Methods 
 
The study and all procedures in human subjects were approved by the Lothian 
Research Ethics committee, approvals, 08/S1102/58, 08/S1103/38, 08/S1103/61 and 
10/S1103/27. All participants gave written informed consent to participate.  
 
2.1 Patients with bronchiectasis and controls 
Patients with bronchiectasis were recruited from a regional specialist bronchiectasis 
clinic at the Royal Infirmary of Edinburgh, Edinburgh, UK. The diagnosis of 
bronchiectasis was based on the presence of bronchial dilatation on high resolution 
CT scanning and a compatible clinical history of cough with sputum production and 
recurrent respiratory infections (Pasteur et al 2010).
 
Patients aged <18 years, patients 
with active allergic bronchopulmonary aspergillosis, active mycobacterial disease, 
cystic fibrosis, asthma, common variable immunodeficiency and current smokers 
(within the previous 2 years) were excluded. We also excluded patients with long 
term use of oral or nebulised antibiotic therapy or long term oral corticosteroid 
therapy at any dose. Full medication histories, including over the counter medication 
use, were obtained at study entry. At the time of inclusion all patients were clinically 





Clinical assessments and management 
All patients underwent clinical assessments including spirometry (forced expiratory 
volume in one second, forced vital capacity with the highest of three technically 
satisfactory measurements recorded)
 
high resolution CT scanning and chest 
radiography (Miller et al 2005). Patients were reviewed at each clinic visit by a 
consultant respiratory physician, specialist registrar or clinical research fellow. 
Patients were managed according to a standardised protocol based on the British 
Thoracic Society guidelines for the management of bronchiectasis (Pasteur et al 
2010).  
 
Symptoms and quality of life 
Patients completed the St Georges Respiratory questionnaire
 
(Wilson et al 1997) and 
the Leicester cough questionnaire (Murray et al 2009) as validated measures of 
quality of life and cough severity in bronchiectasis respectively. The LCQ has a 
score from 3-21 (a score of 3 is most severe cough) and the SGRQ has a score from 
0-100 (100 indicates maximum impairment). The minimal important clinical 
difference is 1.3 Units and 4 Units respectively for these questionnaires (Raj 2009 
and Jones 1991). 
 
Exacerbations and hospitalisation 
Unscheduled hospitalisations in the previous year for severe exacerbations were 
recorded and verified using an administrative database that records all regional 
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hospital admissions. Outpatient antibiotic use for exacerbations of bronchiectasis was 
quantified and verified against prescription records. All patients included were 
followed up every 6 months from 2008-2012. Exacerbations were defined as in the 
British Thoracic Society bronchiectasis guidelines as an acute deterioration with 
worsening of cough, increased sputum production or change in viscosity, increased 
sputum purulence with or without increasing wheeze, breathlessness or haemoptysis 
(Pasteur et al 2010).
 
Hospitalisation was recommended for patients meeting the 
British Thoracic Society criteria for inpatient management of exacerbations 
(development of cyanosis or confusion, breathlessness with respiratory rate > 
25/min, circulatory failure, respiratory failure, temperature > 38
°
C, inability to take 
oral therapy, inability to cope at home and failure of oral antibiotic therapy) (Pasteur 
et al 2010). 
 
Chronic colonisation 
Patients were classified as chronically colonised according to an accepted definition, 
if they grew a potentially pathogenic microorganism on 2 occasions at least 3 months 
apart in 1 year while clinically stable (Pasteur et al 2000).
 
Patients had early morning 
sputum samples for qualitative and quantitative bacteriology at each clinic 
appointment at least twice per year and were provided with sputum pots to provide 







Radiological severity of bronchiectasis was defined according to a modified Reiff 
score (Reiff et al 1995, Pasteur et al 2000). This takes into account the number of 
lobes involved (with the lingula scored as a seperate lobe) and the severity of 




Controls matched for age and sex were recruited from the healthy spouses of patients 
attending the outpatient clinics at the Royal Infirmary of Edinburgh. Controls 
completed a short health questionnaire to establish that they did not have chronic 
respiratory disease. Medication histories were also taken. Controls were excluded if 
they were aged <18 years bronchiectasis, asthma, COPD, were taking inhaled 
corticosteroids, long term oral corticosteroids or other immunosuppressive 
medications. We also excluded controls with chronic liver disease or active 
malignancy.  
 
2.2 DNA extraction and genotyping 
Genomic DNA was isolated from EDTA-anticoagulated whole blood samples using 
the Nuccleon BACC-3 kit (Gen-Probe Inc). 10mls of blood was added to 50ml 
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polypropylene tubes (Falcon) with 40ml of reagent A. This was mixed for 4 minutes 
at room temperature then centrifuged at 1300g for 4 minutes. Pellets were dissolved 
in 2ml of lysis reagent and incubated at 37°C for 10 minutes. Deproteinisation was 
performed by adding 500µl sodium perchlorate and mixing by inverting manually. 
2ml of chloroform was added and inverted 7 times. 300µl of nucleon resin was added 
and the mixture centrifuged at 1300g for 3 minutes. The upper phase containing 
DNA was transferred to a fresh centrifuge tube and centrifuged at 1300g to pellet any 
carried over resin. Two volumes of 100% ethanol (cooled to 4°C) was added and 
inverted manually to precipitate the DNA. DNA was pelleted at 4000g for 5 minutes 
and the supernatant discarded. 70% ethanol was used to wash DNA and the pellet air 
dried for 10 minutes. DNA was resuspended in 1ml of sterile water for 2-4 hours and 
stored at -80°C until use.  
Isolated DNA was quality-tested and genotyping performed at the Wellcome Trust 
Clinical Research Facility Genetics Core, Edinburgh. Validated Taqman allele 
specific PCR primers were purchased from Applied biosystems and PCR performed 
on the Applied Biosystems 7900HT according the manufacturer’s instructions. 
Analysis was conducted with Sequence detection system (SDS) software version 2.4. 













Figure 2.1. A typical allelic discrimination plot (In this case the plot shown is for the 
FCN2 promoter polymorphism at position -986, rs3124952). A small number of 
samples as shown with (X) could not be determined. Such samples were re-extracted 
and retested. 
Ficolin-2 SNP’s 
The authors studied 6 SNPs known to have the greatest effect on Ficolin-2 serum 
levels: the promoter polymorphisms rs3124952 (-986 G>A), rs3124953 (-602G>A), 
rs28969369 (-64A>C), rs17514136 (-4A>G) and the exon 8 polymorphisms 
rs7851696 (Ala258Ser) and rs17549193 (Thr236Met) (Hummelshoj et al 2005). 
Strong linkage disequilibrium between ficolin-2 SNP’s produce 6 well characterised 
haplotypes which are associated with varying serum ficolin-2 levels. These can be 
classified into high, intermediate and low expressing haplotypes as previously 
described (Munthe-Fog et al 2007) . SNP’s in MASP-2 rs72550870 (D120G) 
(Stengaard-Pedersen et al 2003, Thiel et al 2007), FCN3 rs28357092 (1637delC) 
were also determined by the same methods.  
 
MBL genotyping 
The authors studied 6 SNPs known to have the greatest effect on MBL serum levels, 
these are the exon-1 polymorphisms B- rs1800450, C rs1800451, D rs5030737, the 
promoter polymorphisms H/L, rs11003125, X/Y, rs7096206 and the 5’ UTR SNP 
P/Q, rs7095891. These SNP’s comprise 7 well-characterised “secretor haplotypes” 
(HYPA, LYPA, LYQA, LXPA, HYPD, LYPB and LYQC) which strongly influence 
circulating MBL levels (Garred et al 2009). 
117 
 
2.3 Definition of low ficolin-2 serum levels  
The optimal way of defining abnormally low Ficolin-2 levels or ficolin-2 
“deficiency” is not known. Based on a previous pilot study (Kilpatrick et al 2009), a 
priori, low serum Ficolin-2 levels was defined as a serum level <1600ng/ml with a 
sensitivity analysis performed using the lower cut-off of <1200ng/ml.  
There is no genetic definition of Ficolin-2 deficient or insufficiency although it is 
well recognised that ficolin-2 SNP’s form 6 haplotypes (Munthe-Fog et al 2007). 
These can be grouped into high, intermediate and low expressing haplotypes based 









Table 2.1. Described Ficolin-2 haplotypes and the associated predicted effect on 
ficolin-2 serum level.  
 















To determine the optimal genetic definition of low ficolin-2 serum levels, the authors 
conducted an analysis to determine the accuracy of individual SNP’s, haplotypes and 
haplotype combinations to predict low Ficolin-2 serum concentrations (defined as 
<1600ng/ml). Discrimination was determined using the area under the receiver 
operator characteristic curve and curves were compared using the method described 
by Hanley and McNeil (Hanley and McNeil 1983).  This data is presented in chapter 
4. 
 
2.4 Definition of MBL deficiency 
There is no universally agreed definition of MBL deficiency. MBL function may be 
assessed by genotype, serum levels or functional activity in complement activation 
assays (Eisen 2010). Although these are strongly correlated, they do not give 
identical results. To account for this, we present data using 3 definitions of MBL 
deficiency determined a priori-  
1) Genotypes associated with MBL deficiency  
2) Serum levels <500ng/ml  









Table 2.2. Haplotypes and abbreviated genotypes according to serum MBL 
expression. 
 
Repeat measurements of serum MBL 
To determine the impact of changes in MBL on disease severity over time, serum 
MBL was measured at study baseline, mid-point and at the end of the study in all 
patients. In addition, to determine the effect of exacerbations on serum MBL, 68 
patients attending for treatment of exacerbations at the Royal Infirmary of Edinburgh 
bronchiectasis service were recruited.
23
 Serum was taken at day 1 (start of 
exacerbation) and day 14 (end of exacerbation). Patients were treated with 























intravenous antibiotic therapy based on their previous sputum microbiology for 14 
days. Repeat measurements were then made at least 3 months post exacerbation to 
determine return of MBL levels to baseline levels. 
 
2.5 Serum measurement of lectin pathway components   
Ficolin-2 ELISA 
Ficolin-2 ELISA was performed as described (Kilpatrick et al 1999). Microtitre 
plates (Immunlon 4, Dynatech) were coated with (GN4) monoclonal antibody against 
Ficolin-2 (100µl/well) in 0.25M sodium phosphate, pH 7.5 overnight at 4ºC. After 
washing three times (250 µl/well) with 0.1% Tween-20 in PBS, the wells were 
blocked with 1% bovine serum albumin (BSA) in 0.1M sodium phosphate, pH 7.5, 
for 2 h at 37°C. A further 3 washes with 0.1% Tween-20 in PBS were performed. 
Serum samples were diluted 30 fold in 0.1M sodium phosphate, pH 7.5, containing 
0.1% BSA and incubated at 37°C for 2 h. The wells were washed again as above, 
and then incubated overnight at 4°C with biotinylated anti-ficolin-2 (GN5) at 5µg/ml 
in 0.1 M sodium phosphate, pH 7.5, containing 0.1% BSA. After a further wash step, 
avidin–biotin–peroxidase complex (Vectastain ABC kit, Vector Laboratories) was 
added and a further incubation at 37°C for 2 h performed. The wells were then 
washed twice with Tween-PBS followed by a further three washes with just PBS. 
Finally, substrate solution (0.1 mg:ml ABTS in 50 mM citrate phosphate buffer, pH 
5.3, containing 0.015% H2O2) was added and the plates left in the dark at room 
temperature for 20 min. The A405 was measured using an ELISA reader and the 
concentration of ficolin-2 in serum samples determined against a standard curve 
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constructed with doubling dilutions of a serum previously calibrated against purified 
Ficolin-2. For the results presented, the mean intraassay coefficient of variation was 
4.1% and the mean interassay co-efficient of variation was 9.4%.All low values were 
confirmed by reassay at 1 in 10 dilution.  
 
 
Mannose binding lectin ELISA 
Serum MBL measurement was performed as described (Kilpatrick et al 2009).  
To prepare Mannan coated plates, Immulon-4 (Dynex) plates were coated with 
100µl/well of 50µg/ml poly-D-lysine in carbonate buffer ((15mM Na2CO3, 35mM 
NaHCO3, pH 9.6) at 4°C overnight. The plates were washed twice with distilled 
water and then once with phosphate buffered saline. Mannan solution (Sigma) at 
0.1mg/ml was added (100µl/well) followed by 100µl/well of 0.1% glutaraldehyde in 
PBS. After incubation at room temperature for 10 minutes plates were washed three 
times with PBS and stored prior to use.  
Plates were blocked with 3% BSA in PBS for 1 hour at room temperature followed 
by washing with calcium buffer (20mM Tris/0.5M NaCl, 10mM CaCl2 , 1% BSA 
and 0.05% Triton X-100, pH 9.0).  Serum samples were diluted at 1 in 20 in calcium 
buffer and incubated for 1 hour at room temperature. Plates were washed three times 
with calcium buffer followed by incubation with mouse anti-MBL (HYB131-01) at 
1µg/ml followed by goat anti-mouse immunoglobulin conjugated to alkaline 
phosphatase diluted 1 in 4000 in calcium buffer (Sigma) followed by p-nitrophenyl 
phosphate as a substrate (1mg/ml of p-nitrophenyl phosphate in 0.1M glycine buffer, 
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pH 10.3 containing 1mM zinc and magnesium). The reaction was termination with 
3M NaOH (50µl/well) and the A410 was measured. This assay demonstrated intra-
assay coefficient of variation of 3.5% and inter-assay co-efficient of variation of 7%. 
 
 
MASP-2 and Ficolin-3 ELISA 
MBL associated serine protease-2 and Ficolin-3 serum levels were determined using 
commercially available ELISA assay kits (Hycult Biotechnology, Uden, 
Netherlands).  
 
2.6 Measurement of Systemic inflammation 
It has been reported that bronchiectasis and other inflammatory lung diseases are 
associated with systemic elevation of adhesion molecules that are involved in 
leucocyte recruitment to the inflamed lung (Grosso et al 1998, Riise et al 1998, 
Zheng et al 2000). To determine if bacterial load correlates with these markers, 
Soluble Intercellular adhesion molecule-1 (ICAM-1), soluble E-selectin and soluble 
vascular cell adhesion molecule-1 (VCAM-1) were measured in serum using 
commercially available ELISA kits (R+D systems, Abingdon, UK). C-reactive 
protein and Erythrocyte sedimentation rate were also measured as systemic 
inflammatory markers. Measurements of these markers were performed by the 




2.7 Sputum processing  
Patients were taught to provide appropriate early morning sputum samples under the 
direction of a bronchiectasis specialist nurse and respiratory physiotherapist. 
Spontaneous early morning sputum was used for all bacteriology and airway 
inflammation studies. Spontaneous early morning sputum samples containing less 
than 10 squamous cells and more than 25 leukocytes per low power microscope field 
were acceptable (White et al 2003). All sputum processing was performed within 2 
hours of expectoration. Sputum was homogenized and liquified using an equal 
volume of 0.1% dithiothreitol and serially diluted using sterile 0.9% saline to achieve 




. Cetrimide (Difco) Pseudomonas isolation agar, 
chocolate with bacitracin agar and sheep blood agar plates were inoculated with 
100µl of sample. Colony forming units for each predominant pathogen were then 
identified by standard procedures and counted after 48hrs aerobic incubation 
(5%CO2 for growth on chocolate with bacitracin agar) at 37°C  to determine the 
sputum bacterial density, expressed as log10 colony forming units/ml (cfu.ml
-1
) 
(Murray et al 2010). 
 
For measurement of markers of airway inflammation, sputum, not treated with DTT, 
was ultracentrifuged at 50,000×g for 90 minutes at 4ºC. The sol phase was removed 
and immediately frozen at -80ºC.  
Myeloperoxidase activity was measured as a marker of neutrophi mediated airway 
inflammation. 25µl of patient sputum sol diluted in PBS or purified myeloperoxidase 
(Sigma) were added to 96 well microplates (Serotec). 25µl of the colorimetric 
substrate 3,3’,5,5’-Tetramethylbenzidine (TMB) was added for approximately 5 
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minutes and the reaction then terminated with 50µl of sulfuric acid. Plates were read 
in a microplate reader at 450 and 560nm. 
Neutrophil elastase activity was measured by chromogenic assay. Human neutrophil 
elastase (Sigma) was diluted in 50mM sodium acetate, 200mM NaCl, pH 5.56 and 
stored at -80ºC until use. Elastase or patient sputum sol samples were diluted in 
50mM HEPES, 150mM NaCl + 0.05% Igepal CA630, pH 8. Sputum samples were 
diluted 1 in 50. Standard or samples were then added to 96 well microplates, 40µl 
per well. The synthetic substrate N-Methoxysuccinyl-Ala-Ala-Pro-Val p-nitroanilide 
(MeoSAAPvN) was dissolved in DMSO at a stock concentration of 50mM. 200µl of 
the stock substrate was diluted in 4.8mls of 50mM HEPES, 150mM NaCl + 0.05% 
Igepal CA630, pH 8 and 40µl added to each well. Cleavage of the substrate was 
monitored by kinetic assay in a microplate at 37°C for 30 minutes. Reads were 
performed every 2 mins. Values were calculated against a standard curve of doubling 
dilutions of purified neutrophil elastase. 
Interleukin 8, tumour necrosis factor-α and interleukin-1ß were measured by 
commercially available enzyme linked immunosorbant assay (ELISA, R+D systems, 
Abingdon, UK) using kits previously validated for sputum use according to 
established methodology (Stockley and Bayley 2000).   
 
Validation of sputum ELISA’s 
All assays for sputum were validated as described (Stockley and Bayley 2000). 
Standard curves for each assay were obtained using pure mediator provided by the 
manufacturer following the assay protocol. Three pools of sputum sol were prepared 
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from 4 patients each with mucoid (grade 1), muco-purulent (grade 2) and purulent 
sputum(grade 3 or 4) based on a previously published sputum colour chart (Murray 
et al 2009). Three parameters were assessed in validating assays: Reliability, 
recovery of spiked mediators and the effect of sample dilution.   
Reliability: The quantity of mediator in each sputum pool was determined by 
interpolation against the standard curve. Individual samples were assayed 5 times on 
a single plate to obtain the intraassay co-efficient of variation. Each sample was also 
assayed 5 times on different plates to obtain the inter-assay co-efficient of variation.  
Spike and recovery: a known quantity of each mediator was spiked into the 3 pools 
of sputum. These “spiked” samples were then assayed and compared to the values 
obtained for the original pool. The obtained value was divided by the predicted value 
to calculate the % recovery. 
Dilution effect: The 3 sputum pools were assayed at dilutions ranging from 1 in 
1000, to 1 in 5. Low serum dilutions were used to exclude the prozone effect (Hook 
effect) on ELISA at high concentrations of antigen. 
An assay was deemed to be valid if it had a reliable standard curve, an intra-assay 
and inter-assay coefficient of variation <10%, recovery of spiked samples in the 
range 80-120% of predicted and a linear dilution effect (Stockley and Bayley 2000). 
The results of the assays used in this study, for Interleukin-8, tumour necrosis factor-
α and interleukin-1ß are shown below, figure 2.2. These assays passed each 
validation step and were used in the study. Table 2.3, shows the validation data for 
all sputum assays tested. Assays for Interleukin-6 (R+D systems), Interleukin-10 
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(R+D systems), Complement C5a (Hycult biotechnology and R+D systems) were not 
used in the study as they failed validation.   
The figures below show the validation data for the IL-8, TNF-α and IL-1ß. The first 
figure (2.2) shows the linearity of dilution effect. In view of these results, dilution of 
1 in 20 was used for each assay with re-assay at higher or lower dilution in cases 
where results were outside the dynamic range of the assay. 
Figure 2.2. Validation of assays for sputum cytokine measurements: linearity of 
dilution effects for sputum measurement of interleukin-8, tumour necrosis factor-α 
and interleukin-1ß. * indicates outside the dynamic range of the assay. 
Each assay gave a linear, reliable standard curve and representative standard curves 
are shown below (figure 2.3). 
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Figure 2.3. Validation of sputum assays for inflammatory mediators: representative 
standard curves for sputum measurement of interleukin-8, tumour necrosis factor-α 
and interleukin-1ß. 
 
Finally, spike a recovery experiments demonstrated a majority of values between 
80% and 120% of expected recovery with a median recovery and range within 
acceptable levels of variability. The results of the individual spike and recovery 
experiments are shown below (figure 2.4) and the overall assessment of each assay 
tested is shown in table 2.3.  Table 2.3 also contains data for assays that were 












Figure 2.4. Results of spike and recovery experiments for the 3 assays validated for 
use in sputum. The bars show median with interquartile range with each icon 
representing the results of a single spiking experiment. Results are expressed as % 
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2.8 Bacteria and bacterial strains 
Pseudomonas strain PA01, a fully sequenced Pseudomonas strain (Stover et al 
2000), and all other bacterial strains unless otherwise indicated were kindly provided 
by Professor John Govan’s laboratory at the University of Edinburgh.  
Binding and phagocytosis assays were performed using E.coli strain 25922 (ATCC) , 
Streptococcus pneumoniae serotype 3 (ATCC), S. aureus (R6390 a methicillin 
sensitive strain, ATCC), M. catarrhalis (clinical isolate from a patient with non-CF 
bronchiectasis), Haemophilus influenzae (clinical isolate) and Burkholderia 
cenocepacia. 
Environmental strains of Pseudomonas aeruginosa  were obtained from hospital and 
non hospital environments such as sinks, drains, vegetables and ponds. Identification 
was based on colony morphology, blue-green pigmentation and positive oxidase test 
or API 20NE kits and specifies specifc PCR as described (Macdonald et al 2010).  
Clinical isolates of P. aeruginosa from patients with Cystic fibrosis were provided by 
Professor John Govan’s laboratory at the University of Edinburgh. These were first 
isolates of patients with CF aged from 2 months to 40 years All isolates were non-




All Pseudomonas strains were grown overnight in Luria Bertani (LB) broth at 37ºC 
in an orbital shaker at 250rpm overnight (12-16 hours) to achieve a stationary-phase 
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suspension. Before use, bacterial suspensions were diluted 1:20 in fresh LB broth 
and incubated at 37°C for a further 90 minutes to reach log phase. Bacterial 
suspensions were standardised via dilution to an optical density of 0.1 at 595nm 
using a spectrophotemeter (WPA UV 1101, Biotechn Photometer, Biochrom Ltd, 
Cambridge, UK). Bacteria were centrifuged at 1500g for 15 minutes and resuspended 
in the required buffer prior to experimental use. 
 
2.9 Sodium dodececyl-sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
and Western Blotting 
Prior to western blotting, cell samples were washed with PBS and lysed at 4°C in 
lysis buffer (25mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 
7.4, 0.3M NaCl, 1.5mM MgCl
2
, 0.2mM ethylenediaminetetraacetic acid (EDTA), 
0.5% Triton X-100 (v/v), 1mM sodium orthovanadate and 0.5mM dithiothreitol 
(DTT). For non-reducing conditions buffer containing no DTT was used. Lysates 
were shaken for 20 minutes at 4°C and cleared by centrifugation at 13,000rpm for 10 
minutes at 4°C.  
 
Lysates or protein samples were solubilised in 4x SDS-PAGE sample buffer (50mM 
Tris-HCl, 10% glycerol (v/v), 2% SDS (v/v), 0.1% bromophenol blue (v/v), 10% β-
mercaptoethanol (v/v), pH 6.8). For non-reducing conditions the buffer contains no 





10% or 12% SDS-PAGE gels were used for western blotting as appropriate. 
Separating gels consisted of 0.375M Tris base (pH 8.8), 0.1% SDS (v/v), 10-12% 
acrylamide (v/v), 0.1% ammonium persulphate (v/v) and 0.02% 
Tetramethylethylenediamine (TEMED) (v/v).  Stacking gels consisted of 0.13M Tris 
base (pH 6.8), 0.1% SDS (v/v), 4.5% acrylamide (v/v), 0.1% ammonium persulphate 
(v/v) and 0.02% TEMED (v/v).  
.  
Western blotting was performed under reducing and non-reducing conditions 
depending on the experiment, using a vertical electrophoresis tank Biorad Mini 
Protean II system. Samples were electrophoresed at 100–150 volts using 
electrophoresis buffer (50mM Tris base, 250mM glycine, 0.1% SDS (v/v) for 1–2 
hours. Proteins were transferred onto Hybond C nitrocellulose membranes 
(Amersham Pharmacia Biotech) in transfer buffer (210mM glycine, 24.7mM Tris 
base, 20% methanol (v/v)) at 100 volts for 60 minutes, in a Mini Protean II blotting 
tank or at 4°C overnight. Equal protein loading was confirmed by staining with 1% 
Ponceau S (AMS Biotechnology) for 5 minutes to visualise protein bands. Non-
specific binding sites were blocked by incubation with Tris-buffered saline (TBS)-
Tween 20 (150mM NaCl, 20mM Tris HCl (pH 7.4), 0.1% Tween 20 (v/v)) 
containing 5% non-fat dried milk powder for 1 hour at room temperature. 
Membranes were probed with appropriate antibodies diluted in TBS-Tween 20 
containing 5% non-fat dried milk powder for 1 hour or overnight at 4ºC. Membranes 
were then washed in TBS-Tween 20 (3x 10 minutes washes), before exposure to 
appropriate species-specific HRP-conjugated secondary antibodies (DAKO 1:1000 
dilution unless otherwise stated) for 1 hour at room temperature, diluted in TBS-
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Tween 20 containing 5% non-fat dried milk powder. Membranes were then finally 
washed in TBS-Tween 20 (3x 10 minute washes). Bands were identified using 
enhanced chemiluminescence reagent (ECL) (Amersham Pharmacia Biotech) 
according to the manufacturer’s instructions and developed in a Konica SRX-101A 
film processor. Pre-stained molecular weight markers (Invitrogen) were used to 
estimate the size of chemoreactive bands. For western blotting of ficolin-2, anti-
ficolin-2 clone GN5 was used followed by anti-mouse-HRP secondary antibody 
(DAKO).  
 
2.10 Recombinant proteins 
Bacterial expression of ficolin-2 
A full length human ficolin-2 (FCN2) cDNA clone was purchased from 
Geneservice(USA). Polymerase chain reaction was performed using the following 
primers 
FCN2 f:        5'-TAAGGATCCGATGGAGCTGGACAGAGCTGTG-3' 
FCN2 rev      5'-TTCGAATTCCTAGGCAGGTCGCACCTTCAT-3' 
BamH1 and EcoR1 restriction sites (underlined above) were incorporated for 
subsequent cloning. The Ficolin-2 open reading frame (ORF) PCR product was gel 
purified using a Qiagen DNA purification kit. The purified Ficolin-2 ORF was 
subsequently ligated into the pRSET-B expression vector (6-His tagged) with DNA 





Figure 2.5- pRSETB plasmid used for cloning and expression of human ficolin-2. 
 
Transformation of vector into BL-21 strain Eschericia coli bacteria was performed as 
follows. 0.5µg of pcDNA 3.1 vector, with a His-tagged FCN2 insert was added to 
100µl of bacteria, mixed and placed on ice for 30 minutes. Bacteria were heat 
shocked for 50 seconds at 42°C and immediately transferred to ice for 2 minutes. 
900µl of media was added and tubes were incubated for 45 minutes at 37°C shaking 
at 700rpm. Bacteria were pelleted for 5 minutes at 5000rpm and resuspended in 
200µl of media. Serial dilutions were plated onto Luria-Bertani (LB) (Sigma-
Aldrich) agar plates containing 50µg/ml ampicillin (Sigma-Aldrich) and incubated 
overnight at 37°C. The next day colonies were picked and inoculated into 10ml of 
LB broth containing 50µg/ml ampicillin and grown overnight. 2.5ml of overnight  
culture was inoculated into 500ml of LB broth containing 50µg/ml ampicillin. 
Bacteria were grown to an optical density (OD)600 of 0.7 to 0.8 and induced with 
1mM isopropyl ß-D-thiogalactoside (IPTG) (Sigma-Aldrich) and then grown 
overnight at 37°C. Cultures were subsequently centrifuged at 8,000rpm  for 20 
minutes. Pellets were resuspended in 5ml of BugBuster Protein Extraction Reagent 
(Novagen) per gram of wet cell paste followed by the addition of 1µl/ml Benzonase 
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(Novagen). This was separated into 50ml conical tubes, placed on a rotary shaker for 
20 minutes and centrifuged at 11,500rpm for 20 minutes.  
Expressed ficolin-2 was purified from the cleared lysate using Ni-NTA His·Bind® 
Resin. 1ml of Ni-NTA His·Bind® Resin (Novagen), per purification, was washed 
with 4ml 1X Ni-NTA Bind Buffer (300mM NaCl, 50mM sodium phosphate buffer, 
10mM imidazole, pH 8.0), the beads were centrifuged at 1000rpm for 5 minutes, and 
the top bind buffer layer was removed. 4ml of cleared lysate was loaded onto the 
prepared Ni-NTA His·Bind slurry and mixed gently by shaking at 4°C for 60 
minutes. This was then loaded onto a disposable polypropylene column (1-5ml bed 
volume) (Pierce Biotechnology), flow through collected  and 3 washes were carried 
out using Ni-NTA Wash Buffer (300mM NaCl, 50mM sodium phosphate buffer, 
20mM imidazole, pH 8.0), 4x 500ìl elutions were performed with Ni-NTA Elution 
Buffer (300mM NaCl, 250mM imidazole, 50mM sodium phosphate buffer, pH 8.0) 
and elutions were collected in 4x 1.5ml eppendorf tubes. Fractions were analysed 
using SDS-PAGE and elutions dialysed against 1L cold 1X PBS overnight (dialysis 
tubing size – 14.3mm, molecular weight cut off 12-14KDa). The presence of ficolin-




Figure 2.6. The first panel shows results of cloning of the FCN2 gene into the 
pRSETB plasmid. DNA samples were run on a 1% agarose gel. Lanes B and C show 
successful incorporation of the insert into the plasmid while empty vector are shown 
in lanes A and D-G. Following expression and purification of ficolin-2 the presence 
of recombinant protein was confirmed by western blotting (second panel). A band at 
35kDa is shown under reducing conditions corresponding to ficolin-2 monomers.   
 
Mammalian expression of ficolin-2 
Stable CHO K1 cell lines expressing recombinant ficolin-2 were a kind gift from Dr 
Nicole Thielens (Lacroix et al 2009). Ficolin-2 was cloned into the pcDNA 3.1(+) 
mammalian expression plasmid (Invitrogen) containing a neomycin resistance gene. 
Ficolin-2-CHO stable lines were maintained in Dulbecco’s modified eagle medium 
(DMEM) containing 10% heat inactivated FCS and G418 (Invitrogen). 6 days after 
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confluence the supernatants were pooled and Ficolin-2 purified. For purification of 
Ficolin-2, N-acetylglucosamine (GlcNAc) and N-acetylcysteine (CysNAc) beads 
were generated. Sepharose 4CL beads (Sigma) were activated by incubation with 
10% divinyl sulfone. After washing, the beads were derivatized in 0.25
 
M Na2CO3 
containing 10% (w/v) GlcNAc or CysNAc at pH 11 overnight. The beads were 
washed with dH2O, and residual
 
active groups were blocked by incubation with 0.1 
M ethanolamine,
 
pH 9.0.  
The cell culture supernatant was dialysed against 145 mM NaCl, 5 mM CaCl2, and 
20 mM Tris-HCl (pH 7.4). This was then applied to the CysNAc column equilibrated 
in 145 mM NaCl, 5 mM CaCl2, and 20 mM Tris-HCl (pH 7.4) as above. Bound 
ficolin-2 was then eluted using the same binding buffer containing 0.3M GlcNAc. 
The protein containing fractions were dialysed into binding buffer and then 
concentrated by ultrafiltration (Krarup et al 2004). As above, the presence of ficolin-
2 in the elutions was confirmed by ELISA and western blot. Function of the 
recombinant ficolin-2 expressed in both bacterial and mammalian systems was tested 
using binding to acetylated bovine serum albumin in a solid phase binding assay as 
described below.  
 
MBL   
Recombinant mannose binding lectin was purchased from R+D systems (Abingdon, 





Recombinant Ficolin-3 was was purchased from R+D systems (Abingdon, UK) and 
functionality tested by adding increasing concentrations to acetylated BSA coated 
microplates in a functional ELISA as described below.  
 
Pentraxins 
Recombinant Pentraxin-3 and serum amyloid P were purchased from R+D systems. 
Recombinant C-reactive protein was purchased from Sigma.  
 
Complement component C5a 
Recombinant complement component C5a was purchased from R+D systems. 
 
2.11 Isolation of peripheral blood neutrophils and monocytes 
Peripheral blood neutrophils were isolated from patients with bronchiectasis and 
healthy volunteers by Percoll-gradient density centrifugation as previously described 
(Haslett et al 1985).
 
Human peripheral blood was obtained from the antecubital vein of healthy volunteers 
Blood was collected into tubes containing sodium citrate (1% final concentration) to 
prevent coagulation. Erythrocytes were sedimented with 0.6% (w/v) dextran T500 







-free phosphate buffered saline (PBS) with final 
concentrations of Percoll of 55, 70, and 81%) at 720 g for 20 min. Monocytes were 
aspirated from the 55/70 interface, and PMN from the 70/81% interface, and washed 




) before culture. Monocytes were enriched by 
anti-CD14 microbead magnetic cell sorting (Miltenyi Biotec). Cells from the 55/70 
interface we centrifuged at 300g for 10 minutes and resuspended in 16µl of MACS 
buffer (PBS with 2% fetal calf serum and 2mM EDTA) per 10
7
 cells counted with a 
haemocytometer. 4µl of CD14 microbeads (Miltenyi Biotec) were added per 10
7 
cells and incubated for 20 minutes at 4ºC. The MACS column was equilibrated with 
3mls of MACS buffer and placed in a magnet (MACS separator, Miltenyi Biotec). 
Cells were washed with 2mls of MACS buffer per 10
7
 cells and centrifuged at 300g 
for 10 minutes, with the supernatant removed. Cells were resuspended in 1ml of cold 
MACS buffer and applied to the column. Unlabelled cells passing through the 
column were collected and the column washed with 3 x 3ml of MCS buffer. The 
column was then removed from the magnet and flushed with 2 x 5ml of MACS 
buffer. Cells were resuspended in 5ml of RPMI and then resuspended at the indicated 
concentration in RPMI or Iscove’s media (IMDM). Isolated monocytes with typical 
purity of >95% as assessed by flow cytometry with CD14 antibody  (DAKO) were 
matured into macrophages by incubation culture for 5 days in IMDM containing 






2.12 Isolation of sputum neutrophils 
For sputum neutrophil studies patients underwent sputum induction as described with 
3% hypertonic saline. Sputum neutrophils were isolated by a modification of 
previous described methodology (Hartl et al 2007, Voglis et al 2009). Sputum was 
processed immediately upon expectoration. Sputum plugs were selected and sputum 
diluted 8 fold in phosphate buffered saline (PBS). After centrifugation at 800g for 10 
minutes, sputum was mixed with 4 volume of 0.1% dithiothreitol(DTT). Sputum was 
then incubated with DTT for 15 minutes at 4ºC and the homogenised sputum was 
then passed through a 48µm filter. The filtrate was then washed with PBS to remove 
DTT. The cell suspension after filtration consisted of a majority of neutrophils with a 
few alveolar macrophages in bronchiectasis patients. The cell suspension in PBS was 
then applied to a percoll gradient (40% and 50% percoll) and centrifuged for 20 
minutes at 400g. Cell viability was assessed by trypan blue exclusion and cell purity 
assessed by Diff-Quick stained cytospins. Neutrophils were typically 95% pure using 
this method. 
9 healthy volunteers underwent sputum induction with sputum processing as 
described above. Insufficient neutrophils were obtained to perform assessment of 
airway neutrophil receptor expression or to perform phagocytosis assays. Cytospins 
suggested that in healthy non-smokers, induced sputum contained small numbers of 
macrophages with few neutrophils. Consequently sputum neutrophil receptor 
expression in bronchiectasis patients was compared to the patient’s own peripheral 
blood neutrophils stimulated with the synthetic chemoattractant fMLP (0.1µM), an 




Initial experiments in which peripheral blood neutrophils were processed according 
to the sputum neutrophil protocol established that treatment with dithiothreitol and 
the filtration process did not affect surface expression of any of the markers under 
study, or significantly affect phagocytosis or oxidative burst by peripheral blood 
neutrophils (these results are presented in the relevant chapter). Sputum neutrophils 
were examined by flow cytometry on a BD FACSCALIBUR flow cytometer. 
 
2.13 Definitions of severe bronchiectasis for sputum neutrophil and peripheral 
blood neutrophil studies 
Severity of bronchiectasis was determined according to the criteria described by 
Smith (Smith 2011). Patients with severe bronchiectasis have severe radiological 
disease as defined by Reiff criteria (Reiff et al, 1995), are colonised with P. 
aeruginosa, expectorate purulent sputum when stable and have frequent 
exacerbations (typically defined as > 3 per year). Patients with mild bronchiectasis 
have mild radiological disease, are not chronically colonised, expectorate mucoid 
sputum and do not have frequent exacerbations. A priori, patients matched for age 
and sex in these subgroups were identified and recruited.  
 
2.14 Binding assays 
Solid phase binding assay 
The solid phase binding assay was performed as described (Lynch et al 2004). Nunc 
maxisorb microtitre plates were coated with acetylated BSA, Mannan, P. aeruginosa 
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(PA01) or E.coli in coating buffer (15mM Na2CO3, 35mM NaHCO3, pH 9.6). After 
overnight incubation, wells were blocked with 300µl 1% human serum albumin 
(HSA) in TBS (10mM Tris-Cl, 140mM NaCl, pH 7.4) for 1 hour and subsequently 
washed with TBS/0.05% Tween 20 containing 5mM CaCl2. Serum samples or 
recombinant Ficolin-2 was diluted in 100µl of 10mM Tris-Cl, 140mM NaCl, 2mM 
CaCl2, 0.1% HAS, pH 7.4. Diluted samples were added to the wells and incubated 
for 2 hours at 37
o
C. After washing 4 times with wash buffer, bound ficolin-2 was 
detected with biotinylated anti-ficolin-2 GN5 followed by streptavidin-HRP. After 
repeating the wash steps as above, 200μl of 3,3',5,5'-Tetramethylbenzidine was 
added to each well for 30 minutes. The reaction was stopped with 100μl of HCL and 




P. aeruginosa (1 x 10
8
) were incubated with 25µl of serum or recombinant protein in 
TBS (10 mM Tris-HCl (pH 7.4), 140 mM NaCl), 0.05% (v/v) Tween 20, 5 mM 
CaCl2.  GlcNAc-sepharose beads or mannan-agarose beads (Sigma) were used as a 
positive control. After incubation at 4ºC for 1 hour, samples were centrifuged at 
7000g for 10 minutes. Supernatants were collected and unbound proteins quantified 
by ELISA. A result of 100% indicates no binding to microorganisms whereas 0% 
indicates complete binding. Values between 100% and 75% were not considered as 
significant binding as previous described (Hummelshoj et al 2012). <75% was 




Flow cytometry assay 
Bacteria (1 x 10
8
) were blocked for 1 hour at room temperature with 3% BSA in 
PBS. The samples were centrifuged at 3000×g for 15 minutes and the supernatant 
aspirated before re-suspension in the indicated concentration of Ficolin-2, Ficolin-3 
or mannose binding lectin in calcium buffer (0.5M sodium chloride, 20mM Tris-Hcl, 
10mM CaCl2, 1% BSA, pH 7.4. These were incubated at 37
º
C for 1 hour with the 
bacteria before centrifugation at 3000g for 15 minutes, aspiration of supernatant and 
incubation at 4
o
C for 30 minutes with anti-ficolin-2 (5µg/ml), anti-ficolin-3 (5µg/ml) 
or anti-MBL (1µg/ml). Samples were then centrifuged and re-suspended in PBS for 
flow cytometry on a BD FACS Calibur flow cytometer. 
 
2.15 Treatment of neutrophils with sputum sol or reagents 
Healthy donor neutrophils (0.5 x 10
6
 per experiment) were incubated for 30 minutes 
with either purified neutrophil elastase, cathepsin G (Sigma), or patient sputum sol 
(at a final concentration ranging from 10% sputum sol to 0.6% in PBS) or PBS 
control at 37
o
C. Following incubation, cells were washed extensively with PBS and 






2.16 FACS analysis of neutrophil surface markers 
Samples of freshly prepared neutrophils were centrifuged at 300g for 5 minutes and 
resuspended in PBS containing the following primary antibodies or appropriate 
isotype control antibody. The antibodies used were as follows: 
Mouse monoclonal anti-CD88 labelled with Allophycocyanin, Mouse monoclonal 
anti-complement receptor 1 (CD35) Phycoerythrin (clone 594708), mouse 
monoclonal anti-CD16b (clone 245536) labelled with Allophycocyanin (all R+D 
systems, Abingdon, UK), mouse monoclonal anti-complement receptor 3 (CD11b) 
labelled with Allophycocyanin (clone ICRF44) and mouse monoclonal CD62L 
(clone DREG-56) labelled with Phycoerythrin both from BD Bioscience, Oxford, 
UK. Neutrophil viability was assessed by staining with Annexin-V Fluorescein 
isothiocyanate and propidium iodine (Apoptosis detection kit, Sigma Aldrich).  
Antibodies were incubated at 4
o
C for 30 minutes, then centrifuged at 300g for 5 
minutes, resuspended in PBS and immediately subject to flow cytometry on a 
FACSCalibur flow cytometer. A minimum of 10,000 events were counted in all 
analyses.  
In the case of peripheral blood neutrophils, receptor expression was studied with and 
without maximal activation induced by treatment for 15 minutes with 1µM platelet 






2.17 FITC-labelling of bacteria 
P. aeruginosa strain PA01 and E.coli strain (ATCC 25922) were grown on 
Pseudomonas isolation agar and nutrient agar plates respectively. Freshly isolated 
colonies were inoculated into 10mls of Luria-Bertani broth at cultured overnight at 
37
o
C with gentle shaking. Cultures were then subculture 1 in 10 and grown for 3 
hours to enter logarithmic growth phase. Cultures (OD600=0.1) were then labelled 
with Fluorescein isothiocyanate (FITC) as described below.
 
Bacterial suspensions were serially diluted and plated out on agar plates to determine 
colony counts. Overnight cultures of bacteria were heat inactivated 60
º
C for 1 hour 
before centrifugation at 3000×g for 15 minutes and OD brought to 1 with cold PBS. 
Samples were washed with 1%BSA-Hanks’ balanced salt solution (HBSS). 100µL of 
FITC solution (0.5mg/ml in PBS) was added and placed on a rotary mixer at 4
o
C for 
30 minutes. 900µl of ice cold 1%BSA-HBSS was added and samples were 
centrifuged at 10000rpm for 2 minutes, and re-suspended in 1mL 1%BSA-HBSS. 
Labelling was confirmed by FACS analysis and microscopy. Labelled bacteria were 
stored at -80ºC until use. Results of the FACS analysis after labelling are shown 





Figure 2.7. Flow cytometry analysis confirming labelling of Pseudomonas 
aeruginosa strain PA01 with FITC.  
 
2.18 Generation of depleted sera 
Lectin pathway depletion 
To generate serum depleted of all lectin pathway components, pooled serum samples 
from healthy donors were incubated with GlcNAc beads equilibrated in binding 
buffer (50mM Tris-HCl, 200mM NaCL, 10mM CaCl2, pH 7.8) overnight at 4°C 
(Krarup et al 2004). Following incubation the concentration of Ficolin-2, MBL and 
Ficolin-3 in the serum was determined by ELISA. This method resulted in complete 




Specific Ficolin-2 depletion 
Serum samples were incubated with anti-Ficolin-2 (10µg/ml) and depleted with 
magnetic pan-mouse IgG dynabeads (Invitrogen) were applied according to the 
manufacturer’s instructions. Ficolin-2 depletion was confirmed by ELISA prior to 
use. 
 
Specific MBL depletion 
Serum samples were applied to a mannan-agarose column (Sigma) equilibrated in 
binding buffer 20mM Tris-HCl, 150mM NaCl, 2mM CaCl2, 1% BSA, pH 7.4, for 2 
hours at 4
º
C. MBL depletion was confirmed by ELISA prior to use. 
 
C1q and MASP-2 negative serum 
C1q depleted serum was purchased from Merck. MASP-2 negative serum was 
obtained from a patient with a homozygous D120G mutation, a condition that results 
in complete MASP-2 deficiency (Stengaard-Pedersen et al 2003, Thiel et al 2007). 
This serum contained normal levels of MBL, Ficolin-2 and Ficolin-3 but no 






2.19 Complement activation assays and Lectin pathway isolation 
Complement can be activated by the classical, alternative and lectin pathways. To 
isolate the pathways responsible for opsonisation of P. aeruginosa and other bacteria, 
and to determine the contribution of the lectin pathway to overall complement 
activation, several inhibitors of complement activation were used.  
Incubation of sera with 10 mM EDTA blocks all 3 complement activating pathways, 
as does heat inactivation at 57ºC for 1 hour. Incubation with 10 mM EGTA + 10 mM 
Mg
2+
 selectively blocks the classical and lectin pathways (Fine et al 1973) allowing 
study of the alternative pathway in isolation. Incubation with 100mM mannose 
primarily inhibits mannose binding lectin while incubation with 100mM N-
acetylglucosamine blocks all lectin pathway components (MBL, ficolin-1, ficolin-2 
and ficolin-3). C1q depleted serum was used to selectively block the classical 
pathway. Purified C1q (Sigma) was added to C1q depleted serum to recapitulate the 
blocked classical pathway. C3 depleted serum was obtained from Sigma and was 
used as a negative control for C3 deposition.  
A literature search identified 3 methods to specifically examine the lectin pathway of 
complement activation. C1q deficient serum was used to exclude classical pathway 
activation. Alternative pathway inhibition was achieved by high ionic strength using 
high NaCl concentration buffer (Petersen et al 2001) and the anticoagulant Sodium 
polyanethole sulfonate (SPS) (Palarasah et al 2011, Heja et al 2012). Low serum 
dilution (0.5%) also results in reduced activity of the alternative pathway (Harboe et 
al 2004, Ferguson et al 2006)  which most accurately reflects the low levels of 
complement components present in the lung. Previously studies suggest the 
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alternative pathway is relatively inactive in the lung (Watford et al 2000). Each of 
these experimental conditions was tested to determine the impact of lectin pathway 
activation on opsonisation of PA01. 
 
C4 cleavage assay 
Lectin pathway activation was quantified as described (Petersen et al 2001). 
Microplate wells were coated with 100µl of P.aeruginosa in coating buffer as 
described above (Lynch et al 2004). After overnight incubation, wells were blocked 
with 300µl 1% human serum albumin (HAS) in TBS (10mM Tris-Cl, 140mM NaCl, 
pH 7.4) for 1 hour and subsequently washed with TBS/0.05% Tween 20 containing 
5mM CaCl2 (wash buffer). Serum samples diluted with or without supplementary 
recombinant ficolin-2 were diluted (typically 1 in 10) in 20mM Tris-Cl, 1M NaCl, 
10mM CaCl2, 0.1% HAS, pH 7.4 which prevents activation of endogenous C4 and 
dissociates the C1 complex (composed of C1q, C1r and C1s). 100µl of diluted 
samples were added to the plate for 2 hours at 37
o
C. Plates were washed with wash 
buffer, followed by addition of 0.1µg of purified human C4. After 90 minutes at 
37
º




Initial experiments identified a dominant role for the alternative pathway in 
complement activation against P. aeruginosa (PA01). As described above, Microtitre 
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plates were coated overnight with 1 x 10
8 
cfu/ml of PA01 in coating buffer. Plates 
were washed 3 times in 10mM Tris-HCl, 140mM NaCl, pH 7.4. 50% pooled human 
serum was diluted in 10mM Tris-HCl, 140mM NaCl, pH 7.4 containing 10mM 
EGTA and 10mM Mg
2+
 with increasing concentrations of sodium polyanethole 
sulfonate (0.1mg to 1mg/ml). Serum samples were incubated for 1 hour at 37°C 
followed by washing 3 times in wash buffer. Complement activation was detected by 
incubation with anti-complement C4 (HYB 162-04, Bioporto) or anti-complement c3 
(HAV 003-05, Bioporto) followed by anti-mouse HRP detection antibody. Complete 
inhibition of alternative pathway activity was defined as an optical density of C4 and 
C3 activation equivalent to the negative control (heat inactivated serum).  
Lectin pathway activity was measured using mannose binding lectin activation on 
mannan using a modification of a previously described protocol (Petersen et al 
2001).  Microtitre plates coated with mannan from Saccharomyces cerevisiae 
(Sigma) at 10µg/ml in coating buffer and incubated overnight at 4°C. Wells were 
blocked and subsequently doubling dilutions of pooled serum were incubated in 
20mM Tris-HCl, 10mM CaCl2, 140mM NaCl, 0.05% triton X-100, 0.1% human 
serum albumin, pH 7.4 containing increasing concentrations of sodium polyanethole 
sulfonate (0.1mg to 1mg/ml).These were incubated at 37°C for 1 hour. Well were 
washed and complement activation detected by incubation with anti-complement C4 
(HYB 162-04, Bioporto) and anti-complement c3 (HAV 003-05, Bioporto) followed 
by HRP detection antibody. Complete inhibition of lectin pathway activity was 
defined as an optical density of C4 and C3 activation equivalent to the negative 




Low serum concentration 
The alternative pathway is relatively inactive at low serum concentrations and is 
therefore thought to have a limited role in complement activation in the lung 
(Watford et al 2000, Ferguson et al 2006). Therefore low concentrations of C1q 
–ve 
serum should only be able to activate complement via the lectin pathway. Using the 
alternative pathway assay described above, very low C3 or C4 deposition was 
detected when incubating serum with 10mM EGTA and 10mM Mg
2+ 
at a 
concentration of 2% serum. Lectin pathway activity was still detectable at 0.5% 
serum concentration and was used for subsequent experiments. These data are shown 
in chapter 4. 
 
2.20 Phagocytosis assays 
Neutrophil phagocytosis assay 
A flow cytometry based phagocytosis assay was used (Farnworth et al 2008). 
Labelled P. aeruginosa and E.coli were opsonised as indicated at 37
o
C for 1 hour. 
Opsonised bacteria were then added at a multiplicity of infection 10:1 to patient or 
control neutrophils (0.5 x 10
6
 per experiment). Phagocytosis was permitted at 37
o
C 
for up to 30 minutes and then terminated by placing the samples on ice. Excess 
bacteria were removed by washing in PBS and cells subsequently analysed by FACS. 
To differentiate phagocytosed (intracellular) bacteria from adherent (extracellular 
bacteria), cells were incubated with 0.1% trypan blue to quench extracellular 
fluorescence. A minimum of 10,000 events were counted.  
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Time point studies were performed to determine the optimum point to terminate 
phagocytosis. These data are shown below. Validation of the assay suggested a 
strong correlation between flow cytometry and microscopy results. Validation that 
the observed increase in fluorescence was the result of phagocytosis was achieved by 
pre-treatment of neutrophils with 100µg/ml cytochalasin-D prior to phagocytosis 
(Mimura and Asano, 1976). This inhibits actin polymerisation in neutrophils and 
therefore prevents bacterial ingestion. 
Figure 2.8 shows a strong relationship between the concentration of serum used for 
opsonisation and the percentage of positive cells, indicating the proportion of 
neutrophils taking up FITC labelled bacteria. After opsonisation with 20% serum, 
neutrophils are saturated within 5 minutes with no further increases in % positive 
cells. Saturation was achieved between 10 and 20 minutes after opsonisation with 
10% serum but 100% phagocytosis was not achieved at concentrations below 10% 
serum. After opsonisation with 1% serum, 98% phagocytosis was achieved after 30 
minutes. As expected, cytochalasin-D completed inhibited neutrophil phagocytosis. 
Even small concentrations of opsonins increase phagocytosis with significant 





Figure 2.8. Flow cytometry phagocytosis assay. Bacteria were incubated with 
increasing concentrations of donor serum and incubated with FITC-labelled PA01 








Examining mean fluorescence, which is thought to estimate the number of bacteria 
ingested per neutrophil, there were similar concentration serum concentration 
dependent increases in phagocytosis. Using two way ANOVA, all serum 
concentrations were significantly different compared to no serum (p<0.0001). The 
same inhibitory effect was observed with cytochalasin-D, these results are shown in 
figure 2.9.  
 
Figure 2.9. Flow cytometry phagocytosis assay. Bacteria were incubated with 
increasing concentrations of donor serum and incubated with FITC-labelled PA01 




Again, even small amounts of serum opsonins increased phagocytosis. These results 
suggested that this assay is sensitive to changes in serum opsonins and would be 
suitable to study the effects of ficolin-2 and mannose binding lectin on phagocytosis.  
To further validate the phagocytosis assay used in these experiments, the neutrophil 
phagocytosis assay was performed in the same way as described above, but instead 
of using flow cytometry, the proportion of positive cells was identified using 
microscopy. Phase contrast microscopy was used to identify neutrophils and 
fluorescence microscopy indicated the presence of intracellular FITC-labelled 
bacteria. The proportion of cells containing bacteria was determined by counting 100 
neutrophils from randomly selected fields.  
 
The figure below shows a representative microscopy image from an experiment in 
which PA01 was incubated with 20% serum for 1 hour following which 
phagocytosis was permitted for 30 minutes at 37ºC. Large numbers of FITC-labelled 




Figure 2.10. Phase contrast and fluorescence microscopy images of neutrophil 
phagocytosis. The panel on the left shows the phase contrast image. Green PA01 is 
clearly visible within the cells and this is confirmed on the fluorescence image (right) 
showing large numbers of labelled bacteria within the cells.  
 
 
The correlation between the observed % phagocytosis rate determined by both flow 
cytometry and microscopy methods is shown below and assessed using linear 
regression. There was a strong correlation between both methods, r=0.97,p<0.001, 




Figure 2.11. Validation of the flow cytometry phagocytosis assay against 
microscopy based methods.  
 
This analysis demonstrated a strong linear correlation between phagocytosis 
determined by flow cytometry and microscopy. Flow cytometry based assays were 
therefore used for subsequent investigations of the effect of ficolin-2 and mannose 





Macrophage phagocytosis assay 
After 5 days incubation, adherent monocyte derived macrophages (0.5 x 10
6
 per 
experiment) were washed with PBS and subsequently incubated for up to 1 hour at 
37°C with FITC-labelled P.aeruginosa and E.coli. Bacteria were opsonised as 
indicated prior to incubation with macrophages After 1 hour, cells were washed 3 
times with PBS to remove non-phagocytosed bacteria. Cells were incubated with 
0.1% trypan blue to quench extracellular fluorescence. Macrophages were then 
removed from plates by incubation with PBS-EDTA and gentle agitation and 
transferred to FACS tubes for flow cytometry. Macrophages were identified by their 
forward and side scatter properties on a BD FACSCALIBUR flow cytometer. A 
minimum of 10,000 events were counted (Farnworth et al 2008).  
 
2.21 Role of Pentraxins 
Previous reports that C-reactive protein enhances complement activation and killing 
of P. aeruginosa via the lectin pathway (Zhang et al 2009)  and that Ficolin-2 
collaborates with pentraxin-3 to enhance complement activation and phagocytosis of 
Aspergillus fumigatus (Ma et al 2009) led us to investigate the role of pentraxins in 
complement activation and neutrophil phagocytosis against P. aeruginosa.  
 
Pentraxin-3 ELISA 
Serum and sputum pentraxin-3 was measured using a commercial sandwich ELISA 
purchased from R+D systems (Abingdon, UK). 
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Pentraxin-3 enhancement of complement activation and phagocytosis 
P. aeruginosa (PA01) were prepared as described above. Bacteria (1 x 10
8
) were 














 serum supplemented with 5µg/ml recombinant ficolin-2 and 
10µg/ml recombinant pentraxin-3, 10µg/ml Serum amyloid P or recombinant C-
reactive protein (10µg/ml). 
C3 deposition was determined by flow cytometry.  Bacteria (1 x 10
8
) were blocked 
for 1 hour at room temperature with 3% BSA in PBS. The samples were centrifuged 
at 3000×g for 15 minutes and the supernatant aspirated before re-suspension in PBS, 
depleted serum or depleted serum containing ficolin-2 and pentraxins as above. Sera 
were diluted in calcium buffer (0.5M sodium chloride, 20mM Tris-Hcl, 10mM 
CaCl2, 1% BSA, pH 7.4). Samples were incubated at 37
º
C for 1 hour with the 
bacteria before centrifugation at 3000×g for 15 minutes, aspiration of supernatant 
and incubation at 4
º
C for 30 minutes with anti-complement C3-FITC (MP 
Biomedicals). Samples were centrifuged and re-suspended in PBS for flow 
cytometry. 
For phagocytosis assays, bacteria were opsonised as described above and then 






2.22 Neutrophil oxidative burst assay 
Neutrophil oxidative burst was measured using the Dihydrorhodamine fluorescence 
method as previously described (Walrand et al 2003, Farnworth et al 2008). 
Neutrophils with or without the indicated treatments were incubated with 0.1mmol/L 
dihydrorhodamine followed by a priming agent (1µM PAF, complement component 
c5a or control) for 15 minutes followed by an activating agent (0.1µM fMLP or 
control) for 15 minutes. DHR fluorescence was then measured as mean FL-1 
fluroescence on a BD FACSCalibur flow cytometer. The mean fluorescence equates 
to the conversion of dihydrorhodamine to rhodamine through the generation of H2O2 
metabolites by activated neutrophils.  
 
2.23 Neutrophil killing assay 
1 x 10
6 
cfu/ml P. aeruginosa PA01 was opsonised for 1 hour at 37°C in complement 
component C5 deficient serum (Sigma). C5 deficient serum was used to prevent 
activation of the terminal complement components and cell lysis as PA01 is sensitive 
to serum killing. Initial experiments indicated that the C5 deficient sera were able to 
opsonise PA01 with C3 normally (see C3 activation assay above) with no bacterial 
killing. Opsonised bacteria were added to 1 x 10
7 
neutrophils (a multiplicity of 
infection of 0.1) and incubated for 90 minutes at 37°C. Bacteria without neutrophils 
were used as a negative control and bacteria treated for 90 minutes with gentamicin 
10µg/ml were used as a positive control (100% killing). Following incubation with 
neutrophils, samples were centrifuged at 1000g for 5 minutes. The supernatants were 
aspirated and the neutrophils lysed with 0.1% Triton x-100 (no effect on PA01 
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viability was observed at this concentration of Triton x-100). Serial dilutions were 
made and 100µl samples plated on LB agar overnight at 37°C in triplicate.  
 
2.24. Regulation of Ficolin-2 secretion 
Expression of ficolin-2 in human liver cell lines 
Immortalised human hepatocyte cells lines HepG2 and HuH-7 were kind gifts from 
Professor Iredale’s laboratory at the University of Edinburgh. Cells were maintained 
in DMEM media containing 10% fetal calf serum, 1% penicillin/streptomycin and 
1% L-glutamine. Cells were grown in 5% CO2 and 95% atmospheric air at 37ºC. 
To investigate regulation of ficolin-2 secretion by hepatocytes, HuH-7 and HepG2 
cells were seeded into 6 well plates (1 x10
4
 cells per plate). After 48 hours, the media 
was changed to 1ml media containing one of the following agents (obtained from 
Sigma) 
- Hormones (T3, human Growth Hormone) 
- Proinflammatory cytokines (interleukin 1-beta, Interleukin-6, Tumour 
necrosis factor-α, transforming growth factor ß) 
- Medications (Simvastatin, Dexamethasone) 
- Lipopolysaccharide 
Cells were cultured for 72 hours after which the culture supernatants were collected 
and stored at -70°C until analysed. Cells were counted using a haemocytometer and 
ficolin-2 and MBL synthesis were measured using ELISA. Results are expressed as 
ng/10
6




Real time polymerase chain reaction 
FCN2 mRNA expression levels were quantified using real time PCR. Total RNA 
was extracted from cells using QIAshredder columns  and the RNeasy mini kit 
(Qiagen) according to the manufacturers instructions followed by DNase treatment. 
For DNase treatment, 2µl RQ1 RNase-Free DNase (Promega) and 2µl 10x reaction 
buffer (Promega) was added to 2µg RNA, made up to a final volume of 20µl with 
nuclease-free H2O and incubated for 30 minutes at 37°C. Immediately, 2µl RQ1 
DNase stop solution (Promega) was added to each tube for 10 minutes at 65°C to 
terminate the reaction. ‘Clean’ RNA was stored at -80°C until further use. cDNA 
synthesis was performed using 1.5µg RNA in a 40µl reaction as follows (10x 
Taqman RT buffer-4µl, 25µM MgCl- 8.8µl, dNTP- 8µl, Random hexamers- 2µl, 
RNase inhibitor- 0.8µl, multiscribe reverse transcriptase- 1µl, RNA- 15.4µl).  
PCR condition were: 25°C: 10 minutes, 48°C: 40 minutes, 95°C: 5 minutes.  
Taqman primer probe mix for ficolin-2 was purchased from Applied Biosystems. 
Real-time PCR was performed in a 25µl volume per well, incorporating 12.5µl of 2x 
Gene expression master mix (Applied biosystems), 1.25µl 20x FCN2 primer/probe 
mix, 8µl dH20 and 1.25µl 18s primer/probe mix (Applied biosystems). 18s was used 
as a house-keeping gene. The amount of mRNA expression is reported as the Ct 





Cardiac surgery study 
We recruited 10 patients undergoing coronary artery bypass surgery, an invasive 
surgical procedure associated with a significant acute inflammatory response that has 
been previously used in the literature as a model for acute phase responses (Bruins et 
al 1997). We measured serum levels of Ficolin-2 and mannose binding lectin 24 
hours pre-operatively and then at 24, 72, 120 and 168 hours after cardiac surgery. 
Acute phase responses of Ficolin-2 and MBL were compared to classical acute phase 
reactant C-reactive protein measured by the biochemistry department at the Royal 
Infirmary of Edinburgh. 
 
2.25 Studying the relationship between airway and systemic inflammation and 
airway bacterial load 
Several studies were performed to determine the relationship between airway 
bacterial infection and airway and systemic inflammation. The aim of these studies 
were to determine if bacterial load was associated with markers of airways and 
systemic inflammation in patients with bronchiectasis, and to determine if antibiotic 
therapy, both during stability and during acute exacerbations could reduce airway 
and systemic inflammation. The studies are summarised in figure 2.12. The methods 




Figure 2.12. Summary of studies into the relationship between airway colonisation 
and airway and systemic inflammation.  
 
In study 1, we investigated the relationship between bacterial load and airway and 
systemic inflammation during clinical stability 
This study included stable serum and sputum samples for 385 patients with 
bronchiectasis recruited as part of the primary study. All patients were clinically 
stable at recruitment and free from antibiotic therapy for at least 4 weeks. The 
inclusion and exclusion criteria are as described above for the study of ficolin-2 in 
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bronchietasis. Data on the relationship between bacterial load and clinical outcomes 
are presented for the first year of follow-up after bacterial load measurement. 
 
In study 2 the effect of long term antibiotic treatment using nebulised gentamicin on 
markers of airway and systemic inflammation was assessed. We used data from a 
randomised controlled trial of nebulised gentamicin. Details of this randomised 
controlled trial have been described previously (Murray et al, 2010). Patients were  
randomised to receive 80mg twice daily nebulised gentamicin or to receive nebulised 
0.9% saline for 12 months. Randomisation was performed by the study pharmacist 
and the study was approved by the NHS Scotland multi-centre research ethics 
committee. The primary outcome of the study was the impact of nebulised 
gentamicin on quantitative bacterial load, and the results of the primary and 
secondary outcomes of the study have been published (Murray et al, 2010). The 
inclusion criteria for the study were culture of pathogenic organisms in at least 3 
sputum samples when clinically stable in the preceding 12 months, at least two 
exacerbations in the past year, and successful toleration of a test dose of gentamicin 
80mg without a fall in FEV1 >15% or >200ml. Patients had to have an FEV1 greater 
than 30% predicted and had to be ex-smkers of at least 1 year with less than 20 pack 
year history. Patients were also required to be clinically stable at study entry defined 
as above, as the absence of requirement for antibiotics in the preceding 4 weeks. 
Exclusion criteria were: current use of long term antibiotics, current smoking, cystic 
fibrosis, active pulmonary mycobacterial infection, active sarcoidosis, active allergic 
bronchopulmonary aspergillosis, chronic obstructive pulmonary disease, poorly 
controlled asthma, creatinine clearance <30ml per minute, vestibular instability and 
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previous documented intolerance to aminoglycosides (including ototoxicity and 
nephrotoxicity).  
The study was not blinded and patients were aware of their treatment allocation. 
The study was performed principally by Dr Maeve Murray.    
To investigate the impact of long term antibiotic therapy on airway and systemic 
inflammation we used sputum and serum samples from the  27 bronchiectasis 
patients randomised to receive nebulised gentamicin 80mg twice daily along with 
samples from 30 patients randomised to receive nebulised 0.9% saline for 12 months. 
Microbiology and assessments of airway and systemic inflammation were performed 
as described above.  
In study 3 the effect of bacterial clearance using 14 days intravenous antibiotic 
therapy on markers of airway and systemic inflammation in stable patients was 
assessed. 15 patients received 14 days of intravenous antibiotics based on their 
previous microbiology results.  Patients were recruited from patients attending the 
specialist bronchiectasis service at the Royal Infirmary of Edinburgh and were free 
from exacerbations or oral antibiotic therapy for at least 4 weeks prior to study. None 
of the patients were receiving long term antibiotic or corticosteroid therapy. A 
sputum sample was obtained and processed immediately from all eligible patients. 
Patients growing >1 x 10
7
 cfu/ml were chosen for study. For comparison, 11 patients 
who attended for routine review and were found to have bacterial loads while 
clinically stable of >1 x 10
7
 cfu/ml had sputum samples taken 2 weeks apart without 
antibiotics therapy. This study was not placebo controlled.  
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In study 4 the effect of bacterial clearance using 14 days intravenous antibiotic 
therapy on markers of airway and systemic inflammation in patients with 
exacerbations of non-CF bronchiectasis was assessed. 34 patients with severe 
exacerbations of non-CF bronchiectasis requiring intravenous antibiotic therapy 
(defined according to BTS guideline definitions, Pasteur et al 2010) were recruited. 
After clinical assessment to confirm exacerbation patients were treated with 
intravenous antibiotic therapy based on their previous microbiology results. Sputum 
and serum samples were obtained taken at baseline and after 14 days of antibiotic 
therapy. 
 
2.26. Statistical methods 
Statistical software used for analyses in this thesis were SPSS version 21 for 
windows (SPSS inc., Chicago, IL)., Graphpad Prism version 5 (Graphpad software, 
San Diego, CA, USA) and Snpalyze version 8 (Dynacom, Japan). 
Results are expressed as median with interquartile range or mean +/- standard 
deviation (SD) as appropriate. Each in-vitro experiment was performed in triplicate 
unless otherwise indicated. For clinical data, comparisons of categorical data were 
performed using chi-square test while continuous data were compared using the 
Mann-whitney U test (2 groups) or Kruskal-Wallis test (more than 2 groups). Pair-
wise comparisons between in-vitro conditions are made using an unpaired students t 
test. Analysis of variance with the Bonferroni posthoc test was used to determine 
differences between multiple groups for in-vitro experiments. 
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The genotype frequencies were checked for consistency among cases and controls 
separately with those expected from the Hardy-Weinberg equilibrium. 
The accuracy of genetic definitions of ficolin-2 insufficiency to predict low serum 
Ficolin-2 levels was assessed using the area under the receiver operator characteristic 
curve. Curves were compared using the method described by Hanley and McNeil 
(Hanley and McNeil 1983). 
Cox-proportional hazards regression analysis was used to investigate the association 
of ficolin-2 serum levels and SNP’s with mortality. These models utilised forced 
entry of all other co-variates to minimise residual confounding. For analysis of 
chronic colonisation or P. aeruginosa colonisation, multivariable analysis was 
performed using logistic regression. Models were constructed adjusted for all 
available, biologically plausible confounders. Model adequacy was assessed with the 
Hosner-Lemeshow goodness of fit test. 






The impact of short and long term antibiotic therapy on airway and systemic 
inflammation in bronchiectasis 
3.1 Introduction 
The vicious cycle hypothesis of bronchiectasis argues that bacterial colonisation of 
the normally sterile respiratory tract provokes and perpetuates airway inflammation 
(Cole, 1986). This neutrophil mediated inflammation leads to airway structural 
damage and further impairment of the mucociliary escalator, leading to increased 
bacterial load (Cole, 1986, Watt et al, 2004, Fuschillo et al, 2008). This cycle repeats 
continuously throughout the course of the disease, leading to the clinical syndrome of 
cough, sputum production and recurrent exacerbations that is characteristic of 
bronchiectasis (Pasteur et al, 2010).
 
According to this hypothesis, if bacteria are the primary drivers of airway 
inflammation, bacterial clearance through the use of short or long term antibiotic 
therapy would be expected to reduce airway inflammation, allow airway healing and 
modify the long term course of the disease. 
There is strong evidence from cystic fibrosis bronchiectasis to support this view, with 
data suggesting that bacterial colonisation is associated with airway inflammation 
and that antibiotic treatment during stability and at exacerbation can reduce markers 
of inflammation (Sagel et al, 2011, Ordonez et al, 2003, Downey et al, 2007).
 
Extrapolation from cystic fibrosis to non- cystic fibrosis bronchiectasis is difficult as 
the pathophysiology is different and the failure of recombinant DNase treatment to 
provide benefit in non-cystic fibrosis bronchiectasis demonstrates that responses to 
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treatment can be very different in cystic fibrosis compared to non-cystic fibrosis 
bronchiectasis (O’Donnell et al, 1998).
 
The evidence base in non-cystic fibrosis 
bronchiectasis is limited, although a study of 49 patients with stable bronchiectasis 
using bronchoalveolar lavage demonstrated a link between bacterial load and airway 
inflammation, and a study of COPD patients included 43 with bronchiectasis (Angrill 
et al, 2001, Hill et al, 2000).
  
Raised systemic inflammation has been shown to be associated with disease severity 
and lung function impairment in 87 stable patients with bronchiectasis (Wilson et al, 
1998).  
There are limited studies evaluating the effect of bacterial clearance in non-cystic 
fibrosis bronchiectasis. A 2007 Cochrane review of randomised controlled trials of 
antibiotic therapy in non-cystic fibrosis bronchiectasis suggested no benefit in terms 
of lung function or exacerbation frequency (Evans et al, 2007).  In addition, some 
studies suggest that antibiotic therapy in bronchiectasis had little or no effect on 
markers of airway inflammation, further questioning the hypothesis that antibiotics 
can “break the cycle” (Tsang et al, 1999) Conversely, three studies of long-term 
antibiotics have demonstrated reduced levels of myeloperoxidase and neutrophil 
elastase activity in sputum following prolonged antibiotic treatment (Murray et al, 
2010, Lin et al, 1997, Hill et al, 1988).  
The aim of the studies described in this chapter was to determine if bacterial load 
was associated with markers of airways and systemic inflammation in patients with 
bronchiectasis, and to determine if antibiotic therapy, both during stability and during 
acute exacerbations impacted on this. Finally, we aimed to determine the association 
171 
 
of bacterial load with key clinical markers of severity in bronchiectasis, including 
exacerbation frequency and health related quality of life. 
 
3.2 Characteristics of the cohort 
The stable cohort in this study included 385 patients. Median age was 67 years, 
interquartile range 56-74, 42.9% of the study cohort were male. 81.6% of patients 
had idiopathic/post-infective bronchiectasis in the stable cohort. The “other” causes 
of bronchiectasis were previous ABPA (n=36), rheumatoid arthritis (n=19), 
inflammatory bowel disease (n=13), and one patient each with alpha-1-antitrypsin 
deficiency, yellow-nail syndrome and Kartagener’s syndrome. 40.3% of the 
population were using inhaled corticosteroids. The demographics of the study 
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Table 3.1. Cohorts included in the studies described in this chapter. 
 
 
3.3 Relationship between airway bacterial load and airway inflammation 
Pathogenic microorganisms were isolated in the baseline sputum cultures from 
75.3% of patients. Of those with positive cultures, predominant organisms isolated 
were Haemophilus Influenzae 38.6%, Pseudomonas aeruginosa 21.0%, S. aureus 
12.4%, M. catarrhalis 11.4%, S. pneumoniae 9.7% and others (primarily enteric 
gram negative organism) 9.3%. Total numbers add up to greater than the total 
number of patients as some patients grew more than one organism.   
Bacterial load was strongly associated with each of the markers of airway 
inflammation measured in sputum (figure 3.1). Compared to the 22.1% of patients 
that grew no potentially pathogenic microorganisms (PPMs), statistically 





median levels of each of the five markers increased progressively with increasingly 
bacterial load. Analyses adjusting for inhaled corticosteroid use found the same 
results (Chalmers, 2012, online supplementary material). The same results were 
observed when examining patients with idiopathic/post-infective bronchiectasis and 






Figure 3.1.  The relationship between bacterial load when stable and markers of 
airway inflammation in sputum. Data are presented as median (boxes) with 
interquartile range (bars). *p<0.05, **p<0.001 ***p<0.0001. All display 
comparisons are Mann-Whitney U test compared to patients growing no PPMs. 
Comparison across multiple groups (Kruskal-Wallis test) showed a direct 
relationship between airway bacterial load and airway inflammation (p<0.0001 for 







3.4 Relationship between airway bacterial load and systemic inflammation 
Analysis of soluble adhesion molecules in serum showed elevated levels of ICAM-1, 
E-selectin and VCAM-1 in patients growing 1 x 10
7
cfu/ml or more compared to the 
group with no PPMs (Figure 3.2). Differences between bacterial loads of 1 x 
10
5
cfu/ml and 1 x 10
6
cfu/ml with the no PPM group were not statistically significant 
(p>0.05).  
When compared to the healthy control population, overall bronchiectasis patients had 
higher levels of ICAM-1 (171ng/ml (interquartile range 114.2–296.2) in controls vs. 
270.2ng/ml (168.7-459.0) in bronchiectasis patients, p<0.0001)), while less striking 
differences in E-selectin (56.8ng/ml (36.4-80.9) in controls vs. 64.9ng/ml (43.7-94.6) 
in bronchiectasis patients, p=0.02) were observed and the levels of VCAM-1 
(582ng/ml (456-924.1) in controls vs. 686.6 (527.8 to 921.4),p=0.07) were not 













Figure 3.2. The relationship between bacterial load when stable and markers of 
systemic inflammation in serum. Data are presented as median (boxes) with 
interquartile range (bars). *p<0.05, **p<0.001 ***p<0.0001. All display 
comparisons are Mann-Whitney U test compared to patients growing no PPMs. 
Comparison across multiple groups (Kruskal-Wallis test) showed a direct 
relationship between airway bacterial load and systemic inflammation (p=0.003 for 
ICAM-1, p=0.001 for E-selectin and p=0.0007 for VCAM-1).   
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3.5 The impact of 14 day antibiotic therapy on markers of airway inflammation 
and systemic inflammation + exacerbations.  
For stable patients, 15 were treated with IV antibiotics for 14 days and 11 received 
no therapy for 14 days.  
Table 3.2 shows the characteristics and microbiology of patients included in the IV 
antibiotic study.  
Sputum and serum markers were then compared between these two groups. At 
baseline, all patients had sputum cultures that grew PPMs at 1 x 10
7
 cfu/ml or 
greater. Following 14 days of intravenous antibiotic therapy, all patients had no 
significant bacterial growth in sputum. In contrast, in the control group that received 
no antibiotic therapy, there was no reduction in the bacterial load (baseline mean 3.2 
x 10
8
 cfu/ml vs. 2.1 x 10
8



























































































































































































































































































Table 3.2. Characteristics and Microbiology of patients included in the IV antibiotic 
study. All patients had a bacterial load of >1 x 10
7





Bacterial clearance through 14 days of antibiotic therapy was associated with a 
significant reduction in all of the markers of airway inflammation measured (figure 
3.3). In addition, antibiotic treatment was associated with a statistically significant 
reduction in ICAM-1 concentration in serum and E-selectin also decreased with 
treatment (76.7ng/ml, 61.7-91.8ng/ml pre-treatment vs. 53.3ng/ml, 44.6 – 68.8ng/ml 
post-treatment, p=0.04). Although VCAM-1 serum levels decreased with treatment 
(782ng/ml, 302.2-1001ng/ml pre-treatment vs. 387.1, 121.3 -919.7 post-treatment), 
this difference was not statistically significant, p=0.4. There were no significant 









Figure 3.3. Response of markers of airway and systemic inflammation to 14 days of 
intravenous (IV) antibiotics. *p<0.05 when compared the day 0 values. All other 
comparisons p>0.05. Box plots show median with interquartile range with the 







For patients with acute exacerbations of bronchiectasis (n=34), all patients had a 
significant growth of pathogens from baseline (the most frequent pathogens were 
H.influenzae in 11 patients, S. pneumoniae 9 patients, P. aeruginosa 8 patients, S. 
aureus 3 patients, M. catarrhalis 2 patients, gram-negative enterobacteriaceae 4 
patients- numbers add up to more than 34 as 3 patients grew more than one 
pathogen). At day 14, only 4 patients still had a significant growth of bacteria (all P. 
aeruginosa). The data demonstrated a significant reduction in all markers of airway 
inflammation (p<0.0001 for all comparisons, figure 3.3) and ICAM-1 (p<0.05) after 
14 days of antibiotic therapy in patients with exacerbations of bronchiectasis, figure 
3.3. Differences in serum E-selectin and VCAM-1 were not statistically significant 
(p=0.1 and p=0.3 respectively).  
 
3.6 The impact of 12 months nebulised gentamicin on markers of airway and 
systemic inflammation 
The organisms isolated in the patients treated with nebulised gentamicin and 
nebulised 0.9% saline in this study have been reported previously (Murray et al, 
2010). In addition, it has been previously reported that nebulised gentamicin resulted 
in a statistically significant reduction in MPO activity and neutrophil elastase activity 
in the treatment group, which was not evident in the saline group (Murray et al, 
2010). Results are therefore only presented for sputum IL-8, TNF-α, IL-1β and the 
soluble adhesion molecules in serum. Nebulised gentamicin resulted in significant 
reduction in sputum IL-8, TNF-α and IL-1β, compared to patients treated with 0.9% 
saline. For the soluble adhesion molecules, reductions were evidence in ICAM-1 
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compared to both baseline and the saline treated groups at 12 months. E-selectin was 
significantly different from baseline in the gentamicin group but did not differ 
compared to the saline group. No differences were evident in the levels of VCAM-1 
at any stage in the study. These data are shown in Table 3.3. 
 
 Gentamicin n=27 Saline n=30 
Time point 
(months) 
0 12 15 (3m post 
treatment) 
0 12 15 (3m post 
treatment) 














































































100% 33.3%*# 66.7% 100% 96.7% 96.7% 
Table 3.3. The impact of nebulised gentamicin treatment on markers of airway and 
systemic inflammation. *p<0.05 when compared with baseline (time point 0). 
# 
p<0.05 when compared with the same time-point in the saline treated group.  
 
3.7 Pseudomonas aeruginosa and radiological severity of bronchiectasis 
influence airway inflammation 
Pseudomonas aeruginosa 
P. aeruginosa was associated with increased airway inflammation independent of the 
bacterial load compared to isolation of other pathogens. Patients with P.aeruginosa 
were each matched by log bacterial load and radiological severity (+/- 1) to patients 
that had isolated other PPMs (n=81 and 162 respectively). The median bacterial load 
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was 4.4 x 10
7
cfu/ml vs. 4.6 10
7
cfu/ml,p=0.3. Median radiological severity was 8 (4-
12) vs. 7 (4-12),p=0.8.   
Patients isolating P.aeruginosa had higher levels of MPO activity- 13.5U/ml (4.0-
38.6) vs. 2.6 (0.6-50.8),p<0.0001, elastase activity- 4.9µg/ml (1.2-68.0) vs. 1.2µg/ml 
(0.4-147.2),p<0.0001 , IL-8- 52.2ng/ml (34.0-64.5) vs. 39.5 (30.0-49.7), p=0.001 and 
TNF-alpha- 2722pg/ml (971.2-5098) vs. 1024pg/ml (277-2529),p<0.0001. The 
difference between the two groups in levels of Interleukin 1-beta- 2.8ng/ml (0.9-5.8) 
vs. 2.3ng/ml (1.3-4.9),p=0.8 was not statistically significant. 
 
Radiological severity 
There was a direct relationship between increasing radiological severity and severity 
of airway inflammation (p<0.0001 for sputum elastase, MPO, TNF-alpha, IL-1beta 






Figure 3.4. The relationship between airway inflammation and radiological severity 










3.8 Spirometry and airway inflammation 
These data demonstrate a significant association between FEV1% predicted and 
airway inflammatory markers. There was a significant association between FEV1% 
predicted and elastase activity (p<0.0001), MPO activity (p<0.0001), Interleukin-8 
(p<0.0001), tumour necrosis factor alpha (p=0.005) and IL-1beta (p<0.0001).  
 
 
Figure 3.5. Relationship between airway inflammation and lung function. The 
relationship between airway inflammation and forced expiratory volume in 1 second. 




3.9 Independent relationship between airway inflammation and bacterial 
colonisation 
A multivariable logistic regression analysis was performed to determine if airway 
inflammation was associated with a positive bacterial culture, independent of 
radiological severity and FEV1 % predicted. Neutrophil elastase (Adjusted Odds 
Ratio (AOR) 1.08, 95% CI 1.03-1.14,p=0.003), myeloperoxidase (AOR 1.18, 95% 
CI 1.09-1.28,p<0.0001), Interleukin-8 (AOR 1.03, 95% CI 1.02-1.05,p<0.0001), 
TNF-alpha (AOR 1.11, 95% CI 1.06-1.15,p<0.0001) and IL-1β AOR 1.61, 95% CI 
1.34-1.94,p<0.0001) were each independently associated with bacterial colonisation. 
Adequate model fit was demonstrated for all analyses by the Hosner-Lemeshow 
goodness of fit test (p>0.05).  
 
3.10 Airway bacterial load predicts exacerbation frequency, hospital admissions 
for severe exacerbations over the subsequent 12 months and patient symptom 
scores.  
The prognostic importance of airway bacterial load was investigated by following 
patients for 1 year after their initial visit. The mean number of self-reported 
exacerbations during this year was 3.3/year (standard deviation 2.9, range 0-15/year).  
After 1 year, there was a significant correlation between the number of exacerbations 
and the airway bacterial load (figure 3.6). Similarly, patients with higher bacterial 
loads had experienced more frequent unscheduled hospitalisations (figure 3.6). After 
adjusting for confounders, bacterial load remained a significant predictor of recurrent 
exacerbations: AOR 1.20, 1.11-1.29, p<0.0001 for each 1 log unit increase in 
bacterial load (for this analysis, recurrent exacerbations were defined as >3 per year). 
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For unscheduled hospitalisations, bacterial load was an independent predictor of 
hospitalisation AOR 1.11, 1.01-1.21, p=0.02 for each 1 log unit increase in bacterial 
load. Adequate model fit was demonstrated for all analyses (p>0.05). There was a 
significant association between bacterial load and subsequent severity of cough 
symptoms using the Leicester Cough Questionnaire (p<0.0001, Kruskal-Wallis test) 
and the St. George’s Respiratory Questionnaire (p<0.0001, Kruskal-Wallis test). The 
differences were greater than the minimal clinically important difference at 
10
5
cfu/ml or greater for the LCQ and at 10
6




Figure 3.6. Outpatient exacerbations, unscheduled hospital admissions and symptom 
questionnaires after 1 year of follow-up. Data are presented as mean and standard 
error (outpatient exacerbations) and as median (IQR) for symptom questionnaires. 
For unscheduled hospital admissions, data are presented as % of patients hospitalised 








This chapter demonstrates a direct relationship between bacterial load and airway 
and systemic inflammation in a large population of patients with non-CF 
bronchiectasis. Over 1 year, patients with high bacterial loads had a higher frequency 
of exacerbations and were more likely to require hospitalisation with severe 
exacerbations. This relationship was independent of severity of bronchiectasis as 
assessed by CT scanning and spirometry. Higher bacterial loads were associated with 
more severe respiratory symptoms, as assessed by the St. George’s Respiratory 
Questionnaire, and more severe cough, as assessed by the Leicester Cough 
Questionnaire. 
These relationships demonstrate a central role for bacterial infection in provoking 
inflammation and affecting short-term prognosis in patients with bronchiectasis, 
providing strong evidence in support of the vicious cycle hypothesis (Cole, 1986).
 
The logical extension of the vicious cycle hypothesis is that bacterial clearance 
through antibiotic therapy should “break the cycle” and thereby have a positive 
impact on inflammation and prognosis.  
This study found a significant improvement in markers of airway inflammation, both 
using short term (14 days) treatment with intravenous antibiotics, and using longer 
term treatment with 12 months of nebulised gentamicin. These data provided strong 
evidence that antibiotic treatment can alter the underlying airway inflammation in 
bronchiectasis, providing hope of improving clinical symptoms and the prognosis of 
the disease. This study provides the basis for future large randomised controlled trials 
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of long term antibiotics in non-CF bronchiectasis. A number of trials of inhaled and 
oral antibiotics in non-CF bronchiectasis are now underway. To date, results of trials 
of long term antibiotics in non-CF bronchiectasis have produced conflicting results, 
with many trials limited in terms of sample size and duration. A systematic review of 
clinical trials published in 2007 reported no benefit of prolonged antibiotics in 
bronchiectasis (9 trials including 378 patients) in terms of reducing exacerbations 
(OR 0.96 95% CI 0.27-3.46) (Evans et al, 2007).
12
 The authors could find no 
evidence on benefits in terms of markers of airway inflammation. A previous study 
randomised patients with bronchiectasis in a double blind placebo controlled study to 
erythromycin or placebo and found no benefit of antibiotic treatment on airway 
inflammatory markers, including IL-1α, IL-8, TNF-α and LTB4 (Tsang et al, 1999). 
Conversely Hill et al showed reduced elastase activity in patient sputum following 
treatment with amoxicillin (Hill et al, 1988). A study of nebulised gentamicin 
demonstrated reduced levels of myeloperoxidase with nebulised antibiotics, and most 
recently our group demonstrated reduced myeloperoxidase and elastase levels in 
patients treated with nebulised gentamicin (Lin et al, 1997, Murray et al, 2010). An 
important finding of the present study was that inflammatory markers returned to 
baseline in patients treated with nebulised gentamicin 3 months after cessation of 
treatment. This suggests that to maintain efficacy, treatment has to be continuous or 
to have off-drug intervals of less than 3 months. This is important for designing 
future antibiotic interventions.  
One of the goals of this study was to demonstrate that bacterial clearance with 
antibiotics reduced markers of airway inflammation. This provides strong evidence 
firstly that bacterial colonisation directly influences airway inflammation, rather than 
191 
 
reflecting the underlying lung damage which should not be affected by antibiotics. 
Secondly it provides a basis for future large trials of long-term antibiotic therapy. If 
bacterial infection directly contributes to airway inflammation and independently 
predicts exacerbations and hospitalisation for severe exacerbations, long term 
antibiotic treatment should be expected to improve the long term prognosis of the 
disease and quality of life (Wilson et al, 1997, Loebinger et al, 2009). A recent study 
has demonstrated that chronic bacterial colonisation, severe exacerbations and 
systemic inflammation were all associated with more rapid lung function decline 
over 24 months (Martinez-Garcia et al, 2007). Our data suggest that these three 
important phenomena are closely linked. 
Bronchiectasis has been described as an “orphan” disease. In contrast to cystic 
fibrosis where guidelines recommend the use of surveillance sputum cultures and the 
evidence base for suppressive antibiotic therapy is strong (Flume, 2007), there is no 
such standard of care in non-CF bronchiectasis. The British Thoracic Society has 
recently published guidelines for the management of non-CF bronchiectasis
4
 that 
includes recommendations to monitor sputum cultures when patients are stable, and 
to consider long term antibiotic therapy in patients with frequent exacerbations. 
These recommendations are based on expert opinion and there is a clear need for 
studies specifically in non-CF bronchiectasis. 
Our study strongly supports the use of surveillance bacteriology in stable patients 
with non-CF bronchiectasis, as bacterial colonisation predicts future exacerbation 
risk, hospitalisations and quality of life. Furthermore, our study provides evidence to 
support antibiotic treatment in stable patients, as both short and long term antibiotic 
treatment were associated with reduced airways and systemic inflammation.   
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The relationship between airway bacterial load and airway inflammation is 
recognised in COPD where several studies have demonstrated a progressive increase 
in MPO, elastase and pro-inflammatory cytokines with increasing bacterial load (Hill 
et al, 2000).
 
The data reported in this study are supported by Angrill et al, who 
performed bronchoalveolar lavage (BAL) on 49 patients with non-CF bronchiectasis, 
and demonstrated an increase in neutrophil numbers, MPO, elastase and cytokines in 
patients with bronchiectasis compared to controls, along with an increase in these 
markers with increasing bacterial load in BAL fluid (Angrill, 2001). 
The present study expands on this previous work by demonstrating the importance of 
bacterial colonisation in a large cohort of patients with exclusively non-CF 
bronchiectasis. The advantage of this large cohort was the ability to adjust for other 
potential modifiers of inflammation, such as the severity of radiological lung disease 
and airflow obstruction. Even after accounting for these variables, patients with high 
bacterial loads had higher levels of airway inflammation.  
We expand on the data in stable patients by demonstrating in patients with 
exacerbations of bronchiectasis that antibiotic treatment for 14 days results in a 
significant reduction in airway and systemic inflammation. 
Bronchiectasis is a neutrophil driven inflammatory disorder (Cole, 1986, Watt et al, 
2004, Fuschillo et al, 2008). Release of pro-inflammatory cytokines – such as 
Interleukin-1β, IL-8, TNF-α and LTB4 – in the airway promote neutrophil 
recruitment from the peripheral circulation (Stockley et al, 1988).  Pro-inflammatory 
cytokines, particularly TNF-α and IL-1β, increase the expression of ICAM-1 and E-
selectin on vascular endothelial cells (Stockley et al. 1988). Activation of 
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CD11/CD18 on circulating neutrophils allows neutrophils to adhere to these ligands 
on the inflamed endothelium, leading to neutrophil migration (Downey et al, 2009). 
In this study we measured ICAM-1, E-selectin and VCAM-1 as soluble vascular 
adhesion molecules. As bacterial load was associated with markers of neutrophil 
mediated airway inflammation, we hypothesised that bacterial colonisation would 
promote neutrophil recruitment through up-regulation of adhesion markers. Previous 
studies have shown that these markers are elevated in patients with bronchiectasis 
compared to controls, and that they are elevated in other inflammatory lung diseases 
including COPD and cystic fibrosis (Riise et al, 1994, De Rose et al, 1998, Zheng et 
al, 2000). Our data showed that ICAM-1 was elevated in bronchiectasis patients 
compared to matched controls and that E-selectin and VCAM-1 were also elevated at 
bacterial loads of 10
7 
cfu/ml or greater. These data suggest that even during clinical 
stability there is an increased drive to recruit leukocytes to the airway, contributing to 
the cycle of inflammation. These findings may have relevance beyond airway 
inflammation as raised levels of endothelium derived inflammatory markers 
(particularly ICAM-1) have been linked to an increased frequency of myocardial 
infarction (Ridker et al, 1998), stroke (Fassbender et al, 1999) and diabetes (Song et 
al, 2007), which are increased in patients with chronic lung disease, in addition to 
predicting lung function decline (Walter et al, 2008). The finding that this marker 
decreases with antibiotic treatment is therefore an interesting area for further 
research.  
It should be noted that although this study found a significant relationship between 
airway cytokines and neutrophil markers with bacterial load, the overlap between the 
groups was large and the role of these markers in clinical practice is unclear. 
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The relevance of this study to the following chapters regarding ficolin-2 and 
mannose binding lectin is clear. Bronchiectasis is a chronic inflammatory disorder 
and we hypothesise that ficolin-2 or mannose binding lectin deficiency may 
predispose to more severe bronchiectasis and greater airway inflammation through a 
failure to clear bacteria via opsonophagocytosis. These studies therefore link airway 
inflammation and airway infection, providing an explanation for why ficolin-2 
“deficiency” may cause disease progression. Furthermore, if short or long term 
antimicrobial treatment is able to reverse airway inflammation in bronchiectasis, a 
logical conclusion is that poor prognosis in patients with ficolin-2 or MBL 
“deficient” SNP’s could be reversed with long term antimicrobial treatment. This 
idea, that patients with a genetic susceptibility to bacterial infection and poor 
outcome may be managed with different treatments, known as pharmacogenetics, is 
the concept that underpins the following chapters.   
Conclusion 
Chronic colonisation with high bacterial loads in non-CF bronchiectasis is associated 
with airway and systemic inflammation, a greater risk of exacerbations and worse 
health-related quality of life. Both short and long term antibiotic therapy reduce 
markers of airway and systemic inflammation. This study highlights the importance 
of monitoring sputum bacteriology when clinically stable, and provides the evidence 
base for future intervention studies to reduce the bacterial burden in the airways. 
CLINICAL TRIAL REGISTRATION 
The randomised controlled trial described in this chapter was registered:  Clinical 




Ficolin-2 in bronchiectasis 
4.1 Introduction 
Bronchiectasis is a chronic inflammatory lung disease characterised by permanent 
dilation of the bronchi leading to a clinical syndrome of cough, sputum production 
and recurrent respiratory infections (Smith 2011) Although bronchiectasis is 
associated with a number of immunodeficiencies, autoimmune disorders and severe 
infections, the cause is not identified in more than 50% of cases even in specialist 
centres (Pasteur et al 2000). It is speculated that a significant number of patients with 
“idiopathic” bronchiectasis have unrecognised immune defects.(Brown et al 2011). 
Bronchial damage allows chronic colonisation of the airway with damaging bacterial 
pathogens, most frequently with nasopharyngeal commensals such as Haemophilus 
influenzae or S. pneumoniae but also with opportunistic bacteria such as P.  
aeruginosa. (Chalmers et al 2012). P. aeruginosa is of particular interest as it has 
been associated with an increased rate of disease progression in cystic fibrosis and 
non-cystic fibrosis bronchiectasis.(Evans et al 1996, Wilson et al 1997, Loebinger et 
al 2009). This pathogen is highly resistant to antibiotics and once initial infection is 
established, P. aeruginosa adapts to its niche by forming biofilms and 
downregulating invasive virulence factors to evade pulmonary innate immunity 
(Singh et al 2000, Parks et al 2009). 
Why some patients with bronchiectasis are susceptible to opportunistic P. aeruginosa 
infection and more severe disease is not clear.  
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Complement is critical to pulmonary immunity against P. aeruginosa and other 
bacteria. (Lavoie et al 2011) Studies in mice and humans suggest that the alternative 
pathway is the dominant pathway for complement mediated defence against P. 
aeruginosa in serum with a small but significant contribution from the lectin 
pathway (Younger et al 2003). The relative importance of each pathway in the 
context of the bronchiectasis lung is less clear. Studies using human bronchoalveolar 
lavage suggest that alternative complement pathway components are present at very 
low levels in the lung, that alternative complement activation is negligible and that 
the majority of complement activation occurs via the classical and lectin pathways 
(Watford et al 2000). 
Ficolin-2 is a component of the lectin pathway of complement and one of the major 
pattern recognition molecules in human serum. (Matsushita et al 1996) Like other 
ficolins it consists of a collagen-like tail and a fibrinogen-like binding domain that 
interacts with a wide range of carbohydrates expressed on bacterial, fungi, viruses 
and host cells.(Ma et al 2004, Krarup et al 2005, Garlatti et al 2007) It is one of a 
small number of molecules able to activate the lectin pathway of complement (along 
with the other ficolins, MBL and CL-L1) via MBL-associated serine protease-2 
(Thiel et al 1997). Single nucleotide polymorphisms in the FCN2 gene lead to low 
ficolin-2 serum levels (Hummelshoj et al 2005) and preliminary data have linked low 
ficolin-2 serum levels with recurrent respiratory tract infections in childhood 
(Cedzynski et al 2009) and with bronchiectasis (Kilpatrick et al 2009). 
The hypothesis of this study was that ficolin-2 may be an important component of 
complement mediated defence against P. aeruginosa and other bacteria and may 
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therefore be associated with bacterial colonisation and disease severity in 
bronchiectasis. 
 
4.2 Bronchiectasis cohort 
The study included 470 patients with non-cystic fibrosis bronchiectasis and 414 
healthy control subjects. The characteristics of the study population are shown in 
Table 4.1. There were no significant differences in demographics or co-morbid 
illnesses between bronchiectasis patients and controls. The majority (80.4%) of the 
cohort had idiopathic/post-infective bronchiectasis. None of the control subjects had 
a history of chronic respiratory disease and none were prescribed inhaled 














Table 4.1. Baseline characteristics of the study cohort and control subjects. 






 Bronchiectasis cohort Control cohort  
N 
Age 
















Co-morbidities    
Chronic cardiac disease 
Cerebrovascular disease 














Causes of bronchiectasis    
Idiopathic/post infective 
Previous ABPA 
Connective tissue disease 










Medications    
Inhaled corticosteroid use 196 (41.7%) 0 (0%) <0.0001 
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4.3 Ficolin-2 SNP’s and Haplotypes: defining Ficolin-2 Insufficiency  
Genotyping success was >95% and all SNP’s were in Hardy-Weinburg equilibrium 
(p>0.05). The expected relationships between FCN2 SNP’s and serum levels were 
observed. As shown in figure 4.1, The promoter polymorphisms had significant 
effects on ficolin-2 serum levels with the lowest serum levels associated with the 
exon-8 polymorphism (Ala258Ser). All of the relationships were statistically 
significant. At p<0.0001 with the exception of the promoter polymorphism at 
position -4 (p=0.0004).  
Figure 4.1. The effect of single nucleotide polymorphisms in the FCN2 gene on 
ficolin-2 serum levels. The graphs show median with interquartile range (boxes) and 
range (bars). N=884 (bronchiectasis patients and controls are shown together as the 





Similarly, the inferred haplotypes had the expected impact on ficolin-2 serum 
concentrations, although with large and overlapping ranges. In view of this large 
variation within individual SNP and haplotype groups, an analysis was performed to 
identify the most accurate way of defining Ficolin-2 insufficiency using genetic data. 
Ficolin-2 insufficiency was defined a-priori as a ficolin-2 serum level <1600ng/ml, 
and receiver operator characteristic curves used to calculate the discriminatory ability 
of each individual SNP, each haplotype or pairs of haplotypes to identify low ficolin-







Table 4.2 Comparison of analysis based on genotype, haplotype and haplotype pairs 
for identifying low serum Ficolin-2 levels. Analysis based on N=1768 chromosomes 
from bronchiectasis patients and controls. 
 
This analysis demonstrated that each individual SNP was relatively poor at 
discriminating between deficient and non-deficient populations. Haplotypes 
improved this discrimination (p<0.05) comparing the area under the curve against 
 Area under the curve 
Individual SNP’s 
FCN2 (pro-986G>A) 
FCN2 -602 G>A 
FCN2 -64 A>C 
FCN2 -4 A>G 
FCN2 (exon 8- T236M) 











0.76 (0.72-0.79), p<0.0001 
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individual SNP’s. Haplotype pairs however, significantly improved the 
discrimination between insufficient and sufficient groups. This method is similar to 
that used in studies of mannose binding lectin (see chapter 1.2 for further details). Of 
the 6 well described FCN2 haplotypes AGGTG and AAACG were classified and 
high expressing haplotypes, GGACG, AGACG and GGATG were classified and 
intermediate expressing haplotypes and GGACT was defined as a low expressing 
haplotype for the purposes of this analysis as previously described (Hummelshoj et al 
2007). The distribution of ficolin-2 serum levels according to haplotype pairs are 















Figure 4.2. Pairs of ficolin-2 haplotypes more accurately stratify patients according 
to ficolin-2 serum levels. Low indicates patients with two low expressing haplotypes 
(GGACT/GGACT), Intermediate/low indicates patients with one intermediate 
expressing haplotype and one low expressing haplotype (GGACG/GGACT, 
AGACG/GGACT and GGATG/GGACT) and so on. 
  
4.4 Single nucleotide polymorphisms in the FCN2 gene are more frequent in 
bronchiectasis patients than controls. 
The high expressing FCN2 haploytype AGGTG was significantly less frequent in 
bronchiectasis patients compared to controls (OR 0.75 95% CI 0.60-0.93). Other 




Table 4.3. The frequency of FCN2 haplotypes in bronchiectasis patients and 
controls. P-values derived from Chi-square test. 95.7% of bronchiectasis patients 
haplotypes and 98.3% of control haplotypes formed the 6 common haplotypes.   
 
The analysis of individual SNP’s are shown below. There were no significant 
differences in the frequency of FCN3 or MASP-2 SNP’s between bronchiectasis and 
control subjects- Table 4.4.  There was a significant relationship between the FCN2 
promoter SNP 986 G>A with the AA genotype, which is associated with higher 
expression of serum ficolin-2, being less frequent in bronchiectasis patients 
compared to controls (p=0.01). The multiple chi square test indicated that the 
distribution of this SNP across the population was significantly different between 
bronchiectasis patients and controls (p=0.04). In addition, there was a significant 
associated between the AA genotype in the FCN2 SNP -4 A>G which also affects 
the promoter region of the gene (p=0.04). This allele is associated with slightly 
higher concentrations of serum ficolin-2 but has a lesser effect on ficolin-2 serum 
concentrations than other SNP’s figure 4.1.  No other statistically significant 
differences were identified. 
 
 
Haplotype Bronchiectasis patients 
N           % patients 
     Controls 
N         % patients 




AGGTG 193 20.5% 213 25.7% 0.75 (0.60-0.93) 0.01 
AAACG 176 18.7% 157 19.0% 0.98 (0.78-1.25) 1.0 
GGACG 364 38.7% 299 36.1% 1.12 (0.92-1.36) 0.3 
AGACG 39 4.1% 34 4.1% 1.01 (0.63-1.62)  0.9 
GGATG 40 4.3% 22 2.7% 1.63 (0.96-2.76) 0.09 













N 470 414    









115 (27.8%)  






















































































































































































Table 4.4. The frequency of single nucleotide polymorphisms in FCN2, FCN3 and 





Serum ficolin-2 was significantly lower between bronchiectasis patients and control 
subjects. Using the previous definitions of low ficolin-2 levels. At <1600ng/ml 
18.7% of bronchiectasis patients were “deficient” compared to 7.8% of 
controls,p<0.0001. Using <1200ng/ml, the figures were 8.1% for patients with 
bronchiectasis and 1.9% for controls,p<0.0001. No relationships between Ficolin-3 
and MASP-2 serum levels with bronchiectasis were observed. 
 
4.5 Impact of Ficolin-2 insufficiency on disease severity 
Patients with serum ficolin-2 insufficiency had more severe disease, as demonstrated 
by a higher frequency of chronic bacterial colonisation, a higher frequency of P. 
aeruginosa colonisation, more frequent exacerbations, more frequent hospitalisations 
for severe exacerbations during follow-up and worse symptoms and health related 
quality of life using the Leicester cough questionnaire and SGRQ. The difference in 
radiological severity of bronchiectasis by CT scoring was not statistically significant 
(p=0.052). These results are shown in Table 4.5. There was no relationship between 
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Table 4.5 Bronchiectasis patients with low serum levels of Ficolin-2 have a higher 
frequency of bacterial colonisation and a greater severity of disease. Abbreviations: 
GNE= gram negative enterobacteriaceae, FEV1= forced expiratory volume in 1 
second, FVC= forced vital capacity, SGRQ= St.Georges respiratory questionnaire, 
LCQ= Leicester cough questionnaire, HRCT= high resolution computed 
tomography, BMI= body mass index. *these data refer to the patients history at 




In the genetic analysis low and intermediate expressing haplotypes were associated 
with a greater disease severity (figure 4.3). This included a higher frequency of 
chronic bacterial colonisation (p=0.02 by chi square test).  
 
Figure 4.3. The frequency of chronic bacterial colonisation (defined as isolation of a 
potentially pathogenic bacterial species on at least 2 occasions 3 months apart while 
clinically stable) stratified by ficolin-2 haplotype.  
 
In addition, there was a strong correlation between FCN2 haplotype and 
hospitalisation for severe exacerbations, with a significantly higher proportion of 
patients in the low, intermediate/low and intermediate expressing haplotype groups 
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being admitted to hospital for severe exacerbations over 4 years follow-up (p<0.0001 
by log-rank test), figure 4.4.  
 
 
Figure 4.4. The frequency of hospitalisation during the study period. p<0.0001 refers 
to log-rank test comparing time to first hospitalisation stratified by ficolin-2 
haplotype.   
 
There were also significant relationships between FCN2 haplotype status and quality 
of life, as measured by the St Georges respiratory questionnaire (p=0.003 by 
Kruskal-wallis test) and the Leicester cough questionnaire (p=0.009 by Kruskal-


















Figure 4.5. Quality of life using the St.Georges Respiratory Questionnaire and cough 
severity using the Leicester cough questionnaire assessed at the start of the study and 
displayed according to FCN2 haplotype. Data are presented as median (lines), 
interquartile range (boxes) and range (bars). Statistical comparisons refer to Kruskal-
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wallis test. Abbreviations- SGRQ= St Georges Respiratory Questionnaire, LCQ= 
Leicester cough questionnaire. 
  
Patients with low expressing haplotypes (median 5 IQR 1-8) and intermediate/low 
expressing haplotypes (median 4 IQR 1-5) had higher annual exacerbation frequency 
compared to the others groups (p=0.02), see figure 4.6. There were no significant 
differences in the scoring for radiological severity between FCN2 haplotype groups.  
 
Figure 4.6. Exacerbation frequency and radiological severity in patients with 
bronchiectasis stratified according to FCN2 haplotype. Data are presented as median 





Examing spirometry results at entry into the study, there were no significant 
differences in forced expiratory volume in 1 second or forced vital capacity between 
haplotype groups, figure 4.7.  
Figure 4.7. forced expiratory volume in 1 second and forced vital capacity at study 
entry stratified according to FCN2 haplotype. Data are presented as median (lines), 
interquartile range (boxes) and range (bars). Statistical comparisons refer to Kruskal-
wallis test. 
 
After 4 years follow-up, patients in the intermediate/high and high expressing groups 
had the lowest mortality (10.5% and 5.8%) respectively and patients in the low and 
intermediate/low haplotypes had the highest mortality rates, 20% and 16.3% 
respectively, but these differences were not statistically significant (p=0.2 by log 




Figure 4.8. Impact of ficolin-2 haplotypes on survival in bronchiectasis. Statistical 
significant is shown in each figure. P-value refers to comparison of time to death 
using the log-rank test.  
 
In addition to having worse severity of disease using clinical indices, there was a 
significant relationship between FCN2 haplotype, bacterial load and airways 
inflammation. The frequency of P. aeruginosa was significantly higher in the low, 
intermediate/low and intermediate group compared to patients with high expressing 
haplotypes. Other enteric Gram-negative organisms were also less frequent in 
patients with high expressing haplotypes, see figure. The frequency of H. influenzae 







Figure 4.9. Relationship between FCN2 haplotype and bacterial colonisation. There 
was a statistically significant relationship between FCN2 haplotype and P. 
aeruginosa colonisation (p<0.0001 by chi square test) and colonisation with enteric 




 All the markers of airway inflammation measured were higher in patients with lower 
expressing FCN2 haplotypes with the exception of interleukin-8 where not 
significant relationship was observed (p=0.5). Figure 4.10.  
 
Figure 4.10. The relationship between FCN2 haplotype and inflammatory markers 
measured in sputum from patients with bronchiectasis. Comparisons refer to 





As expected based on the results in chapter 3, airway inflammation was dependent 
on bacterial load and the higher levels of inflammatory markers present in patients 
with low expressing FCN2 haplotypes was associated with higher bacterial loads in 
sputum- figure 4.11.  
 
 
Figure 4.11. The relationship between FCN2 haplotype and sputum bacterial load in 
patients with bronchiectasis. Comparisons refer to Kruskal-wallis test. Data are 




In multivariable analysis, adjusted for age, gender, smoking status, spirometry, 
radiological severity, BMI and inhaled corticosteroid use there was a significant 
relationship between FCN2 haplotype status and chronic colonisation. Table 4.6 
shows the results of the multivariable analyses. Survival was analysed by cox-
proportional hazards regression while colonisation and P. aeruginosa colonisation 
was analysed by logistic regression. There was a significant relationship between the 
presence of low/intermediate haplotypes and chronic colonisation, and a strong 
relationship between these haplotypes, and a combination of intermediate expressing 
haplotypes with P. aeruginosa colonisation. None of the groups had a significantly 















Table 4.6. Multivariate analysis of ficolin-2 haplotypes and serum levels with 
chronic colonisation, P.  aeruginosa colonisation and survival. Statistically 
significant relationships are highlighted in bold: *p=0.004, **p=0.01, ***p<0.001, 







Group Colonisation Pseudomonas 
aeruginosa 
















































4.6 Regulation of Ficolin-2 expression in hepatocytes 
In view of the large variation in serum concentrations of ficolin-2 in patients with 
bronchiectasis and controls within different haplotypes/genotypes, we hypothesised 
that ficolin-2 would be influenced by external factors. A leading hypothesis for the 
higher frequency of low ficolin-2 serum levels in bronchiectasis patients was that 
ficolin-2 may be consumed during the inflammatory response. It is known, for 
example, that complement components such as C3 ad C4 may be consumed in 
diseases involving immune complex deposition and widespread complement 
activation such as systemic lupus erythematosus (Birmingham et al, 2010). In 
addition, although many blood proteins are upregulated during acute inflammatory 
responses (including mannose binding lectin) some may be negatively regulated by 
the acute phase response, serum 25 hydryoxyvitamin-D being one example (Gama et 
al, 2012). 
We therefore investigated whether hormones, pro-inflammatory mediators or the 
acute phase response may influence expression and secretion of ficolin-2.  
 
In-vitro studes 
Since ficolin-2 is exclusively expressed in hepatocytes, in-vitro studies to investigate 
possible hormonal factors affecting ficolin-2 expression and secretion were 
performed in hepatocyte cells lines. Two cell lines, HepG2 and HuH-7 (kind gifts 
from the laboratory of Professor John Iredale) were used. First, expression of ficolin-
2 in these cell lines were confirmed by western blot (figure 4.12 ). Both cells lines 
secreted significant quantities of ficolin-2 into the media as shown. Western blotting 
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under reducing conditions is shown and found a band at 80kDa. The molecular 
weight of ficolin-2 is 35kDa. Subsequently this was found to be a dimer of ficolin-2 
with MASP-2, which is also produced by the hepatocytes (Krarup et al, 2004).  
 
Figure 4.12. Detection of ficolin-2 secretion by HepG2 and HuH-7 hepatocyte cell 
lines. Actin loading controls are shown. The band was found to correspond to ficolin-
2/MASP-2 dimers (approximately 80kDa).  
 
We then proceeded to test possible modifiers of hepatocyte ficolin-2 expression by 
ELISA and real time PCR. HuH-7 cells were used for these experiments with the 
ELISA results verified by also performing in HepG2 cells. Possible modifiers were 
selected on the basis of previous data showing that mannose binding lectin 
expression in hepatocytes was increased by growth hormone, interleukin-6 and 
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thyroid hormones.  mRNA expression was compared to expression for the 
housekeeping gene 18s. Cells were counted using a haemocytometer and ficolin-2 
and MBL synthesis were measured using ELISA. Results are expressed as ng/10
6
 
cells. The results of the real time PCR are shown in figure 4.13 and figure 4.14. None 
of the agents testing caused a statistically significant increase in mRNA expression 
with the exception of high doses of lipopolysaccharide. 
 
 
Figure 4.13. The effect of hormones and selected drugs on mRNA expression of 






Figure 4.14. The effect of inflammatory mediators and lipopolysaccharide on 
mRNA expression of FCN2. Data are presented as mean with standard error of the 
mean from 3 independent experiments. 
 
These results were further tested by measuring secreted protein in the culture media.  
The results of this analysis are shown in figure 4.15 and figure 4.16. No significant 
differences were identified using this method, suggesting that hormones and pro-
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inflammatory mediators did not have a large effect on FCN2 expression and 
secretion in hepatocytes. 
 
 
Figure 4.15. Ficolin-2 secretion by HuH-7 treated with hormones and selected 






Figure 4.16. Ficolin-2 secretion by HuH-7 treated with pro-inflammatory mediators 
and lipopolysaccharide. Data are presented as mean with standard error of the mean 
from 3 independent experiments. 
 
In-vivo studies of acute phase response 
10 patients were recruited prior to cardiopulmonary bypass surgery, a procedure 
known to be associated with acute phase response and previously used in studies of 
acute phase responses (Eisen et al, 2007). Blood samples for serum measurement of 
ficolin-2 and mannose binding lectin were taken pre-operatively, pre-operatively and 
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then at 24, 72, 120 and 168 hours after cardiac surgery. Acute phase responses of 
Ficolin-2 and MBL were compared to classical acute phase reactant C-reactive 
protein measured by the biochemistry department at the Royal Infirmary of 
Edinburgh. 
8 patients completed the study with blood samples taken at all 5 time-points and the 
data for those patients completing the study is shown in figure 4.17. All patients 
exhibited a typical post-operative acute phase response with significant elevation in 
C-reactive protein peaking at 72 hours and declining following this. Mannose 
binding lectin increased during the acute phase response (repeated measures 
ANOVA p=0.01) with a peak increase above baseline at 72 hours of 114%. No 
significant increase in serum levels of ficolin-2 was observed (p=0.9). 
Figure 4.17. Acute phase response in 8 patients undergoing cardiac bypass surgery.  





4.7 Ficolin-2 is present in sputum from bronchiectasis patients but not from 
healthy controls. 
Sputum ficolin-2 was measured by ELISA in 72 patients with bronchiectasis using 
spontaneous sputum and 10 control subjects provided induced sputum. None of the 
control subjects had detectable levels of ficolin-2 in induced sputum.  
Ficolin-2 was detectable by ELISA in 47 of the 80 bronchiectasis sputum samples. 
The median level in patients with detectable ficolin-2 was 383.1ng/ml (187.0-
620.7ng/ml). The highest detectable level was 3.1ng/ml, equivalent to the levels 
found in serum. 
In the 72 patients studied, there was a correlation between serum and sputum ficolin-
2 levels, p<0.0001, figure 4.18. None of the patients with ficolin-2 levels 
<1600ng/ml had detectable sputum ficolin-2. 
   
Figure 4.18. Correlation between sputum and serum measurement of ficolin-2.  
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These data would suggest that ficolin-2 is present in the bronchiectasis airway in 








Bronchiectasis is a chronic inflammatory lung disease characterised by chronic 
airway bacterial infection, exacerbations, hospitalisation and premature death in the 
most severe cases (Smith 2011, Chalmers et al 2011, Loebinger et al 2009). Despite 
significant advances in the understanding of chronic lung disease over past decades, 
the underlying cause of bronchiectasis in the majority of patients remains unknown 
(Pasteur et al 2000, Brown et al 2011). It is presumed that unrecognised immune 
defects are present in a proportion of patients with idiopathic bronchiectasis. The 
clinical course of the disease varies, with some patients having a relatively benign 
course with little impact on quality of life, and others having severe impairment of 
lung function and frequent exacerbations (Pasteur et al 2010, Chalmers et al 2011). 
Modifiers of this clinical course have not previously been identified in non-CF 
bronchiectasis, although it is well recognised in cystic fibrosis that genes other than 
CFTR modify outcome, including TGF-ß, SERPINA1 and mannose binding lectin 
(Collaco and Cutting 2008, Dorfman et al 2008, Chalmers et al 2011). 
This study therefore sought to investigate whether the components of the lectin 
pathway of complement were implicated in susceptibility to bronchiectasis, with 
severity of bronchiectasis or susceptibility to P.  aeruginosa. P. aeruginosa is of 
considerable interest in bronchiectasis because it is associated with worse lung 
function, worse impairment of quality of life and decreased survival in multiple 
studies .(Evans et al 1996, Wilson et al 1997, Loebinger et al 2009). 
We report a significant association between low expressing FCN2 haplotypes and 
disease severity in bronchiectasis, and a strong associated with P. aeruginosa 
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colonisation. The findings of this study are supported by both in-vitro and in-vivo 
data in the literature.  A study of 96 patients with cystic fibrosis found a strong and 
statistically significant effect of FCN2 polymorphisms (rs7865453 and rs7851696) 
and earlier onset of P. aeruginosa colonisation (Haerynck et al 2012). This 
polymorphisms (rs7865453- Ala258ser) results in low serum ficolin-2 concentrations 
and was also the variant most strongly associated with P. aeruginosa colonisation in 
the present study. Variants in the MBL2 and FCN1 genes were also significantly 
associated with earlier P. aeruginosa colonisation in the study by Haerynck et al 
suggesting a very important role for the lectin pathway in susceptibility to 
colonisation with P. aeruginosa. Susceptibility to P. aeruginosa in bronchiectasis 
and in cystic fibrosis remain poorly understood and our data are the first 
demonstration of genetic susceptibility to P. aeruginosa colonisation in non-CF 
bronchiectasis. 
There are a number of recognised underlying causes for bronchiectasis, including 
severe infections such as pneumonia and tuberculosis, immunodeficiencies such as 
common variable immunodeficiency, allergic bronchopulmonary aspergillosis and 
connective tissue diseases (e.g rheumatoid arthritis) and inflammatory bowel disease 
(Pasteur et al, 2010). Circumstantial evidence links ficolin-2 to a number of these 
conditions. A study in MASP-2 knockout mice has identified an important role for 
the lectin pathway in defence against pneumococcal pneumonia, the most common 
cause of pneumonia worldwide. Ficolin-2 was found to be the major lectin pathway 
component responsible for defence against pneumococcal infection (Ali et al 2012). 
Most diseases that predispose to severe pneumonia have been associated with 
bronchiectasis as severe infections are reported as the most frequent cause of 
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bronchiectasis in adults (Pasteur et al, 2010). In addition, ficolin-2 binds to, and 
activates complement against Mycobacteria (Carroll et al 2009) and has been linked 
to recurrent respiratory tract infections in childhood (Cedzynski et al 2009). As 
discussed above, a role for ficolin-2 in defence against Aspergillus fumigatus has 
been demonstrated (Ma et al 2011). In the present study, the majority of patients had 
idiopathic bronchiectasis with smaller number of other causes. No interaction was 
found with underlying cause and either low ficolin-2 serum levels or P. aeruginosa 
colonisation. This is an area for future research in larger cohorts.  
The method used to study Ficolin-2 “deficiency” has varied across the limited 
number of disease association studies to date (Chapman et al 2007, de Messias-
Reason 2009, Faik et al 2011). Many use individual SNP’s (Chapman et al 2007, 
Haernyck et al 2012, Meijvis 2011), while others have examined individual 
haplotypes (Chapman et al 2007, de Messias-Reason 2009, Faik et al 2011). We 
demonstrated that although on the population level individual SNP’s have a 
significant effect on serum ficolin-2 levels, they are unreliable to predict individual 
patients serum ficolin-2. The strong linkage disequilibrium between FCN2 SNP’s 
produce 6 common haplotypes (Hummelshoj et al 2007). Haplotypes also have 
strong effects on ficolin-2 levels,with patients carrying the GGACT having the 
lowest serum ficolin-2 levels. In this study we used a new approach combining low, 
intermediate and high expressing ficolin-2 haplotypes to produce haplotypes pairs 
that was significantly more discriminatory in identifying individuals with low serum 
ficolin-2. This is the same approach as is used in disease association studies for 
mannose binding lectin, where only individuals with 2 MBL deficient haplotypes 
have complete MBL deficiency (Kilpatrick 2003). This approach should be repeated 
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in independent cohorts to confirm if this should become the standard method of 
defining ficolin-2 “insufficiency”.  
A leading hypothesis for why low serum ficolin-2 concentrations were more frequent 
in bronchiectasis patients was that chronic inflammation may cause consumption of 
complement components, or that ficolin-2 may be a negative acute phase reactant. 
Our in-vitro studies in hepatocytes and in-vivo studies in patients undergoing cardiac 
surgery suggest no significant acute phase response and no evidence that low ficolin-
2 serum levels are due to consumption.  
We demonstrate that ficolin-2 is presented in the infected bronchiectasis airway by 
measuring ficolin-2 in sputum. Induced sputum from healthy donors contained no 
ficolin-2, consistent with the hypothesis that ficolin-2 may diffuse into the airway 
under conditions of inflammation. This is already known to be the case for mannose 
binding lectin (Fidler et al, 2010).  We found low levels of sputum ficolin-2 in 
patients with with low serum levels, again consistent with the hypothesis that under 
conditions of acute inflammation in patients with low ficolin-2 serum levels, ficolin-
2 may fail to diffuse into the airway to enhance opsonophagocytosis. 
This study is the largest genetic study of patients with non-CF bronchiectasis and the 
only study the authors of aware of to demonstrate a genetic modifier of disease 
severity. The largest previous study the authors could identify was a study of 96 
patients with idiopathic bronchiectasis that identified an association between 
bronchiectasis and homozygous HLA-C group 1 (Boyton et al 2006). A key stage in 
any genetic study is the validation of a genetic association in an independent cohort. 
This is challenging in bronchiectasis as no large genetic studies have previously been 
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undertaken. Although our previous pilot data (Kilpatrick et al 2009), the data from 
cystic fibrosis (Chalmers et al 2011) and the in-vitro data (discussed in chapter 5) 
strongly support our findings, it is essential that future genetic studies of 
bronchiectasis should validate the role of ficolin-2. As large international 
collaborations begin to develop for this disease, it is hoped that more genetic studies 
will be conducted in bronchiectasis (Aksamit et al 2012). 
 
Conclusions 
Single nucleotide polymorphisms associated with low ficolin-2 serum levels are 
associated with disease severity and susceptibility to P. aeruginosa infection in 
bronchiectasis. Ficolin-2 should be further evaluated as an important disease 









The role of Ficolin-2 in opsonophagocytosis of Pseudomonas aeruginosa in 
bronchiectasis 
5.1 INTRODUCTION 
In the previous chapter, we have demonstrated a significant association between 
single nucleotide polymorphisms in the ficolin-2 gene and susceptibility to chronic 
bacterial colonisation, particularly with P. aeruginosa. Up to 80% of patients with 
bronchiectasis grow pathogenic micro-organisms when clinically stable, suggesting 
that bronchiectasis is associated with a failure to remove bacteria from the airways 
by phagocytosis.  
Clearance of inhaled particles, including microbes but also allergens, irritants and 
environmental particulates is a key function of the innate immune system in the lung. 
This is achieved through co-ordinated processes involving the mucociliary escalator, 
secretion of antimicrobial peptides and mucins by epithelial cells, and leucocytes 
both present in the airway, such as the alveolar macrophage, and recruited to the 
airway during inflammatory responses. (Hiemstra, 2006).  
While macrophages are the dominant phagocyte in the healthy lung (Martin and 
Frevert, 2005), neutrophils are the dominant cell type identified in the airways of 
patients with bronchiectasis (Fuschillo et al, 2008) as well as other chronic lung 
diseases such as cystic fibrosis and chronic obstructive pulmonary disease. The 
primary function of neutrophils is to phagocytose and kill bacterial pathogens. 
Phagocytosis is dependent on two classes of neutrophil receptors, the Fcγ receptors 
(FcγRIIA (CD32) and FcγRIIIb (CD16) and the complement receptors CR1 (CD35) 
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and CD3 (CD11b/CD18 integrin). After engagement of phagocytic targets, primarily 
with FcγRIIIb and CD11b, pseudopods encircle and engulf bacteria, followed by 
fusion of phagocytic granules. Bacterial killing occurs through proteases, anti-
microbial peptides and reactive oxygen species. It has also been reported that 
neutrophils are able to kill some pathogens extracellularly through neutrophil 
extracellular traps (Brinkmann et al, 2004). These NETS are principally composed of 
DNA with granule products such as elastase and myeloperoxidase. Their role in 
chronic lung disease is a subject of ongoing research. 
Successful neutrophil phagocytosis requires opsonisation of pathogens with soluble 
particles that permit recognition by specific receptors. Complement is the primary 
system for opsonising pathogens (reviewed in Chapter 1) and complement activation 
results in deposition of C3b (recognised by complement receptor 1/CD35 on 
phagocytes) or C3bi (recognised by complement receptor 3/CD11b). Pathogens may 
be opsonised directly with immunoglobulin (recognised by FcγRIII (CD16) 
(Greenberrg and Grinstein, 2002). Without this mechanism for enhancing pathogen 
recognition by phagocytes, the process of pathogen clearance is significantly 
impaired. Nevertheless, non-opsonic phagocytosis does occur. The mechanisms of 
non-opsonic phagocytosis in neutrophils are poorly described compared to 
macrophages where a large number of scavenger receptors involved in non-opsonic 
clearance have been described (among them mannose receptor, CD136, CD163 and 
CD36) (Donnelly and Barnes, 2012).  
Other receptors are involved in phagocytosis without being direct phagocytic 
receptors. For example, complement activation generates complement component 
C5a, which interacts with its receptor CD88 expressed on macrophages, epithelial 
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cells and particularly neutrophils. Among its effects, CD88 engagement primes 
neutrophils to enhance functional responses such as phagocytosis and the generation 
and release of granule enzymes and superoxide anions which are critical to bacterial 
killing (Mollnes 2002, Hopken et al 1996). C5a/CD88 interaction is reported to 
shows a paradoxical effect, enhancing phagocytic and killing functions at low 
concentrations but caused impaired leukocyte function at higher concentrations as 
occur in sepsis (Ward 2004).   
The persistence of bacteria within the airway suggests a possible role for phagocytic 
failure in the bronchiectasis lung. When investigated the majority of patients with 
bronchiectasis do not have defects in the classical or alternative complement 
pathways by conventional screening.  
Neutrophil elastase has emerged as an important mediator of phagocytic dysfunction 
in cystic fibrosis, where it has been shown to cleaves FcγRIIIb and complement 
receptor 1 in vivo (Berger et al, 1989). Elastase also cleaves iC3b from the surface of 
pathogens, leading to an important opsonin/receptor mismatch (Tosi et al, 1990).The 
role of elastase in non-CF bronchiectasis has not been extensively investigated. 
Voglis et al, showed phagocytic defects associated with human neutrophil peptides in 
non-CF bronchiectasis (Voglis et al, 2009). 
Since ficolin-2 is involved in complement activation via the lectin pathway, it is 
reasonable to hypothesise that low expression of ficolin-2 due to single nucleotide 
polymorphisms may lead to phagocytic failure due to reduce opsonisation.  
In the clinical studies described in chapters 3 and 4, we have shown first, high levels 
of neutrophil elastase in the airway of patients with non-CF bronchiectasis and 
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bacterial colonisation, and secondly an association between low expression of 
ficolin-2 and bacterial colonisation and disease severity in bronchiectasis. We now 
investigate the in-vitro relevance of these findings to opsonophagocytosis and 
neutrophil function.   
Given the strikingly higher frequency of P. aeruginosa in patients with low 
expressing FCN2 haplotypes demonstrated in the preceding chapter, we focus on the 
in-vitro activity of ficolin-2 against P. aeruginosa.  
 
5.2 Recombinant ficolin-2 and mannose binding lectin 
Recombinant ficolin-2 was expressed in both a bacterial and mammalian system as 
described in chapter 2, materials and methods. The functional ability of these ficolins 
to bind to ligands and activate complement via MASP-2 was assessed as described 
(Lynch et al, 2004) using microplates coated with lipoteichoic acid from S. aureus, a 
known ligand of ficolin-2.  
 
As shown in figure 5.1, bacterial ficolin-2 was non-functional and did not bind 




Figure 5.1. Binding of ficolin-2 in serum and ficolin-2 expressed in E.coli to 
lipoteichoic acid from S. aureus. Approximately 100ng/ml of recombinant protein 
and a pool of serum containing 2000ng/ml ficolin-2 measured by ELISA was diluted 
1 in 20 and applied to the binding assay. 
 
Subsequent discussions indicated that other researchers had established that ficolins 
undergo extensive post-translational modifications and that attempts to express 
functional ficolin in both bacteria and insect cells had been unsuccessful (Dr Nicole 
Thielens, personal communication). Ficolin-2 was therefore expressed in a stable 
CHO cell line provided by Dr Nicole Thielens. Ficolin-2 expressed by this method 
bound to lipoteichoic acid, as did the positive control in both experiments (ficolin-2 







Figure 5.2. Binding of ficolin-2 to lipoteichoic acid from S. aureus. 100ng/ml of 
recombinant ficolin-2 expressed in CHO cells and diluted in TBS was applied to the 
binding assay and serially diluted. Binding of this recombinant ficolin-2 was 
compared to a serum pool containing 2000ng/ml ficolin-2 and diluted 1 in 20 in TBS. 
 
Mannose binding lectin was purchased from R+D systems and functionally tested 
using binding to mannan by ELISA. Recombinant MBL was found to be functional 




Figure 5.3. Binding of recombinant mannose binding lectin to mannan in a 
functional ELISA.  
 
5.3 Ficolin-2 binding to Pseudomonas aeruginosa and other respiratory 
pathogens 
Figure 5.4 shows the relative binding of the lectin pathway components Ficolin-2, 
mannose binding lectin and Ficolin-3 to respiratory pathogens. Binding is expressed 
as a percentage of the binding observed compared to a positive control (Acetylated 
BSA for Ficolin-2 and ficolin-3 and Mannan for MBL). Ficolin-2 bound strongly to 
P. aeruginosa PA01, Haemophilus influenzae, and S. pneumoniae serotype 3. Lesser 
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binding was observed to M. catarrhalis, S. aureus and E. Coli. No binding of ficolin-
2 to B. cepacia  or mannan was observed.  
 
 
Figure 5.4. Binding of lectin pathway components to respiratory pathogens. Binding 
is expressed as a percentage of the positive control control (acetylated BSA for 
ficolin-2 and mannan for MBL). Binding assays represent the mean with standard 
error (SE) of 3 independent experiments performed in duplicate.  
 
Ficolin-2 binding to P. aeruginosa was dose dependent and partially inhibited by N-
acetylglucosamine and EDTA consistent with binding via for fibrinogen-like domain 
(figure 5.5, p<0.0001 by ANOVA). Mannose binding lectin by contrast did not bind 
to PA01 but did bind to B. cepacia and S. aureus (figure 3.12). No binding of ficolin-
3 to any of the pathogens investigated was found. P. aeruginosa binding assays were 
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performed by by microplate and flow cytometry based methods to confirm that 
ficolin-2 bound specifically to PA01. Dose dependent binding of ficolin-2 to P. 
aeruginosa was observed by flow cytometry (figure 5.5). In each case, where 
recombinant ficolin-2 was added, mean fluorescence was significantly increased 
relative to control fluorescence (p<0.05 by students t test).   
 
Figure 5.5. Binding of ficolin-2 to P. aeruginosa using both microplate and flow 
cytometry based binding assays.  For the left graph, results are mean with standard 
error of the mean of 3 independent experiments. 
 
Binding was subsequently investigated in a range of environmental and clinical 
strains of P. aeruginosa (figure 5.6). No significant difference in % binding of 
ficolin-2 was observed between environmental and clinical strains (p=0.5) and 
ficolin-2 bound to all of the strains investigated, while minimal binding of MBL was 
observed, figure 5.6. 
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These results suggest that ficolin-2 binding to P. aeruginosa is conserved across 
multiple strains and that adaptations to chronic infection by clinical P. aeruginosa 
isolates from patients with cystic fibrosis do not include evading binding by ficolin-
2. 
Figure 5.6. Binding of P. aeruginosa environmental and clinical isolates. Binding is 
expressed as a percentarge of a positive control (Acetylated BSA for ficolin-2 and 
Mannan for mannose binding lectin).   
 
Binding of Ficolin-2 was associated with a dose dependent increase in complement 
C4 activation on PA01 using the Petersen assay with a strong correlation between 
ficolin-2 serum concentration and C4 deposition in this lectin pathway complement 
assay (r=0.73, p<0.0001) while MASP-2 serum concentration did not correlate with 






Figure 5.7. Complement activation using a lectin pathway C4 deposition assay 
(Pedersen et al, 2004). Increasing concentrations of ficolin-2 resulted in a significant 
increase in C4 deposition on PA01. 
 
Confirmation of the binding results was obtained by depletion assay showing the 
same spectrum of microbial specificity, figure 5.8. This demonstrated binding of 
MBL to S. aureus, B. cepacia and E. coli with no significant binding to the other 
pathogens identified. No binding of ficolin-3 to any of the pathogens was observed, 
but binding to N-acetylglucosamine-sepharose was demonstrated. The spectrum of 
ficolin-2 binding observed was similar to the direct microplate assay and included 
specific binding to PA01, H. influenzae, S. aureus and S. pneumoniae.  
Note that in these assays, positive binding is indicated by a low optical density, as the 
lectin pathway components are depleted from samples by binding, following which 




Figure 5.8. Depletion binding assay. Values are expressed as relative binding 
compared to the negative control (1.0). Values <0.25 were regarded as positive 
binding. Binding assays represent the mean (SE) of 3 independent experiments 




Complement activation using C3 activation on microtitre plates confirmed that the 
alternative pathway was the dominant pathway for complement activation at high 
serum dilutions (20%) with only a small contribution from the lectin pathway (figure 
3.17). For these experiments, microtitre plates were coated overnight with 1 x 10
8 
cfu/ml of PA01 in coating buffer. Plates were washed 3 times in 10mM Tris-HCl, 
140mM NaCl, pH 7.4. The indicated concentration of pooled human serum was 
diluted in 10mM Tris-HCl, 140mM NaCl, pH 7.4 containing 10mM EGTA and 
10mM Mg
2+
 (for selective study of the alternative pathway), 100mM GlcNac 
(depletion of the lectin pathway of complement by inhibiting the binding of Ficolin-
1, Ficolin-2, ficolin-3 and mannose binding lectin). 10mM EDTA was used as a 
negative control as this is known to inhibit all 3 pathways of complement activation. 
100mM mannose was used to selectively inhibit binding of mannose binding lectin 
without affecting binding of the other lectin pathway components.  Experiments were 
performed using 20% serum, 0.5% serum and 20% serum diluted in sodium 
polyanethole sulfonate at a concentration of 0.6mg/ml which selectively inhibits the 
classical and alternative pathways (see chapter 2).  
Serum samples diluted in the appropriate conditions were incubated for 1 hour at 
37°C followed by washing 3 times in wash buffer. Complement activation was 
detected by incubation with mouse anti-complement C3 (HAV 003-05, Bioporto) 
followed by anti-mouse HRP detection antibody. Complete inhibition of alternative 
pathway activity was defined as an optical density of C3 activation equivalent to the 




20% serum dilution was used given the results of neutrophil phagocytosis assays 
displayed in chapter 2 which showed effective opsonisation of PA01 for 
phagocytosis at this serum concentration. Depletion of the lectin pathway with N-
acetylglucosamine resulted in only an 11.5% reduction in C3 deposition. Selective 
depletion of ficolin-2 with anti-ficolin-2 antibody produced a similar reduction 
(mean 11%) consistent with ficolin-2 being the major lectin pathway component 
responsible for complement activation on PA01 (figure 5.9). C1q depletion has little 
effect under any of the conditions testing indicating that in this serum pool and under 
these experimental conditions, the classical pathway was not a major contributor to 
C3 activation on PA01.  
Under conditions of low serum dilution the alternative pathway was less active, with 
lower values obtained in the presence of EGTA-Mg which selectively inhibits the 
classical and lectin pathways allowing the contribution of the alternative pathway to 
be determined.  Under these conditions lectin pathway and ficolin-2 depletion had a 
more marked effect. Figure 5.9 illustrates these results at 0.5% serum dilution, the 
lowest serum dilution at which C3 deposition could be detected in this assay). 
Similarly, in the presence of 0.6mg/ml SPS, the alternative pathway was inhibited 
and the lectin pathway was responsible for majority of complement activation. 
Values are expressed as a percentage of the positive control (a pool of serum from 
healthy donors). It should be noted that the overall C3 deposition was significantly 








Figure 5.9. Determining the impact of the individual complement pathways 
contributing to C3 deposition on PA01. Data represent the mean of 3 independent 




5.4 Ficolin-2 enhances phagocytosis of Pseudomonas aeruginosa strain PA01 





or no serum at either low serum dilution (0.5% serum for 1 hour at 37°C) or in 
the presence of 0.6mg/ml SPS which was found to selectively inhibit the alternative 
pathway without affecting the lectin pathway for 1 hour at 37°C. Sera were depleted 
of all lectin pathway components by affinity chromatography as described in the 
materials and methods and then supplemented with increasing concentrations of 
Ficolin-2 or mannose binding lectin. As show in figure 5.10, increasing 
concentrations of ficolin-2 caused an increase in neutrophil phagocytosis of PA01, as 
measured by both mean fluorescence and % of positive cells. Data are displayed for 
experiments run using opsonisation with 1 hour at 37ºC with 0.5% serum with 
phagocytosis permitted for 30 minutes.  
 
 
Figure 5.10. Enhancement of phagocytosis of P. aeruginosa strain PA01 with 
recombinant ficolin-2 supplementation to serum. Results are the mean of 5 
independent experiments and are presented as mean with standard error of the mean. 
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(p<0.0001 compared C1q-ve serum with both MASP-2 deficient and no serum by 
two way ANOVA). 
 
Statistically significant differences were observed for phagocytosis (compared to 
baseline with no supplemental rficolin-2) at 5µg/ml and higher (p<0.05). MASP-2 
depleted serum was associated with higher rates of phagocytosis than no serum, 
consistent with the presence of opsonins other than complement present in serum 
(p<0.0001). No enhancement effect was seen adding ficolin-2 to MASP-2 deficient 
serum suggesting ficolin enhancement of phagocytosis is dependent on complement 
activation. Supraphysiological doses of ficolin-2 (10 and 20µg/ml) were used in 
these experiments to demonstrate if there was a dose dependent increase in 
complement activation with higher concentrations of ficolin-2, and also because it 
was not known if recombinant ficolin-2 was as efficient at activating complement as 
native ficolin-2.  
  
No effect was seen by supplementing sera with recombinant mannose binding lectin 






Figure 5.11. Supplementation of serum with recombinant mannose binding lectin at 
increasing concentrations does not enhance phagocytosis of P. aeruginosa stain 
PA01. Experiments with MASP-2 deficient sera were not performed to save reagents 
as no effect was observed with supplementing C1q-ve sera, no effect would be 
expected in the absence of MASP-2. Data are the mean of 3 independent experiments 
with standard error of the mean. 
 
Microscopy confirmed that the observed results were due to phagocytosis with large 
numbers of FITC-labelled PA01 visible within neutrophils, figure 5.12. Images were 
obtained by simultaneous phase contrast and fluorescence microscopy after adhering 





Figure 5.12. Phase contrast and fluorescence microscopy demonstrating 
phagocytosis of FITC labelled PA01 by neutrophils. In this experiment, PA01 was 
opsonised with 10µg/ml ficolin-2 in 0.5% serum prior to incubation with healthy 
donor neutrophils for 30 minutes.  
 
Representative flow cytometry plots, showing the increasing % phagocytosis with 










Figure 5.13. Representative flow cytometry data from phagocytosis experiments 
using FITC-labelled PA01. The threshold for FITC positive cells was set by running 
neutrophils not exposed to PA01 and setting the threshold at 0% FL-1 positive cells.  
 
The results suggest that under appropriate conditions of low serum concentration 
with inhibition of the alternative complement pathway, ficolin-2 is able to cause 
complement activation and enhance opsonophagocytosis of P. aeruginosa strain 
PA01.  
 
5.5 Neutrophil killing of Pseudomonas aeruginosa 
Neutrophil killing required opsonisation with serum and the presence of neutrophils. 
In this experiment, PAO1 was opsonised in C5 depleted sera obtained from Sigma, to 
prevent formation of the membrane attack complex ensuring that all killing was due 
to neutrophils rather than complement mediated killing. After exposure of opsonised 
P. aeruginosa to neutrophils for 90 minutes at 37ºC, the supernatants were aspirated 
and the neutrophils lysed with 0.1% Triton x-100. Serial dilutions of the supernatants 
and cells were made and 100µl samples plated on LB agar overnight at 37°C in 
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triplicate. Bacterial load in the supernatants (non-phagocytosed bacteria) and in the 
cell lysates (phagocytosed bacteria that were not killed) was determined by colony 
counts. 
As expected, incubation with 10µg/ml gentamicin for 60 minutes resulted in 100% 
killing (not shown). Following opsonisation with 50% C5a depleted serum, 
incubation with neutrophils caused a progressive reduction in viable P. aeruginosa 
with a reduction equivalent to 97% killing following opsonisation with C5 depleted 
serum, and a reduction equivalent to 88% killing following opsonisation with C5 
depleted and GlcNAc depleted serum (to remove lectin pathway components)- figure 
5.14. This difference was not statistically significant (p>0.05). When this assay was 
repeated after opsonisation in the presence of 0.6mg/ml SPS to inhibit the classical 
and alternative pathways, killing was still observed in 50% serum (a log unit 
reduction equivalent to 72% killing at 90 minutes). This was reduced by depletion of 
lectin pathway components with GlcNAc (log unit reduction equivalent to 19% at 90 
minutes). This was restored to 76% with the addition of 20µg/ml ficolin-2. The 
differences between 50% C5
-/-
 serum and 50% C5
-/-
/GlcNAc depleted serum and 
50% C5
-/-
/GlcNAc depleted serum +20µg/ml ficolin-2 were statistically significant 




Figure 5.14. Killing of P. aeruginosa following incubation with neutrophils from 
healthy donors. No neutrophils indicates PA01 incubated with 50% C5 depleted 
serum without neutrophils for 90 minutes. +20µg/ml ficolin-2 refers to reconstitution 
of 50% C5
-/-
/GlcNac depleted serum with 20+20µg/ml recombinant ficolin-2. Data 




5.6 Macrophage phagocytosis 
Similar results were obtained with macrophage phagocytosis as with neutrophil 
phagocytosis. Ficolin-2 supplementation during opsonisation enhances macrophage 
phagocytosis in a dose dependent manner, with the requirement for serum and 
MASP-2. This is shown below in figure 5.15. The difference between C1q and the 
other curves was statistically significant (p=0.01). Representative flow cytometry 
plots show monocyte derived macrophages exposed to FITC-labelled P. aeruginosa 
strain PA01 opsonised with the indicated sera or control (buffer) depleted of lectin 
pathway components and then supplemented with recombinant ficolin-2 at the 
indicated concentration.  
 
Figure 5.15. Phagocytosis of PA01 by human monocyte derived macrophages is 





5.7 Peripheral and sputum neutrophils from bronchiectasis patients and 
controls demonstrate significant neutrophil dysfunction in the bronchiectasis 
airway 
28 patients with non-cystic fibrosis bronchiectasis were studied for peripheral blood 
and sputum neutrophil studies.  5 patients underwent sputum induction and blood 
sampling but were ultimately excluded as sputum samples were of poor 
quality/contained too few neutrophils (N=4) or because the patient was subsequently 
found to be ineligible (N=1). 23 patients therefore completed the study.  
Characteristics of the included patients are shown below, table 5.1. All patients 




 Severe Moderate Mild p-value 
N 8 8 7  
Age (years) 63.3 (11.5) 65.4 (8.2) 69 (7.6) 0.3 
Gender (male) 5 (62.5%) 5 (62.5%) 5 (71.4%) 0.8 
FEV1 %predicted 56.4 (20.9) 72.4 (26.4) 77.7 (12.9) 0.2 
FVC % predicted 71.8 (28.0) 81.5 (26.5) 87.9 (39.6) 0.6 
FEV1/FVC 62.7 (7.4) 71.1 (12.0) 72.7 (11.9) 0.9 
BMI kg/m
2
 23.9 (4.1) 28.2 (5.9) 25.8 (5.0) 0.3 
%Hospitalised in 
previous year 
100% 25% 0% <0.001 
Outpatients 
exacerbations/yr 
4.7 (2.0) 3.5 (1.5) 1.8 (0.9) 0.2 
Chronically colonised 100% 100% 0% <0.0001 
% Pseudomonas 
aeruginosa 
100% 0% 0% <0.0001 
Quality of life (SGRQ) 62.9 (11.8) 44.1 (23.0) 35.6 (18.8) 0.03 
Table 5.1. Characteristics of patients undergoing sputum and peripheral blood 
neutrophil studies. Abbreviations: SGRQ= St. Georges Respiratory Questionnaire, 
FEV1= forced expiratory volume in 1 second, FVC= forced vital capacity, BMI= 
body mass index. Yr= year. 
 
Compared with healthy control subjects, peripheral blood neutrophils from patients 
with bronchiectasis did not show reduced phagocytosis of FITC-labelled E.coli or 
P.aeruginosa, figure 5.16. In this experiment, organisms were opsonised for 1 hour 
with 20% pooled donor serum followed by incubation with patient or healthy donor 




Figure 5.16. Phagocytosis by peripheral blood neutrophils from bronchiectasis 
patients and healthy control subjects. Measurements were performed by flow 
cytometry as described in the text. Phagocytosis (mean fluorescence intensity) is 
expressed as % of the mean value for 9 healthy controls. N=23 for bronchiectasis 
patients.  
   
Receptor expression was similar between peripheral blood neutrophils from healthy 
donors and from patients with bronchiectasis, with no significant differences within 
the bronchiectasis sub-groups, figure 5.17. Results are expressed as a ratio of 
expression (mean fluorescence by flow cytometry) on neutrophils from 9 healthy 
controls subjects, indicated by the white bars in figure 5.17. 
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Figure 5.17. Neutrophil receptor expression in peripheral blood neutrophils between 
healthy control subjects (N=9) and bronchiectasis patients (N=23). Values are 
expressed as relativel expression compared to healthy control subjects (1.0). 
Abbreviations: CR1= complement receptor 1, CR3= complement receptor 3 
     
Compared to healthy peripheral blood neutrophils, all patients sputum neutrophils 
demonstrated reduced expression of CR1, consistent with previous reports from 
cystic fibrosis (Berger et al 1989). There was also reduced expression of FCγRIIIb in 
patients with bronchiectasis, and reduced expression of FCγRIIIb correlated with the 
severity of bronchiectasis, p=0.01 by Kruskal-wallis test.(figure 5.18) 
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Sputum neutrophil studies showed substantial variation in receptor expression and 
neutrophil phagocytosis between individual bronchiectasis patients. Again, in figure 
5.18, results are expressed as a ratio of peripheral blood neutrophil receptor 
expression from 9 healthy control subjects, except that for sputum neutrophil studies 
the control neutrophils were maximally activated with platelet activating factor 
followed by fMLP as described in chapter 2.  
 
Figure 5.18. Sputum neutrophil receptor expression in patients with bronchiectasis 
compared to maximally activated peripheral blood neutrophils from 9 healthy 
controls. Abbreviations: PA= P. aeruginosa. CR1= complement receptor 1, CR3= 
complement receptor 3. Data are shown at the mean (SE) from 23 patients with 





Patients demonstrated similar expression of CR3 and CD62L to activated peripheral 
blood neutrophils, with no significant differences observed according to severity of 
bronchiectasis (p>0.05). Treatment of sputum neutrophils with platelet activating 
factor and fMLP did not increase CD11b expression or reduce CD62L expression, 
suggesting that airway neutrophils are maximally activated, figure 5.19. 
Figure 5.19. CD11b expression and C62L expression as markers of neutrophil 
activation. Mean fluorescence for peripheral blood neutrophils is shown in red.  
 
After treatment with the negative control (phosphate buffered saline) neutrophils 
show low expression of CD11b and high expression of CD62L. Following activation 
with platelet activating factor (PAF) followed by fMLP, there was a significant 
upregulation of CD11b (p<0.0001) and shedding of CD62L (p<0.0001). In contrast, 
in sputum neutrophils (green bars), prior to treatment sputum neutrophils had high 
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expression of CD11b and low expression of CD62L. Further treatment with PAF-
fMLP did not significantly affect expression of these markers (p>0.05 for both 
comparisons).  
Sputum neutrophil phagocytosis varied significantly. There was no difference 
between patients with mild and moderate bronchiectasis in terms of sputum 
neutrophil phagocytosis but there was a significant reduction in phagocytosis in 
patients with severe bronchiectasis and P. aeruginosa colonisation compared to the 
other two groups (p=0.004 for phagocytosis of P. aeruginosa and p=0.008 for 





Figure 5.20. Sputum neutrophil phagocytosis. The mean fluorescence intensity and 
standard error of the mean are displayed relative to the values obtained for 
maximally activated peripheral blood neutrophils from 9 healthy donors (N=23 for 
bronchiectasis patients). Abbreviations- PA= P. aeruginosa.  
 
CD88 expression was lower in patients with severe bronchiectasis compared to 
mild/moderate bronchiectasis. (Figure 5.18). Expression was reduced to 83% 
(standard deviation 20.3) of control in mild bronchiectasis, compared to 54% 
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(standard devation 33.7) of control in moderate bronchiectasis and 24.6% (standard 
deviation 20.8) of control in severe patients (p=0.007).  
CD88 is the receptor for complement component C5a. As one of the major functions 
of ficolin-2 is the activation of complement and therefore the generation of C5a, we 
sought to investigate the importance of CD88 in bronchiectasis neutrophils in more 
detail. 
 
5.8 Neutrophil elastase is responsible for loss of CD88 on sputum neutrophils 
There was a significant correlation between CD88 expression and phagocytosis of P. 
aeruginosa (r=0.59,p=0.002) and E. coli (r=0.63,p=0.0009), (figure 5.21) and a 
significant correlation between CD88 expression and oxidative burst in sputum 
neutrophils (r=0.54,p=0.006). Oxidative burst was measured by the 
dihydrorhodamine method (see chapter 2). 
CD88 correlates with phagocytosis of PA01


























CD88 correlates with phagocytosis of E.coli


























CD88 correlates with oxidative burst
by sputum neutrophils






































Figure 5.21. Correlations between sputum neutrophil CD88 expression and 
phagocytosis of P. aeruginosa and E.coli labelled with FITC. Phagocytosis is 
expressed as a ratio of the phagocytosis observed in peripheral blood neutrophils as 




A pool of sputum from 5 patients with non-CF bronchiectasis caused loss of CD88 
from healthy neutrophils after 30 minutes incubation, while a pool of induced sputum 
from the 9 healthy donors without lung disease did not cause any significant 
reduction in neutrophil expression of CD88. At the dilutions used (up to 10% v/v 
sputum sol), sputum sol treatment for 30 minutes did not induce neutrophil apoptosis 
or necrosis as demonstrated by annexin-V and PI staining. (figure 5.22). 
 
Figure 5.22. Flow cytometry assessment of apoptosis in peripheral blood neutrophils 
from healthy controls treated for 30 minutes with a pool of sputum from patients 
with bronchiectasis. The X-axis shows Annexin-V-FITC staining and the Y-axis 






















Initially I hypothesised that C5a present in sputum would be responsible for CD88 
downregulation by bronchiectasis sputum sol, since it is known that C5a binding to 
its receptor causes rapid internalisation of CD88 and reduced surface expression 
(Ward, 2004). As expected, C5a treatment of healthy neutrophils led to 









































Figure 5.23. Downregulation of CD88 in response to increasing concentrations of 
recombinant complement C5a. Results show the mean (SE) of 3 separate 
experiments. The mean fluorescence intensity was significantly different to untreated 




Loss of CD88 was, however, observed after exposure of neutrophils to highly diluted 
(0.6%) sputum sol that contained no detectable C5a by ELISA.  
Neutrophils from healthy donors were treated with increasing doses of purified 
neutrophil elastase. The results demonstrated a dose dependent reduction in CD88 
expression in elastase treated neutrophils. Importantly, marked CD88 cleavage was 
demonstrated at levels of neutrophil elastase activity (<0.5µg/ml) lower than those 
present in patients with severe bronchiectasis and other disorders such as COPD or 















Figure 5.24. Neutrophil elastase and CD88 expression on neutrophils. Elastase or 
sputum sol treatment of neutrophils causes dose dependent loss of CD88 from 
neutrophils. This loss is inhibited by the specific neutrophil elastase inhibitor -
methoxysuccinyl-Ala-Ala-Pro-Val-chloromethyl ketone (MeOSu-AAPV-CMK). 
Data are shown as mean (SE) from 3 individual experiments for elastase and mean 
(SE) from 3 individual pools of sputum sol for sputum studies.  
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Treatment with another neutrophil protease, Cathepsin G, did not affect CD88 
expression, nor did activation with fMLP (figure 5.25).  
 
Figure 5.25. Treatment with 1µg/ml neutrophil elastase caused a statistically 
significant loss of CD88 from neutrophils (p<0.0001) while the protease cathepsin-G 
and fMLP had no effect on CD88. Results are the mean of 3 independent 
experiments and results are expressed as mean fluorescence with standard error of 
the mean 
 
The reduction in CD88 expression on donor neutrophils by elastase was completed 
abrogated by addition of a specific inhibitor of neutrophil elastase N-
methoxysuccinyl-Ala-Ala-Pro-Val-chloromethyl ketone at a concentration of 1mM. 
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(figure 5.24). This concentration of N-methoxysuccinyl-Ala-Ala-Pro-Val-
chloromethyl ketone was sufficient to fully inhibit elastase activity in sputum sol 
samples at the dilutions used in a microplate assay using the synthetic substrate N-
methoxysuccinyl-Ala-Ala-Pro-Val p-nitroanilide (MeoSAAPvN) (figure 3.26). 
 
Figure 5.26. Inhibition of sputum neutrophil elastase activity with the neutrophil 
elastase inhibitor N-methoxysuccinyl-Ala-Ala-Pro-Val-chloromethylketone. Results 
are mean of 3 independent experiments using four representative patient samples.  
 
Pre-treatment of sputum samples with N-methoxysuccinyl-Ala-Ala-Pro-Val-
chloromethyl ketone prevented cleavage of CD88 when sputum samples were 
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incubated with neutrophils confirming that elastase was primarily responsible for 
loss of CD88 induced by sputum sol, figure 5.24.  
 
Treatment with leukocyte elastase impaired C5a mediated enhancement of 
phagocytosis and oxidative burst, implicating CD88 cleavage by elastase in airway 
neutrophil dysfunction in bronchiectasis. 
C5a is known to prime neutrophils for activation, superoxide production and 
phagocytosis (Mollnes 2002). To determine if elastase cleavage of CD88 has 
functional consequences for bronchiectasis neutrophils, we studied superoxide 
production by dihydrorhodamine fluorescence following treatment of neutrophils 
with C5a (1nM) followed by fMLP (0.1 µmol/L). Since platelet activating factor 
(PAF) also primes neutrophils but by a mechanism that does not involves CD88, 
treatment with PAF (1µmol/L) followed by fMLP (0.1 µmol/L) was used for 
comparison. Neutrophils were incubated at 37°C for 30 minutes in either PBS 
(control) or 1.5µg/ml purified neutrophil elastase prior to priming and activation.  
The data demonstrated a typical priming response to c5a in the untreated neutrophils, 
with a significant increase in fluorescence between the C5a-fMLP treated neutrophils 
compared to PBS-fMLP treated neutrophils. In contrast, the difference between C5a-
fMLP and PBS-fMLP treated neutrophils was not statistically significant following 
elastase treatment of neutrophils, suggesting a failure of CD88 dependent priming, 
figure 5.27.  
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Figure 5.27. The effect of neutrophil elastase pre-treatment on oxidative burst. Data 
are presented as fold increase from control (1). Differences were statistically 
significant for PAF-fMLP treated neutrophils in both conditions (p<0.05) and for 
C5a-fMLP, pbs-fMLP and PAF-C5a treated neutrophils in untreated neutrophils 
(p<0.05) but not in elastase treated neutrophils. All other comparisons p>0.05. Data 
are shown as mean (SE) from 3 independent experiments. PAF= platelet activating 
factor, fMLP=N-formyl-methionyl-leucyl-phenylalanine, PBS= phosphate buffered 
saline.  
 
30 minutes pretreatment of neutrophils with 100pM to 10nM recombinant C5a 
induced a dose dependent increase in phagocytosis after exposure to E.coli or 
P.aeruginosa (p<0.0001 for both by Kruskal-wallis test). Elastase treatment 
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(1.5µg/ml purified elastase or PBS control) for 30 minutes resulted in a reduction in 
phagocytosis, but also prevented the enhancement of phagocytosis induced by C5a 
(p=0.5 for E.coli and p=0.3 for P.aeruginosa by Kruskal-wallis test). Figure 5.28 
























































































































Figure 5.28. The effect of elastase cleavage of CD88 on C5a enhancement of 
neutrophil phagocytosis.  
 
 
5.9 Opsonisation with Ficolin-2 enhances phagocytosis of P. aeruginosa by 
sputum neutrophils 
Despite the neutrophil receptor and functional changes described above, sputum 
neutrophils responded similarly to peripheral blood neutrophils to serum opsonins. 
Increasing serum concentration increased the rate of phagocytosis over 30 minutes 
and phagocytosis was prevented by treatment of cells with cytochalasin-D as 
described for peripheral blood neutrophils. 
Opsonisation of PA01 with increasing Ficolin-2 concentrations resulting in a dose 
dependent increase in phagocytosis as measured by both mean fluorescence (p=0.001 
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by two way ANOVA) and % phagocytosis (p=0.006 by two way ANOVA) (figure 
5.29). This opsonisation was MASP-2 and serum dependent. Representative flow 
cytometry plots are shown.  
Figure 5.29. Sputum neutrophil phagocytosis is enhanced by opsonisation with 
recombinant ficolin-2 in the presence of serum and MASP-2. The image in the top 
left shows forward and side scatter properties of isolated sputum neutrophils. There 
is a clearly identified neutrophil population with associated debris which was a 
typical finding after sputum neutrophil preparation. In the presence of complement 
and recombinant ficolin-2 there was a dose dependent increase in phagocytosis 
quantified by mean fluorescence and percentage of FITC positive cells. This is 
reflected in the lower panels which show representative flow cytometry data. The 





Since neutrophil elastase was found to be major contributor to neutrophil 
dysfunction, we tested whether neutrophil elastase affected ficolin-2 binding to 
PA01. Non-reduced western blotting after incubation with 0.5µg/ml elastase for 1 
hour suggested a minor effect of elastase on oligomerisation of ficolin-2, with 
qualitatively fewer high order multimers and more monomers compared to untreated 
ficolin-2 (figure 5.30). This did not have a significant impact on the amount of bound 
ficolin-2 in a solid-phase binding assay of PA01 (p>0.05 for comparisons at all 
concentrations). 
 
Figure 5.30. No effect of neutrophil elastase or Cathepsin G on binding of 





5.10 Interaction between ficolin-2 and pentraxin-3 enhances phagocytosis of 
Pseudomonas aeruginosa 
It has been reported that Ficolin-2 dependent complement activation can be enhanced 
by interaction with pentraxins. To investigate this further, I investigated binding of 
Ficolin-2 to Pentraxin-3, serum amyloid P and C-reactive protein. Significant 
binding to all three pentraxins was observed, Figure 5.31A. Opsonisation of PA01 in 
the presence of ficolin-2 and pentraxin-3 (10µg/ml) resulted in significantly greater 
deposition of C3 by flow cytometry (figure 5.31B) and phagocytosis of FITC-PA01 
(figure 5.31B). In view of a previous report (Zhang et al 2009) that C-reactive 
protein could enhance phagocytosis of P. aeruginosa in collaboration with ficolin-2, 
assays were repeated adding CRP at 10µg/ml along with ficolin-2. No effective on 
complement activation or phagocytosis was observed. 
Pentraxin-3 was found to be present in induced sputum in significant quantities. 
Pentraxin-3 was measured in induced sputum from 30 stable patients with 
bronchiectasis and 30 healthy control subjects. Higher levels of pentraxin-3 were 
demonstrated in bronchiectasis sputum compared to healthy control subjects. 












Figure 5.31. Interaction of ficolin-2 with pentraxins boost complement deposition 
and phagocytosis of PA01. Figure A- % binding is shown compared to the positive 
control (binding to Acetylated BSA-100% and the negative control, BSA). 
Significant binding of each Pentraxin was statistically significant compared to the 
negative control (p<0.0001). Data in figure 5.31A and 5.31B shown the mean (SE) 





In this chapter, we demonstrate a role for ficolin-2 in the opsonophagocytic clearance 
of bacteria by neutrophils and macrophages and specifically demonstrate a role in the 
clearance of P. aeruginosa. Enhancement of phagocytosis was demonstrated in both 
peripheral blood neutrophils and, importantly, in airway neutrophils from patients 
with bronchiectasis when opsonisation was enhanced with recombinant ficolin-2. 
Enhancement of phagocytosis was dependent on the presence of MASP-2 and C3, 
indicating that complement activation through the lectin pathway was the underlying 
mechanism.  
Ficolin-2 bound to a wide range of clinically relevant bacteria, and binding was 
accompanied by complement activation. In keeping with our clinical findings, 
ficolin-2 was the critical regulator of complement activation, with the amount of C3 
deposited on cells dependent on the ficolin-2 serum concentration and not on the 
concentration of MASP-2. This would suggest that the enzyme MASP-2 is present in 
excess in serum and that it is engagement of the fibrinogen-like domain of ficolin-2 
to pathogens that is required for complement activation. Having demonstrated 
enhanced phagocytosis and killing of PA01 in healthy neutrophils we went on to 
investigate airway neutrophils in bronchiectasis.  
Neutrophils are the major inflammatory cell present in the bronchiectasis airways 
(Eller et al 1994). The number of neutrophils migrating to the airway is increased in 
stable patients and the numbers increase further with bacterial infection and 
exacerbation (Chalmers et al 2011). Despite the large numbers of neutrophil 
phagocytes in the airway, these cells fail to effectively phagocytose and kill bacteria 
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leading to chronic bacterial colonisation (Angrill 2002). The reasons for this in 
bronchiectasis are unknown. The present study provides a large amount of data on 
neutrophil function in bronchiectasis. We found no differences in complement 
receptor 1, complement receptor 3, CD62L, CD88 and FcγRIIIb expression on 
peripheral blood neutrophils between healthy controls and patients with 
bronchiectasis. Healthy and bronchiectasis peripheral blood neutrophils had similar 
phagocytic ability. Together these suggest that neutrophils are relatively normal prior 
to migrating to the bronchiectasis airway. This is consistent with the previous work 
by Pasteur et al, who also did not find evidence of abnormal neutrophil function in a 
significant number of patients with bronchiectasis (Pasteur et al 2000). 
There were, however, marked differences between peripheral blood and airway 
neutrophils. Airway neutrophils, isolated from sputum, had reduced expression of 
complement receptor 1, FcγRIIIb and CD88 compared to peripheral blood 
neutrophils from the same patients. Down-regulation of these receptors correlated 
with the severity of bronchiectasis, with the lowest levels observed in patients with 
P. aeruginosa infection. Similarly, patient’s airway neutrophils had reduced 
phagocytosis of E. coli and P. aeruginosa compared to peripheral blood neutrophils. 
The present study is the first to describe neutrophil elastase mediated reduction in 
CD88 expression on the surface of neutrophils, the receptor for complement 
component C5a. Complement component c5a is a potent regulator of the 
inflammatory response (Guo and Ward 2005) produced by the cleavage of 
component c5 during complement activation via the classical, lectin or alternative 
pathways. C5a exerts multiple pro-inflammatory effects via its receptor CD88. CD88 
is expressed on monocytes and bronchial epithelial cells, but is most abundant on 
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neutrophils where the effects of C5a are consequently most pronounced (Chenoweth 
and Hugli 1978). C5a primes neutrophils to enhance functional responses such as 
phagocytosis and the generation and release of granule enzymes and superoxide 
anions which are critical to bacterial killing (Mollnes 2002).   
Generation of c5a causes local vasodilation, oedema and is a powerful 
chemoattractant for neutrophils and other leucocytes (Marder et al 1985). C5a also 
protects neutrophils from apoptosis (Perianayagam et al 2002). When regulated, 
these processes are protective against bacterial infection and beneficial to the host. It 
has been reported that the very high levels of c5a generated during sepsis can be 
harmful to neutrophils by suppressing chemotaxis and phagocytosis (Huber-Lang et 
al 2002, Ward 2004).
 
The c5a receptor, CD88 is nevertheless critical to host defence, as demonstrated by 
markedly increased neutrophil influx and failed bacterial clearance in CD88 deficient 
mice infected with P. aeruginosa (Hopken et al 1996).
 
This study found that neutrophil elastase caused loss of CD88 by neutrophils and 
impaired CD88 mediated functions of C5a. Elastase is already known to damage 
epithelial cells, slowing ciliary beat frequency and promoting mucous hypersecretion 
in bronchiectasis (Voynow, 1999, Amitani, 1991). Elastase is directly pro-
inflammatory. Destruction of elastin, basement membrane collagen and 
proteoglycans by elastase and other neutrophil proteases contributes directly to 
disease progression (Shun, 2000, Stockley, 1984).
 
Importantly however, there is strong evidence that elastase also impairs neutrophil 
phagocytosis by multiple mechanisms. Elastase cleaves FcγRIIIb, and has also been 
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shown to cleave complement receptor 1 in patients with cystic fibrosis (Voglis, 2009, 
Berger, 1989). Elastase also cleaves iC3b from the surface of pathogens leading to an 
important opsonin/receptor mismatch.(Tosi et al, 1990). The present study identified 
a novel mechanism of elastase induced neutrophil dysfunction in bronchiectasis. 
Elastase treatment of neutrophils led to a reduction in CD88 expression. Incubation 
of neutrophils with bronchiectasis sputum also reduced CD88 expression and this 
could be inhibited by neutrophil elastase inhibitors. Elastase or sputum treatment 
impaired complement C5a induced enhancement of phagocytosis and oxidative 
burst.  
Despite the marked neutrophil dysfunction identified in bronchiectasis, ficolin-2 was 
still able to enhance phagocytosis of P. aeruginosa, adding validity to our hypothesis 
that ficolin-2 may be important in defence against P. aeruginosa in the airway. 
We went on to investigate the role of the pentraxins and their interaction with 
ficolins in phagocytosis of P. aeruginosa. Zhang et al demonstrated enhanced 
complement mediated killing of P. aeruginosa in the presence of C-reactive protein 
under inflammatory conditions, demonstrating the ability of Ficolin-2 to enhance C4 
deposition and phagocytosis of P. aeruginosa (Zhang et al 2009). In the present 
study, we investigated the effect of the pentraxins on complement activation and 
phagocytosis of P. aeruginosa and found enhancement of phagocytosis in the 
presence of pentraxin-3, but not c-reactive protein. This is consistent with the work 
of Ma et al who have demonstrated the interaction between pentraxin-3 and ficolin-2 
could enhance complement activation on Aspergillus fumigatus. In this study, we 
found that pentraxin-3 could enhance complement activation on P. aeruginosa and 
phagocytosis (Ma et al 2011). Importantly, pentraxin-3 was present in induced 
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sputum from patients with bronchiectasis raising the possibility that this interaction is 
relevant in-vivo. Unlike CRP, where the collaboration is reported to only occur at 
low pH and in inflammatory conditions (Zhang et al 2009), ficolin-2 collaborated 
with Pentraxin-3 at physiological pH and osmotic conditions in the present study. 
Pentraxin-3 is critical to host defence against P. aeruginosa (Garlanda 2002). Mice 
lacking pentraxin-3 are more susceptible to P. aeruginosa infection and pentraxin-3 
has been evaluated as a possible novel therapy for chronic P.aeruginosa infections 
(Moalli 2011). The apparent interaction between ficolin-2 and pentraxin-3 is an 
important area for future study. 
 
Complement activation in human serum against P. aeruginosa occurs largely by the 
alternative pathway with a small contribution from the lectin pathway (Younger et al 
2003). In mice, MASP-2 deficiency which completely prevents lectin pathway 
activation did not lead to increased susceptibility to P. aeruginosa pneumonia 
(Kenawy et al 2012). This is in contrast to work in mice by Moller-Kristensen which 
found that MBL knockout mice had increased susceptibility to P. aeruginosa 
infection following burn injury (Moller-Kristensen et al 2006), and to the increasing 
body of evidence of a role for the lectin pathway against P. aeruginosa infection in 
humans (Garred et al 1999, Zhang et al 2009, Chalmers et al 2011, Haerynck et al 
2012). Several important differences between mice and humans may explain these 
contradictory findings. In mice, there are only 2 ficolins:.Ficolin A is present in liver 
and blood plasma and is analogous to ficolin-2 in humans, while ficolin B (60% 
identical) is expressed in bone marrow and spleen and is associated with 
macrophages, analogous to ficolin-1 (Fujimori et al 1998). Ficolin-3 is absent in 
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mice (Endo et al 2004). Although ficolin-A in mice is analogous ficolin-2 in humans, 
there are significant differences in binding specificity (Hummelshoj et al 2012). 
Mannose binding lectin is represented by two proteins (MBL-A and MBL-C) in mice 
compared to a single molecule in humans (Liu et al 2001). In addition, given the 
emerging evidence of a role for pentraxins in amplifying the lectin pathway, it 
important to note differences between human and murine pentraxins. In humans, C-
reactive protein is the major acute phase reactant in human plasma (Smith 1995), in 
contrast to mice where serum amyloid P is the major acute phase reactant and CRP is 
virtually absent (Yuste 2007). Pentraxin-3 is present in mice and has been shown to 
be critical to response against P. aeruginosa as well as the fungal pathogen 
Aspergillus fumigatus (Garlanda 2002).  Thus, while there are many similarities 
between murine and human lectin pathway components, there are critical differences 
that mean studies in mice cannot be easily extrapolated to humans. 
It is interesting to speculate on how defects in the lectin pathway of complement lead 
to increased susceptibility to infection in patients with chronic lung disease such as 
non-CF bronchiectasis, cystic fibrosis and COPD. Low ficolin-2 and MBL levels are 
common in the general population and do not appear to significantly increase the risk 
of infections with P. aeruginosa or other micro-organisms in otherwise healthy 
individuals. The “double-hit” hypothesis holds that the lectin pathway of 
complement is redundant and that a second innate immune defect is required before 
lectin pathway deficiency becomes important (Fevang et al 2005). This explains the 
apparent importance of MBL deficiency in diseases as diverse as common variable 
immunodeficiency (Fevang et al 2005), HIV infection (Catano et al 2008) and CF 
(Chalmers et al 2011). An alternative hypothesis, that is supported by our finding that 
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pentraxin-3 enhances complement activation, is that the lectin pathway is important 
in the context of chronic inflammation. We speculate that local and systemic release 
of pentraxins may enhance complement activation via the lectin pathway at 
inflammatory sites such as the lung, under conditions that inhibit the other 
components of the complement pathway (Zhang et al 2009, Gout et al 2011, Ma et al 
2011). Unique features of the lectin pathway are its resistance to high salt 
concentrations, neutrophil proteases and inhibitors such as SPS (Petersen et al 2001, 
Palarasah et al 2011). The high-salt hypothesis in cystic fibrosis proposes that high 
ionic strength disables multiple anti-bacterial mechanisms in the bronchiectasis 
airway (Bals et al 1998). Whether this hypothesis is relevant to the development of 
CF-associated bronchiectasis is a matter of debate (Matsui et al 1998), and the 
osmotic conditions of the non-CF bronchiectasis airway have not been described. It 
is true, however, that Ficolin-2 is resistant to high salt concentrations and ionic 
strengths that inhibit the alternative and classical pathways.  
In summary therefore, the present study links 3 important mechanisms with P. 
aeruginosa colonisation in bronchiectasis: low expression of ficolin-2, the 
collaboration between ficolin-2 and pentraxin-3 and the loss of CD88 from airway 
neutrophils. CD88 and pentraxin-3 are already known to be critical to defence 
against P. aeruginosa but this is the first demonstration of the relevance of this in 
bronchiectasis (Hopken et al 1996, Garlanda et al 2002).  
The in-vitro studies used in the present report were established methods identified 
from the literature for studying the lectin pathway and took advantage of the growing 
knowledge in this area (Petersen et al 2001, Palarasah et al 2011, Ma et al 2011) . 
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Ficolin-2 enhances phagocytosis of P. aeruginosa through complement activation 
under conditions of low serum concentration. In-vitro, ficolin-2 collaborates with 
pentraxin-3 and enhances complement mediated phagocytic clearance of P. 
aeruginosa. Significant neutrophil dysfunction was found in bronchiectasis airway 
neutrophils with neutrophil elastase implicated both in-vivo and in-vitro. CD88 
cleavage by neutrophil elastase further impairs complement mediated defence against 
P. aeruginosa but opsonophagocytosis is still enhanced by ficolin-2 in dysfunctional 
bronchiectasis airway neutrophils. Ficolin-2 should be evaluated as a new therapeutic 





Mannose binding lectin and disease severity in bronchiectasis 
6.1 Introduction 
As previously discussed, bronchiectasis is a chronic inflammatory lung disease 
characterised by permanent dilatation of the bronchi (Pasteur, 2010). Patients suffer 
daily cough, sputum production and recurrent respiratory infections (Pasteur, 2010). 
Central to the pathogenesis of bronchiectasis is a vicious cycle of failed bacterial 
clearance, airway inflammation and airway structural damage (Cole, 1986). Patients 
become chronically colonised with pathogens due to a failure of host immune 
defences (Fuschillo, 2008). Recognised immunological defects associated with 
bronchiectasis include antibody deficiencies (common variable immunodeficiency, 
x-linked agammaglobulinaemia, IgG subclass deficiency), neutrophil and 
macrophage defects and secondary immunodeficiency (such as following 
chemotherapy or transplantation), but from published data, only around 7% of adult 
patients with bronchiectasis have an identifiable primary immunodeficiency (Nicotra 
et al, 1995, Pasteur et al, 2000, Kelly et al, 2003).The cause of adult bronchiectasis in 
the majority of adult patients is unknown. 
Mannose binding lectin (MBL) is a soluble pattern recognition molecule of the 
innate immune system (Kilpatrick, 2002). MBL binds to glycoconjugates containing 
mannose, fucose or N-acetylglucosamine on the surface of a wide range of clinically 
important bacteria, viruses and fungi, activating the lectin pathway of complement 
(Neth et al, 2000, Moller-Kristensen et al, 2006). Through activation of the 
associated enzyme MBL-associated serine protease-2, MBL promotes opsonisation 
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of pathogens for phagocytosis (through complement component C3 or direct 
interaction with phagocytes), direct cell lysis (through generation of the membrane 
attack complex) and can also promote inflammatory cell chemotaxis and activation 
through generation of complement component C5a (Thiel et al, 1997, Wallis, 2007). 
MBL may also have a role in the resolution of inflammation in the lung through the 
clearance of apoptotic cells and in suppressing pro-inflammatory cytokine secretion 
(Hodge et al, 2010, Wang et al, 2011).
 
Deficiency in mannose binding lectin is one of the most common immunological 
defects in humans, affecting 10%-30% of the population depending on the definition 
of deficiency used (Eisen, 2010). MBL deficiency has been associated with recurrent 
respiratory infections, and is associated with the presence of bronchiectasis in 
patients with common-variable immunodeficiency (Fevang et al, 2005, Litzman et al, 
2008)
 
In addition, although mannose binding lectin is not the cause of cystic fibrosis, 
several studies have found evidence that MBL deficiency modifies the course of 
disease in cystic fibrosis, leading to a more rapid decline in FEV1, earlier acquisition 
of Pseudomonas aeruginosa, infection with B. cepacia, and death (Garred et al, 
1999, Dorfman et al, 2008, McDougall et al, 2011, Chalmers et al, 2011).   
We therefore sought to investigate whether mannose binding lectin deficiency was 
associated with disease severity in adult non-cystic fibrosis bronchiectasis.  
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6.2 Patient characteristics 
The study included 470 patients with non-cystic fibrosis bronchiectasis and 414 
healthy control subjects. The characteristics of the study population are shown in 
Table 6.1 (repeated from the previous chapter). There were no significant differences 
in demographics or co-morbid illnesses between bronchiectasis patients and controls. 
The majority (80.4%) of the cohort had idiopathic/post-infective bronchiectasis. 
None of the control subjects had a history of chronic respiratory disease and none 
were prescribed inhaled corticosteroids (table 6.1). 
 
 
Bronchiectasis cohort Control cohort p-value 
N 
Age 
















Co-morbidities    
Chronic cardiac disease 
Cerebrovascular disease 














Causes of bronchiectasis    
Idiopathic/post infective 
Previous ABPA 
Connective tissue disease 










Medications    
Inhaled corticosteroid use 196 (41.7%) 0 (0%) <0.0001 
 
Table 6.1. Clinical characteristics of the study population. Note this is a duplication of table 3.1 and is 





6.3 Frequency of MBL deficiency in non-CF bronchiectasis patients and 
controls 
The expected relationships between MBL haplotypes and serum levels were 
observed and are shown in figure 6.1. Patients with high expressing haplotypes had a 
median serum MBL of 2100ng/ml (1400-3200ng/ml), compared to 600ng/ml (400-
1300ng/ml) in intermediate expressing haplotypes and 0ng/ml (0-200ng/ml) in 
patients with the low expressing MBL groups. 
 
Figure 6.1. The relationship between MBL haplotypes and MBL serum levels. (all 
comparisons p<0.0001). 
 
In examining genotype frequencies, there were no significant differences between 
bronchiectasis patients and controls. Table 6.2 shows the frequency of MBL 



























































Table 6.2. Genotype frequencies and serum levels in patients with non-CF 
bronchiectasis and controls. 
 
6.4 MBL deficiency and chronic bacterial colonisation 
Chronic bacterial colonisation was present in 76.8% of the population. Haemophilus 
influenzae was the most frequently isolated pathogen (141 patients, 30%), followed 
by Pseudomonas aeruginosa (68 patients- 14.5%), M. catarrhalis (54 patients- 
11.5%), enteric gram negative organisms (46 patients- 9.8%), S. aureus (43 patients- 
9.1%), S. pneumoniae (30 patients- 6.4%) (note that percentages add up to greater 
than 100% as some patients were colonised with more than one pathogen).  
There was a higher frequency of bacterial colonisation (85.4%) in the MBL deficient 
group as determined by genotype (table 6.3) and serum levels (table 6.4). Differences 
between the intermediate expressing genotype group and the high expressing group 
were not statistically significant, p=0.4. Using both serum level cut-offs, there was a 
higher frequency of bacterial colonisation, H.influenzae and P.aeruginosa 
colonisation in the MBL deficient group, but this was not evident when the patients 
with the low expressing genotype were excluded, suggesting this effect was entirely 
due to these patients (p=0.9 for bacterial colonisation, p=0.9 for H.influenzae and 
290 
 
p=0.7 for P.aeruginosa). After adjustment for age, radiographic severity and FEV1 % 
predicted, the logistic regression analysis did not show a statistically significant 
effect of MBL deficient genotypes on chronic colonisation – adjusted odds ratio 
(AOR) 1.85 95% 0.96-3.59,p=0.06. The relationship between MBL deficient 
genotypes and P.aeruginosa was not statistically significant after adjustment for age, 
radiographic severity and FEV1 % predicted, AOR 1.25 95% CI 0.55-2.83,p=0.6. 
There were no statistically significant relationships with other bacterial species and 
MBL deficiency, although the numbers in each group were small. Only one patient 













FEV1 % predicted 
FVC % predicted 
Exacerbations and QOL 









































































Table 6.3. Markers of severity in patients with MBL deficiency according to 
genotype. *in the year prior to the study. Data during prospective follow-up are 
presented under long-term prognosis. FEV1= forced expiratory volume in 1 second, 
FVC= forced vital capacity. SGRQ= St. George’s Respiratory Questionnaire, LCQ= 
Leicester cough questionnaire, HRCT= high resolution computed tomography, BMI= 
body mass index. 
 
 
6.5 Pulmonary function and radiological severity of bronchiectasis 
There was no significant relationship between MBL deficiency, defined using 
genotype or serum levels, and either FEV1 % predicted or FVC % predicted (see 
tables 6.3 and 6.4). MBL deficient patients had more severe radiological 
bronchiectasis using the modified Reiff score (table 6.3), as did patients with an 
MBL <200ng/ml. This difference was not evident using serum levels <500ng/ml. 




6.6 Exacerbation frequency, hospitalisations and quality of life 
Baseline exacerbation frequency was higher in the MBL deficient group using 
genotype, mean per patient/year of 4·2 (standard deviation 3·4) in the deficient group 
vs 2·6 (2·5) and 2·7 (2·8) in the intermediate and high expressing groups,p=0·001 
(table 6.3). There was no difference between the intermediate and high expressing 
genotype groups. Patients with serum levels <200ng/ml had more frequent 
exacerbations compared to those with higher MBL levels. (table 6.4). For quality of 
life, this secondary care population of bronchiectasis patients had marked impaired 
of quality of life. SGRQ scores were higher for MBL deficient patients by genotype 
(table 6.3). The difference was greater than the 4 point minimal clinically important 
difference,p=0·0069. There was no significant difference between intermediate and 
high expressing MBL genotypes (p=0·35). Using the Leicester cough questionnaire, 
patients with MBL deficient genotypes had more severe cough symptoms (table 
3),p=0·029, with differences greater than the 1·3 minimal clinically important 
difference. There was no significant difference between the intermediate and high 
expressing groups, p=0·49. Serum levels did not show significant relationships with 













Serum > 500ng/ml 
p-value MBL deficient 
Serum <200ng/ml 
MBL sufficient 
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Table 6.4. Markers of severity in patients with MBL deficiency according to serum 
levels. Abbreviations: FEV1= forced expiratory volume in 1 second, FVC= forced 
vital capacity. SGRQ= St. George’s Respiratory Questionnaire, LCQ= Leicester 




6.7 Measures of airways inflammation 
Patients with MBL deficient genotypes had higher levels of airway inflammation 
(p<0.05 for all markers tested) overall. These differences were primarily due to 
higher bacterial loads in sputum for patients with MBL deficiency compared to those 







) vs. 5.7 x 10
6




 vs. 4.8 x 10
6
 (1.5 x 10
5






After accounting for this by analysing groups according to bacterial load (figure 6.2), 
significantly higher levels of each marker were identified in the MBL deficient group 
at 10(8) cfu/ml or greater (p<0.05). 
 
Figure 6.2. Measures of airway inflammation in MBL groups stratified by airway 
bacterial load. Data are presented as median (symbols) with interquartile range 
(bars). *comparisons by Kruskal-wallis test, all other comparisons p>0.05. X-axis 







6.8 Long term prognosis 
Longitudinal measurement of MBL serum levelsAs previously reported, MBL serum 
levels are largely genetically determined and there was no statistically significant 
variation in MBL serum levels comparing the start, middle and end of the study 
(p>0·05 for all comparisons, figure 4.3). In sub-analyses, changes in serum MBL 
over time did not correlate with deteriorating lung function or changes in bacterial 
colonisation but there was a significant increase in MBL serum levels at the onset of 
exacerbations (figure 6.3). The authors studied 24 patients with high expressing 
haplotypes, 26 patients with intermediate expressing haplotypes and 18 patients with 
MBL deficient haplotypes who attended for blood and sputum sampling at the onset 
of exacerbations and repeat measurement at completion of 14 days antibiotics. In the 
high expressing MBL group, MBL increased by a mean of 27·3% at start of 
exacerbation, p=0.007). The same pattern was observed in the intermediate 
expressing group, mean increase 20·2% but the difference was not statistically 
significant (p=0·37). MBL deficient patients failed to upregulate MBL serum levels 
significantly during exacerbation (figure 6.3).  
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Figure 6.3. Repeat measurement of MBL serum levels during the study. A/A 
indicates the high expressing MBL haplotypes, A/O indicates the intermediate 
expressing MBL haplotypes. XA/O and O/O indicate the deficient MBL haplotypes. 
Blood samples were taken at recruitment into the study (baseline) on day 1 (onset of 
exacerbation) and day 14 (end of exacerbation) and repeated when clinically stable at 
least 3 months after exacerbation (stability). Data are shown as mean with (95% CI). 
Increase in MBL during exacerbation was only significantly different for the high 
expressing (A/A) haplotypes (see text).  
 
Exacerbations and hospitalisation 
Patients with MBL deficiency had a higher frequency of exacerbations and 
hospitalisations during follow-up. MBL deficient patients had a mean exacerbation 
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rate (per patient per year) of 2·7 (standard deviation 1·8) compared to patients with 
intermediate (mean 1·9 per patient per year, SD 1·2) or high expressing MBL 
genotypes (mean 1·9 per patient per year SD 1·3),p<0·0001. The mean difference 
between the low expressing and the other two groups was 0.72 95% CI 0.34-1.1 
exacerbations per patient per year. A higher proportion of MBL deficient patients 
were hospitalised on at least 1 occasion during follow-up (49·1% in the MBL 
deficient group compared to 31·1% in the intermediate MBL group and 31·4% in the 
high expressing group, p=0·032).  
 
Mortality 
There were 42 deaths during follow-up, with 59.5% of these deaths deemed to be 
directly related to bronchiectasis or respiratory infections. In this exploratory 
analysis, there were 8 deaths in the group with MBL deficient genotypes, (14.5%), 
10 deaths in the intermediate expressing group (7.4%) and 24 deaths in the high 
expressing MBL group (8.6%). Figure 6.4 shows the kaplain-meier analysis. The 
difference between the groups was not statistically significant by log-rank test 
(p=0.4). A cox-proportional hazard regression analysis adjusting for age, FEV1, 
bacterial colonisation and radiological severity of bronchiectasis did not establish 
significantly higher mortality in the MBL deficient group (hazard ratio 1.58 95% CI 
0.73-3.4,p=0.4). Similarly, although there was a trend towards more rapid decline in 
FEV1 over four years in the MBL deficient group, this difference was not statistically 
significant (p=0.3).  
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Figure 6.4. Long term prognosis in patients with bronchiectasis according to MBL2 
genotype. A- survival over 4 years, B- Lung function decline over 4 years. 
 
6.9 MASP-2 and Ficolin-3 
There was no significant relationship between MASP-2 and Ficolin-3 serum levels 
with any of the clinical markers of severity investigated in this study. A summary of 





Figure 6.5. Relationship of ficolin-3 and MASP-2 serum levels with clinical severity 
in bronchiectasis. All comparisons p>0.05. 
 
22 patients with bronchiectasis were heterozygous for the MASP-2 D120G 
polymorphism, with 1 patient homozygous and showing complete MASP-2 
deficiency. There was a strong statistically significant relationship between the 
MASP-2 SNP and MASP-2 serum levels (p<0.0001), figure 6.6. 9 patients with 
bronchiectasis were heterozygous for the FCN3 polymorphism (L117fs). Ficolin-3 
serum levels were significantly lower in this group (p<0.0001). 
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Figure 6.6. The relationship between MASP-2 and FCN3 SNP’s with serum levels. 
p<0.0001 by Mann-Whitney U test comparing MASP-2 A/A with A/G and 
comparing FCN3 C with C/-. 
 
There were insufficient patients with bronchiectasis and these MASP-2 and FCN3 
SNP’s to make meaningful statistical comparisons or conclusions about an effect on 
phenotype.  
 
6.10 Co-inheritance of lectin pathway single nucleotide polymorphisms 
As this study has identified a severity phenotype associated with SNP’s in both the 
ficolin-2 and MBL genes, one hypothesis would be that co-inheritance of both low 
expressing ficolin-2 haplotypes and MBL deficiency combined would lead to a very 
severe phenotype. The study sample size was not sufficiently large to investigate 
conclusively whether this was the case. 
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No patients had combined MBL deficiency and two low expressing ficolin-2 
haplotypes. 3 patients had MBL deficiency and a low/intermediate expressing 
ficolin-2 haplotype and 9 patients had MBL deficiency and intermediate/intermediate 
expressing ficolin-2 status.  7 patients had MBL deficiency based on genotype and a 
low serum ficolin-2 concentration. 6 patients had both MBL deficiency and 
heterozygosity for the MASP-2 D120G polymorphisms. The modifying effect of 
MASP-2 heterozygosity was investigated based on the previous findings of 
modification of MBL effects by two gene interactions (Olesen et al 2004, Dorfman et 
al 2008). 8 patients had one of the low or intermediate expression ficolin-2 
haplotypes and heterozygosity for MASP-2 D120G.  
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Table 6.5. Characteristics of patients groups carrying more than one lectin pathway 
deficient single nucleotide polymorphism, or patients with MBL deficiency and low 
serum levels of ficolin-2. Abbreviations: FEV1= forced expiratory volume in 1 
second, FVC= forced vital capacity. SGRQ= St. George’s Respiratory Questionnaire, 
LCQ= Leicester cough questionnaire, HRCT= high resolution computed 
tomography, BMI= body mass index. 
 
6.11 Discussion 
This study demonstrated a significant relationship between MBL deficiency and 
disease severity in a large cohort of patients with non-cystic fibrosis bronchiectasis.  
Deficiency of mannose binding lectin arises from variants in exon-1 and in the 
promoter region of the MBL2 gene. The exon-1 alleles designated B, C and D have a 
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profound dominant effect of MBL serum levels. Patients homozygous for exon-1 
mutations or compound heterozygous for an exon 1 mutation and the X/Y promoter 
polymorphism, have very low serum MBL levels, typically less than 200ng/ml 
(Kilpatrick, 2002, Eisen, 2010, Chalmers et al, 2011).  
This study identified that these patients, with the lowest serum MBL levels, have a 
higher frequency of chronic bacterial colonisation with a higher incidence of both 
Haemophilus influenzae and P. aeruginosa. Patients with MBL deficiency had more 
severe bronchiectasis as assessed by radiological scoring, and a higher frequency of 
outpatient exacerbations and hospitalisations for severe exacerbations over the period 
of follow-up. These patients also had greater impairment of quality of life and worse 
cough severity as assessed by the Leicester cough questionnaire. The differences in 
spirometry values were not statistically significant. Patients with MBL deficiency 
had significantly higher measures of neutrophil mediated airway inflammation, 
primarily related to higher bacterial loads present in the airways of patients with 
MBL deficiency. An exploratory analysis suggested a trend towards higher mortality 
rates and a faster decline in lung function in the MBL deficient group. Our study was 
not powered for this end-point and larger multicentre studies are needed to 
investigate this. 
Importantly, this study did not find any evidence of an effect of intermediate 
expressing MBL genotypes on disease severity, with no significant differences 
observed in these markers of disease severity between intermediate expressing and 
high expressing MBL genotypes. 
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When we used definitions of serum MBL deficiency determined a priori (serum level 
<500ng/ml or <200ng/ml) we observed significant relationships between serum 
MBL and bacterial colonisation, hospitalisations, exacerbations and radiological 
severity. These differences were, however, entirely due to the presence of the most 
severe MBL deficient patients in this group, as exclusion of patients with low 
expressing MBL genotypes abolished these relationships. We therefore conclude that 
patients with intermediate expressing MBL genotypes are not at higher risk of severe 
disease. 
We previously reported no differences between bronchiectasis patients and controls 
in serum MBL concentrations and have now confirmed these findings in a larger 
cohort (Kilpatrick, 2009). One previous study has investigated the role of impact of 
MBL deficiency on disease severity in 133 patients with non-CF bronchiectasis 
(MacFarlane, 2012). This study measured serum MBL levels but did not perform 
genotyping. This study found no difference in disease severity between patients with 
serum levels <600ng/ml compared to those with >600ng/ml. Patients with serum 
levels <100ng/ml had a trend towards more severe disease with more P. aeruginosa 
and H.influenzae and a higher frequency of exacerbations, but this group included 
only 13 patients and was underpowered to show significant differences. The results 
appear to therefore support the findings of our present study, indicating that only 
patients with severe MBL deficiency have a worse phenotype. There were other 
differences between the MacFarlane study and the current study. MacFarlane et al 
performed a retrospective study of patients having MBL measurements for clinical 
reasons and therefore included a much higher frequency of patients colonised with 
P.aeruginosa than has been typically reported in the literature (MacFarlane, 2012).  
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Recently an association between MBL levels and the progression of allergic 
bronchopulmonary aspergillosis and other aspergillus related lung diseases have been 
reported (Lambourne et al, 2009, Harrison et al, 2012). The present study excluded 
patients with active ABPA, and the group of patients reporting a past history of 
ABPA in this study was too small to make realistic conclusions.   
Several large studies have now confirmed a relationship between mannose binding 
lectin deficiency and disease severity in cystic fibrosis. A meta-analysis of studies in 
adults with cystic fibrosis demonstrates that MBL deficiency is associated with early 
acquisition of P. aeruginosa, increased infections with B. cepacia and increased 
mortality (Chalmers et al, 2011). Importantly, the largest studies suggest that the 
poor prognosis associated with variant MBL alleles is only evident in those with low 
expressing MBL genotypes (O/O and XA/O) (Dorfman et al, 2008, McDougall et al, 
2010). Our meta-analysis found no significant effect on lung function or markers of 
CF severity with the intermediate expression genotypes (Chalmers et al, 2011). This 
supports the findings of the present study that poor prognosis is associated with the 
low expressing genotypes but that intermediate MBL expression is not associated 
with greater disease severity. 
The mechanism by which MBL predisposes to more severe disease is not entirely 
clear although it has been reported that MBL binds P. aeruginosa, S. aureus and B. 
cepecia along with other clinically relevant bacteria leading to complement 
activation and enhanced clearance (Neth et al 2000, Moller-Kristensen 2006). MBL 
deficient mice are susceptible to more severe infections with P. aeruginosa (after 
burn injury) and S. aureus than wild-type mice (Shi et al, 2004, Moller-Kristensen et 
al, 2006). Furthermore, although MBL is a serum protein, it accumulates in the lung 
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during inflammatory diseases in quantities sufficient to promote phagocytosis and 
cause complement activation (Reading et al, 1997, Fiddler et al, 2009). It is therefore 
possible that MBL deficiency leads to a failure to clear microorganisms through 
reduced opsonophagocytosis.  
There are, however, other potential mechanisms not related to MBL’s role in 
bacterial clearance. MBL appears to be important in clearance of apoptotic cells, a 
key mechanism for the resolution of inflammation (Haslett, 1999). Hodge et al 
observed low levels of MBL in the airway of subjects with COPD
 
(Hodge et al, 
2008) and, importantly, this correlated with reduced apoptotic cell clearance. 
Azithromycin was found to enhance mannose receptor expression on macrophages 
and restore defective apoptotic cell clearance (Hodge et al, 2008). The importance of 
MBL was confirmed in smoke-exposed mice, where treatment with MBL improved 
the resolution of cigarette smoke induced inflammation (Hodge et al 2010). 
The relationship of MBL with P. aeruginosa and other organisms is controversial. 
MBL has been shown to bind to P.aeruginosa in some studies and not in others 
(Neth et al, 2000, Moller-Kristensen et al, 2006). We investigated MBL binding 
extensively as described in chapter 3.1 and found no binding of MBL to P. 
aeruginosa by any of the methods tested. Studies in MASP-2 deficient mice, which 
are unable to activate complement via the lectin pathway, demonstrate no significant 
role for the lectin pathway in defence against P.aeruginosa in mice (Kenawy, 2011). 
The alternative pathway is the major mechanism for defence against P.aeruginosa in 
health (Younger et al, 2003). Despite this, both this study and the literature from 
cystic fibrosis suggest a relationship between MBL deficiency and P. aeruginosa. 
During acute inflammation there is increased production of acute phase reactants, 
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including the pentraxins: C-reactive protein, serum amyloid P and pentraxin-3. 
Recent data suggest that these interact with MBL to enhance the lectin pathway (Ma 
et al, 2011). This may explain why MBL deficiency becomes important during 
inflammatory diseases such as bronchiectasis, or following burn injury as reported by 
Moller-Kristensen et al (Moller-Kristensen et al, 2006).  
What are the implications of this study? The identification of a group of patients at 
higher risk of exacerbations and poor outcome should stimulate further research to 
improve outcomes in bronchiectasis. Currently, there are few evidence-based 
treatments for this disease (Pasteur, 2010). MBL replacement therapy has been 
developed and has been suggested as a new therapeutic avenue for diseases 
associated with MBL-deficiency (Garred et al, 2002). Hodge et al demonstrated that 
azithromycin could restore the failure of apoptotic cells associated with MBL 
deficiency, and raises the question of whether future trials should target long-term 
macrolide treatment for patients with MBL deficiency to improve outcome. 
Limitations of our analysis must be acknowledged. The number of patients with 
severe MBL deficiency was small (n=55) and larger studies arising from multicentre 
collaborations are now needed. Others have found that the impact of MBL can be 
modified by other genes including TGF-beta and can be influenced by linkage 
disequilibrium with other genes including other collectins (Dorfman et al, 2008, 
Garcia-Laorden et al, 2012). Our study was designed in 2008 before these effects 
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General discussion and future work 
7.1 Ficolin-2 in bronchiectasis 
The lectin pathway of complement has now been linked with diverse processes 
including innate immune response to bacteria (Kilpatrick and Chalmers, 2012), 
viruses (Pan et al, 2012) and fungi (Ma et al, 2009), the clearance of apoptotic cells 
(Kuraya et al, 2005), coagulation (La Bonte et al, 2012) and ischaemic reperfusion 
injury (Schwaeble et al, 2011). Investigations in these areas are at an early stage but 
suggest that this pathway may be critical to many pathologies and therefore of 
relevance to a number of human diseases.  
Compared to the intensively studied mannose binding lectin, little is known to date 
about the physiological function, the regulation or disease associations of the ficolins 
in humans (Kilpatrick and Chalmers, 2012). 
This thesis has described an association between single nucleotide polymorphisms 
causing low serum levels of ficolin-2 and disease severity in bronchiectasis. Defining 
low levels of ficolin-2 was challenging because no established or accepted definition 
of “deficiency” exists and because large variations in ficolin-2 serum levels are 
observed, even among patients with the same genotype (Hummelshoj et al, 2005). 
We attempted to correlate serum levels with combinations of FCN2 haplotypes and 
found that the serum level could be predicted with a greater degree of accuracy and 
that low serum levels could therefore be identified most accurately using a 
combination of low, intermediate and high expressing haplotypes, with the lowest 
levels observed in patients with 2 low expressing haplotypes or with a combination 
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of low and intermediate expressing alleles. This analysis should be replicated in a 
non-diseased cohort in larger numbers of patients but has the potential to become the 
standard method for defining the functional relevance of FCN2 genotypes.  
We found this method to be significantly more predictive of ficolin-2 serum levels, 
using the area under the receiver operator characteristic curve, than using individual 
SNP’s alone. This approach is used successful in research with the closely related 
molecule mannose binding lectin where haplotypes can be used to predict serum 
levels and deficiency with a high degree of accuracy (Kilpatrick, 2002).  
Having defined low levels of ficolin-2 in this way, we demonstrated a correlation 
between low expressing ficolin-2 genotypes and serum levels with accepted markers 
of disease severity, including exacerbation frequency, hospitalisation for severe 
exacerbations and health related quality of life. There was also a striking relationship 
between low ficolin-2 levels and P. aeruginosa colonisation.  
There was also an apparent different in the frequency of ficolin-2 haplotypes 
between patients with bronchiectasis and controls. We used spouses and partners of 
patients attending the clinics at the Royal Infirmary of Edinburgh to provide a 
population that was largely matched by age, gender and to some extent environment 
and socioeconomic status. We observed lower levels of serum ficolin-2 in patients 
than in controls, confirming previous findings in a pilot cohort (Kilpatrick et al, 
2009), and we observed a higher frequency of the high expressing AGGTG 
haplotype in controls. Possible explanations for this are that high ficolin-2 levels 
protect against the development of bronchiectasis. This is speculative, but as the true 
aetiology of bronchiectasis is unknown, this warrants further study. Perhaps a more 
311 
 
likely explanation given our other findings is that patients attending a specialist clinic 
at the Royal Infirmary of Edinburgh are more likely to be selected on the basis of 
more severe disease. Therefore the low frequency of patients with the AGGTG 
haplotype may reflect a reduced severity in these patients rather than a true increased 
susceptibility to bronchiectasis. This hypothesis requires further study. 
 
Future work in this area will focus on replicating the findings of the present study in 
a larger cohort of patients with bronchiectasis from different centres. The present 
study is the largest genetic study of non-CF bronchiectasis that the authors are aware 
of and one of the only studies to describe genetic associations with disease severity. 
Previous studies have investigated the role of CFTR mutations (the cause of cystic 
fibrosis) in patients with diffuse bronchiectasis not due to cystic fibrosis and 
suggested that this may modify the disease presentation to some extent (Bienvenu et 
al, 2010). Multicentre collaborations are now underway in the United States 
(Aksamit et al, 2012) and within the UK with genetic analysis of large patients 
groups one of the stated aims of such collaborations (De Soyza et al, 2012). This may 
provide the opportunity to replicate the present findings on a large scale. There are 
several end-points associated with survival, such as decline in lung function and 
particularly survival that will only be adequately addressed by large, well powered 
and longitudinal studies involving multiple centres. 
Prior to these confirmatory studies, it would be inappropriate to make any 
recommendations about the implications of our findings to clinical practice. There is 
no evidence at this stage that patients with low expressing ficolin-2 haplotypes 
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should be managed differently. If our results are confirmed in a larger cohort, it may 
be that such patients would benefit from more intensive follow-up, surveillance for 
bacterial colonisation, P. aeruginosa eradication and perhaps long term prophylactic 
antibiotic therapy. There is an ongoing debate in the literature about how best long 
term antibiotic therapy should be targeted in bronchiectasis and better ways of 
predicting long term outcome in this disease are needed (Wilson and Wells, 2012). 
  
To aid further studies of ficolin-2 and susceptibility to disease it would be beneficial 
to study a large cohort of healthy individuals for ficolin-2 serum levels and to 
identify the optimal method of defining low ficolin-2 expression. We have made an 
attempt to do so in the present study, but it is likely that other FCN2 single 
nucleotide polymorphisms affecting serum levels will be identified. Within the 
currently accepted haplotype groups there is wide variation in ficolin-2 serum levels 
and a dedicated genetic study examining large numbers of FCN2 SNP’s and serum 
levels in healthy individuals would help to better define this. We attempted to 
identify some non-genetic factors that may influence circulating ficolin-2 levels, but 
did not identify a significant impact of hormonal or inflammatory stimuli, in-vitro or 
in-vivo. Further studies to identify the regulators of ficolin-2 expression in humans 
are needed.  
This study utilised traditional culture based microbiological techniques to identify 
and quantify bacterial species in sputum samples and to define colonisation. Newer 
molecular techniques utilising the bacterial 16s rRNA gene have been developed and 
are transforming our view of respiratory tract microbiology (Blaser, 2010). It was 
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traditionally held that the healthy airway is sterile but this appears not to be the case 
with a very diverse microbiome evident in healthy control subjects (Charlston et al, 
2011). All such studies should be treated with a degree of caution at this stage as the 
upper airway is not sterile and some of these studies may be confounded by 
contamination from the upper respiratory tract. Nevertheless, studies in cystic 
fibrosis and chronic obstructive pulmonary disease reveal extraordinary diversity of 
bacterial species within respiratory samples, with often >1,000 individual 16S rRNA 
sequences identified in each sample (Sze et al, 2012, Fodor et al, 2012). Less than 
1% of bacteria can be cultured using traditional laboratory methods as employed in 
the present thesis. It appears that in patients in whom a single organism, such as 
Haemophilus influenzae is cultured from sputum we may be missing at least 99.99% 
of the bacterial composition of the lower respiratory tract (Zemanick et al, 2011). 
The clinical relevance of these other organisms is yet to be defined. Future work will 
certainly involve trying to correlate innate immune defects in bronchiectasis with the 
findings of these novel microbiological assays. Airway infection is a major clinical 
problem in cystic fibrosis related bronchiectasis and chronic obstructive pulmonary 
disease. A logical extension of the present work would be to test for single nucleotide 
polymorphisms of the ficolin-2 gene in these populations, where P. aeruginosa 
colonisation is common. A small study has already been published suggesting a 
relationship between SNP’s in FCN2 and earlier P. aeruginosa colonisation and 
larger studies are now needed (Haerynck et al, 2012).  
The surprisingly high prevalence of P. aeruginosa in patients with low expressing 
ficolin-2 haplotypes led us to investigate the role of ficolin-2 in opsonophagocytosis 
of P. aeruginosa and other bacteria in in-vitro. These studies were complicated by 
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the lack of an established assay for selectively studying the lectin pathway of 
complement, while inhibiting the classical and alternative pathways. We used C1q 
depleted sera to prevent activation of the classical pathway and either high ionic 
strength or low serum dilutions to inhibit the alternative pathway. These assays 
resulted in conditions which permitted study of the lectin pathway in relative 
isolation. Without these conditions the alternative pathway was found to be the 
dominant pathway for complement activation on P. aeruginosa with only a small 
contribution from the lectin pathway. These results would suggest that in the absence 
of another immunodeficiency, ficolin-2 deficiency would not greatly increase 
susceptibility to systemic P. aeruginosa infection. This is consistent with recent 
findings from a mouse model of pneumonia in which the lectin pathway of 
complement was found to be non-essential for house defence against intranasal P. 
aeruginosa infection in MASP-2 knockout and wild type mice (Kenawy et al, 2012). 
In bronchiectasis, however, the infection is not systemic but localised and affects the 
bronchial mucosa. The mechanisms of host defence in this context are less well 
understood but it is known that serum components are present at much lower 
concentrations and that the alternative pathway is relatively inactive (Younger et al, 
2003). We therefore hypothesise that ficolin-2 may diffuse into the lung during acute 
and chronic inflammation and enhance opsonophagocytosis of P. aeruginosa and 
other organisms. The animal models of bronchiectasis are limited and so further 
work to determine the contribution of ficolin-2 to airway mucosa defence will 
require in-vitro studies. Specifically, it would be important to establish the microbial 
spectrum against which ficolin-2 is active and whether susceptibility to infections 




Ficolin-2 binding to carbohydrate ligands is necessary for complement activation via 
the lectin pathway. We did not find any activity of ficolin-2 in the absence of 
complement and further study of how ficolin-2 binding triggers complement 
activation would be important. Similarly, we have not yet identified the ligand(s) on 
P. aeruginosa and other bacteria to which ficolin-2 binds. This would be important if 
the therapeutic potential of ficolin-2 is to be realised. Ultimately, I hope a greater 
understanding of how ficolin-2 is able to opsonise and promote clearance of bacterial 
pathogens may lead to the development of a new therapeutic approach to this disease 
that presenting has few effective treatments.  
 
7.2 Mannose binding lectin 
This study also observed a significant association between mannose binding lectin 
deficiency and disease severity in bronchiectasis. The finding of a strong association 
with P. aeruginosa infection, chronic colonisation and the frequency of exacerbations 
would be consistent with data from cystic fibrosis (Chalmers et al, 2011). Several 
large studies in cystic fibrosis, which were consolidation into a meta-analysis in 
chapter 1 of this thesis, support the view that MBL deficiency is associated with a 
more rapid progression of the disease, worse lung function and premature death.  
The present study is the first demonstration of this disease modifying effect in 
bronchiectasis. As with the data on ficolin-2, confirmation in an independent and 




The results of our in-vitro studies raise important questions about how MBL may be 
modifying disease severity in bronchiectasis. MBL deficiency was found to be 
associated with a higher frequency of P. aeruginosa colonisation in patients, and yet 
in-vitro MBL did not bind to P. aeruginosa and opsonisation with rMBL did not 
enhance neutrophil or macrophage phagocytosis of P. aeruginosa. Ficolin-2 was 
found to be the major lectin pathway component responsible for opsonisation of P. 
aeruginosa with no significant contribution from MBL. How then, can this 
association be explained? 
Although not involved in host defence against P. aeruginosa, MBL does bind to and 
opsonise a number of important pathogens including Aspergillus fumigatus (Crosdale 
et al, 2001), multiple viruses include influenza virus (Kase et al, 1999), and bacteria 
including S. aureus (Shi et al, 2004). It is possible to susceptibility to other pathogens 
such as viruses causes recurrent exacerbations and that this leads to progressive lung 
damage, with P. aeruginosa colonisation an indirect consequence of the lung damage 
rather than being directly due to a failure of phagocytic clearance. 
Similarly, MBL has been shown to bind to, and enhance the clearance of apoptotic 
cells (Kuraya et al, 2005). MBL deficient mice have a defect in apoptotic cell 
clearance in-vivo although unlike C1q deficiency which is associated with 
autoimmunity, MBL deficiency does not appear to contribute to autoimmunity 
(Stuart et al, 2005). Apoptotic cell clearance by macrophages is a critical mechanism 
for the resolution of inflammation as failure to clear these cells results in secondary 
necrosis and release of pro-inflammatory intracellular contents into surrounding 
tissues (Savill et al, 2002). This is thought to be an important contributor to 
inflammatory diseases and autoimmunity. The neutrophil is the dominant cell type in 
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the airway of patients with bronchiectasis and a potentially important future area of 
study would be to establish if MBL is involved in clearance of apoptotic neutrophils 
by macrophages (Rossi et al, 2007). Failure of this mechanism in the bronchiectasis 
airway would lead to enhanced lung damage by neutrophil granule contents. I 
speculate that our findings of more severe lung disease and chronic colonisation with 
bacteria may be a consequence of this process, rather than a failure of 
opsonophagocytosis of bacteria, since we were unable to demonstrate any such 
defect in-vitro with MBL. 
MBL deficiency is potentially clinically important because of the availability of 
therapies that can reverse the basic defect associated with MBL deficiency. 
Recombinant MBL has been successfully administered to mice under experimental 
conditions to rescue phenotypes associated with MBL deficiency. MBL-null mice 
infected with S. aureus had reduced survival compared to wild-type but this was 
reversed by the administration of rMBL (Shi et al, 2005).  
In early trials in humans, plasma derived MBL and rMBL administered to restore 
MBL to normal levels (>1000ng/ml) in those with MBL deficiency was shown to be 
safe and was not immunogenic (Valdimarsson et al, 2004). Recent data suggest that 
although administration of MBL replacement restored serum levels to normal, higher 
than normal doses were required to restore normal complement activation capacity 
(Brouwer et al, 2009). MBL has to be given as regular infusions, making chronic 
treatment potentially impractical. There have been no phase II or phase III trials of 
MBL replacement therapy and the only limited evidence of efficacy comes from 
uncontrolled case reports of patients given MBL replacement on compassionate 




If MBL deficiency identifies a sub-group of patients at risk of bacterial colonisation, 
airway inflammation and disease progression, this would argue strongly for a 
targetted approach to treatment. There is evidence that azithromycin can reverse the 
phagocytic defects caused by MBL deficiency in-vitro and in-vivo (Hodge et al, 
2008). Azithromycin causes up-regulation of mannose receptor on macrophages 
which enhances the uptake of apoptotic cells, reversing a failure of apoptotic cell 
clearance demonstrated with MBL deficiency (Hodge et al, 2008). It is now known 
that azithromycin is an effective treatment for bronchiectasis and that long term 
azithromycin reduces exacerbations in COPD (Wong et al, 2012, Albert et al 2011). 
The optimal group of patients to benefit from this treatment is unknown. Macrolides 
have a number of side effects including not just gastrointestinal effects but also a 
significant risk of hearing impairment (Albert et al, 2011) and in some studies, 
cardiovascular events (Jespersen et al, 2006). It is therefore unlikely that 
azithromycin will be a treatment suitable for all patients with bronchiectasis, but may 
be targeted to patients most at risk of complications. A pharmacogenetic approach to 
treatment, in which MBL deficient patients are given azithromycin to reverse their 
increased risk of disease progression, is the ultimate objective of this work.   
 
 
7.3 Neutrophil function in bronchiectasis 
Bronchiectasis is a neutrophil driven disorder. Neutrophils are the most frequent cell 
type identified in the bronchiectasis airway (Eller et al, 1994, Angrill et al, 2002), 
and neutrophil derived granule products and in particular, neutrophil elastase have 
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been directly linked to disease progression and severity (Tsang et al, 2000, Lloberes 
et al, 1992). Despite this, relatively little is known in the literature about neutrophil 
function in non-CF bronchiectasis. Pasteur et al found no abnormal values of 
peripheral neutrophil surface markers in bronchiectasis (Pasteur et al, 2000) and 
Voglis et al demonstrated phagocytic dysfunction in sputum neutrophils in 
bronchiectasis induced by exposure to neutrophil neutrophil peptides (α-defensins) 
(Voglis et al, 2009). Our study is therefore one of the first to extensively study 
neutrophil function in non-CF bronchiectasis. We found no difference in peripheral 
blood neutrophil receptor expression or phagocytosis in bronchiectasis compared to 
healthy controls. This finding is not unexpected, as the majority of patients with 
idiopathic bronchiectasis do not have an increase in susceptibility to infection out-
with the respiratory tract and therefore a generalised neutrophil disorder or neutrophil 
dysfunction would not be expected in these patients. Sputum neutrophils, however, 
showed significant changes compared to peripheral blood neutrophils. Reduced 
levels of the phagocytic receptor FcγRIIIb and complement receptor 1 were 
demonstrated, with an apparent correlation between the level of expression and the 
severity of lung disease. Furthermore, we demonstrated a reduction in CD88, the C5a 
receptor that correlated with the severity of lung disease and was found to be due to 
cleavage through neutrophil elastase. 
There are certainly limitations to the methods used in these neutrophil studies. 
Significant numbers of neutrophils could not be obtained from healthy control 
sputum and so comparisons were made with maximally activated peripheral blood 
neutrophils. Although this is an approach that has been used previously (Berger et al, 
1989) it is not a direct comparison of like with like and a superior study design 
320 
 
would be to use cells obtained by bronchoalveolar lavage, where cells could also be 
obtained from healthy controls. 
Our study was concerned primarily with opsonophagocytosis and complement 
activation through the lectin pathway of complement and so our studies of neutrophil 
surface markers focussed on those involved in neutrophil adhesion, activation and 
phagocytosis. It is therefore likely we present a very incomplete view of the 
neutrophil dysfunction in the airway in bronchiectasis. Further studies will be needed 
to investigate neutrophil properties such as chemotaxis (Yoshikawa et al, 2007) and 
neutrophil extracellular trap formation (Young et al, 2011) which may be equally 
important as phagocytosis in the pathophysiology of chronic lung disease.  
Neutrophil elastase appears to be a key mediator of disease severity in bronchiectasis 
and was found to be strongly associated with bacterial infection in this study. 
Elastase was reduced by short or long term antibiotic treatment, suggesting the 
hypothesis that antibiotic treatment may, to some extent, reverse the defects seen in 
bronchiectasis neutrophils. An important area for future study would be to 
investigate whether the abnormalities we observed in sputum neutrophils could be 
reversed by antibiotic or anti-inflammatory treatment. Neutrophil elastase has long 
been recognised as a target for therapy in chronic lung disease and oral neutrophil 
elastase inhibitors are currently undergoing phase I and phase II clinical trials 
(Stevens et al, 2011). We await the results of such trials with interest.  
Failure of bacterial clearance in bronchiectasis is likely to be multi-factorial and a 
greater understanding of the mechanisms underlying chronic bacterial colonisation, 
including the role of ficolin-2, MBL and other innate immune molecules are needed  
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In conclusion, I have shown that single nucleotide polymorphisms in the lectin 
pathway of complement activation molecules ficolin-2 and mannose binding lectin 
are  associated with disease severity and bacterial colonisation in bronchiectasis. The 
clinical and therapeutic implications of these findings require further study but may 
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